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SUMMARY 
Nowadays, life expectancy has increased and gradually the prevalence of neurodegenerative 
disorders in the aging population began to represent a major public health problem. 
Alzheimer’s disease (AD) is the most common dementia and affects millions of older adults. 
Despite recent advances in the knowledge of AD biomarkers of pathophysiological processes, 
clearly the phenotype remains aetiologically heterogeneous. Understanding the clinical 
phenotype variation contingent to the neuropathological progression is crucial to provide 
intervention in the earliest phases of neurodegeneration. Newly research biomarkers have 
been proposed for early diagnosis of AD, however cognitive impairment remains a prominent 
and early feature of AD. Neuropsychological markers could offer a relatively inexpensive and 
noninvasive indicator of future progression to dementia because biological markers are 
expensive, some of them only available at few specialized centers, and, in the case of lumbar 
puncture, invasive. Therefore, it would not be reasonable to offer the newer and expensive 
biomarker techniques to all patients with cognitive complaints. Importantly, new treatments of 
disease modification approach require the selection of those patients with higher risk of 
conversion to dementia. Thus, the main goal of the present thesis was to improve the 
predictive value of neuropsychological measures to future conversion to dementia of patients 
presenting with cognitive complaints who do not fulfil the dementia criteria. Four steps were 
conducted in order to reach that main goal: 
 
1. º Original published articles reporting values of sensitivity, specificity and effect sizes for 
neuropsychological tests to predict conversion to dementia in patients at risk of future 
cognitive decline were analysed in a systematic review of literature. Twenty-four studies 
published in the last 20 years were selected. Neuropsychological tests administered vary 
considerably among studies, yet the battery of tests applied generally assessed verbal memory 
performances, and many included also cognitive areas such as executive functions, attention 
and language. Methodological constrains limited the ability to provide reasonable predictive 
values; some studies have reported rather disparate global sensitivity and specificity rates for 
the neuropsychological tests to predict conversion to dementia. Conversely, other studies 
reported high and balanced sensitivity/specificity ratios (≥80%), mainly for verbal episodic 
memory tests, however the follow-up period of those studies was generally short (≈2 years). 
Certainly, it would be important to achieve a consensus according to the more feasible and 
accurate neuropsychological tests to administer for the assessment of patients at risk of 
conversion to dementia. On the other hand, cohort studies with longer follow-up periods 
would be important to propose neuropsychological tests with higher predictive accuracy and 
clinical relevance regarding conversion to dementia. 
 
Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints  
Biomedical Sciences Doctoral Program – Faculty of Medicine – University of Lisbon 
 
xii Dina Lúcia Gomes da Silva 
2. º Newer statistical classification methods derived from data mining and machine learning 
methods were applied to improve accuracy, sensitivity and specificity of predictors obtained 
from neuropsychological testing. Data used to perform the comparison of classification 
methods was extracted from a cohort study (CCC – Cognitive Complaints Cohort) with 775 
elderly non-demented patients with cognitive complaints referred for neuropsychological 
evaluation. Seven non-parametric classifiers derived from data mining methods (Multilayer 
Perceptrons Neural Networks, Radial Basis Function Neural Networks, Support Vector 
Machines, CART, CHAID and QUEST Classification Trees and Random Forests) were 
compared to three traditional classifiers (Linear Discriminant Analysis, Quadratic 
Discriminant Analysis and Logistic Regression) in terms of overall classification accuracy, 
specificity, sensitivity, Area under the ROC curve and Press’Q. Model predictors were 10 
neuropsychological tests currently used in the diagnosis of dementia. Comparison of 
classifiers highlighted three methods more adequate to study the predictive value of 
neuropsychological tests in longitudinal clinical cohort studies. Support Vector Machines 
demonstrated the larger overall classification accuracy (Median (Me) = 0.76) and area under 
the ROC (Me =0.90). However, this method showed high specificity (Me = 1.0) but very low 
sensitivity (Me = 0.3). Random Forests ranked second in overall accuracy (Me = 0.73) with 
high area under the ROC (Me = 0.73), specificity (Me = 0.73) and sensitivity (Me = 0.64). 
Linear Discriminant Analysis also showed acceptable overall accuracy (Me = 0.66), with 
acceptable area under the ROC (Me = 0.72), specificity (Me = 0.66) and sensitivity (Me = 
0.64). Results indicated the innovative data mining method of Random Forests, along with 
more traditional methods, namely the Linear Discriminant Analysis, should be the option in 
cohort studies of neuropsychological predictors of future dementia. 
 
3. º Verbal memory is one of the first cognitive areas to decline, therefore, the predictive 
value of Mild Cognitive Impairment (MCI) for the conversion to dementia when using four 
different verbal memory tests (Logical Memory, LM; California Verbal Learning Test, 
CVLT; Verbal Paired-Associate Learning, VPAL; and Digit Span, DS) was analysed. 
Participants were consecutive patients with subjective cognitive complaints who performed a 
comprehensive neuropsychological evaluation and were not demented, observed in a memory 
clinic setting. At baseline, 272 patients from CCC reporting subjective cognitive complaints 
and not demented were included. During the follow-up time (3.0±1.9 years), 58 patients 
converted to dementia, and 214 did not. Statistically significant differences between the 
converters and non-converters were present in LM, VPAL and CVLT. A multivariate Cox 
regression analysis combining the 4 memory tests revealed that only the CVLT test remained 
significant as predictor of conversion to dementia. Non-demented patients with cognitive 
complaints diagnosed as MCI according to abnormal (< 1.5 SD) learning in the CVLT test 
had 3.6 higher risk of becoming demented in the follow-up. As so, the verbal memory 
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assessment using the CVLT should be preferred in the diagnostic criteria of MCI for a more 
accurate prediction of conversion to dementia. 
 
4. º The predictive value for future conversion to dementia of a comprehensive 
neuropsychological battery applied to a cohort of nondemented patients followed-up for 5 
years was presented. Two hundred and fifty subjects were selected from CCC having 
cognitive complaints, assessment with a comprehensive neuropsychological battery, and 
follow-up of at least 5 years (if patients have not converted to dementia earlier). During the 
follow-up period (2.6±1.8 years for converters and 6.1±2.1 for non converters), 162 patients 
(64.8%) progressed to dementia (mostly Alzheimer’s disease), and 88 (35.2%) did not. A 
Linear Discriminant Analysis (LDA) model constituted by Digit Span backward, Semantic 
Fluency, Logical Memory (immediate recall) and Forgetting Index significantly discriminated 
converters from non-converters (λ Wilks=0.64; χ2(4)=81.95; p<0.001; RCanonical=0.60). 
Logical Memory (immediate recall) was the strongest predictor with a standardized canonical 
discriminant function coefficient of 0.70. The LDA classificatory model showed good 
sensitivity, specificity and accuracy values (78.8%, 79.9% and 78.6%, respectively) of the 
neuropsychological tests to predict long-term conversion to dementia. Results showed that it 
is possible to predict, on the basis of the initial clinical and neuropsychological evaluation, 
namely with routine tests from a comprehensive neuropsychological battery, whether non-
demented patients with cognitive complaints will probably convert to dementia, or remain 
stable. This prediction is obtained with very good accuracy values (≈80%), similar to those 
reported for the newly research biomarkers, and at a reasonably long and clinically relevant 
term (5 years). 
 
 
Conclusion: 
Cognitive impairment is a prominent and early feature of AD, thus neuropsychological 
markers could offer a relatively inexpensive and non-invasive indicator of future progression 
to dementia. The present thesis shows that neuropsychological tests have good long-term 
predictive values for future conversion to dementia in non-demented patients with cognitive 
complaints. Nowadays, clinicians have to reconcile assistance to a large number of patients 
with cognitive complaints, novel expensive diagnostic techniques, promising disease-
modifying treatments, and marked financial constraints. Therefore, it is crucial to assess as 
early as possible if patients have a low probability of progression to dementia, in which case a 
regular follow-up and general preventive measures might be indicated, or a high probability 
of progression to dementia, so that complex ancillary examinations and new disease-
modifying treatments might be proposed. 
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RESUMO 
 
A esperança média de vida tem vindo a aumentar e consequentemente, de modo gradual, 
também a prevalência de doenças neurodegenerativas, representando actualmente na 
população mais envelhecida um alarmante problema de saúde pública. A doença de 
Alzheimer é a forma mais comum de demência e afecta milhões de indivíduos adultos. 
Recentemente tem sido possível alcançar avanços significativos na compreensão e no 
conhecimento sobre os biomarcadores que traduzem os processos patofisiológicos associados 
à doença de Alzheimer, no entanto, é importante salientar que o fenótipo manifestado pode 
ainda ser de etiologia heterogénea. Compreender melhor a variação das expressões de 
fenótipo contigentes ao processo neuropatológico é essencial para uma identificação e 
intervenção mais precoce no processo neurodegenerativo. Recentemente foram propostos 
novos biomarcadores, ainda limitados ao âmbito da investigação, com o propósito de realizar 
mais cedo o diagnóstico de doença de Alzheimer. Não obstante o seu potencial, será de referir 
que a presença de significativas alterações cognitivas continua a ser um elemento de 
diagnóstico incontornável e um indicador precoce da doença de Alzheimer. Os marcadores 
neuropsicológicos poderão oferecer indicadores de uma futura progressão para demência que 
serão economicamente mais acessíveis e clinicamente menos invasivos do que a realização 
dos métodos necessários aos marcadores biológicos, que além de serem mais dispendiosos, 
apenas se encontram disponíveis em alguns centros médicos especializados e serão em alguns 
casos métodos invasivos (e.g., recolha de líquido cefalorraquidiano através de punção 
lombar). Por conseguinte, não será razoável assumir que se irá disponibilizar a todos os 
indivíduos com manifestas queixas subjectivas de alterações cognitivas os recentes 
biomarcadores, por requerem técnicas dispendiosas e/ou invasivas. Por outro lado, é 
importante referir que a abordagem em presente desenvolvimento para tratar a doença 
incidindo na modificação dos seus factores causais requer uma selecção inicial do maior 
número possível de indivíduos para os quais o risco de progressão para demência seja 
significativo. Assim sendo, o objectivo central da presente tese foi o de melhorar o valor 
preditivo das medidas neuropsicológicas para a determinação de uma futura progressão para 
demência de indivíduos com queixa de alterações cognitivas que contudo não preenchem 
ainda os critérios para o diagnóstico de demência. De modo a concretizar o objectivo central, 
quatro estudos foram desenvolvidos: 
 
1.º - Uma revisão sistemática da literatura foi realizada com base em estudos originais 
publicados sobre o valor preditivo da avaliação neuropsicológica de uma futura progressão 
para demência, apresentando para tal os valores de sensibilidade, especificidade e magnitude 
do efeito para cada uma das provas neuropsicológicas. A selecção dos artigos permitiu a 
identificação de 24 artigos publicados nos últimos 20 anos. Os testes neuropsicológicos 
aplicados mudavam consideravelmente consoante o estudo em questão, contudo verificava-se 
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que no conjunto de estudos era consistente a aplicação de provas de avaliação da memória 
verbal, mas também de avaliação de funções executivas, capacidade de atenção e linguagem. 
A presença de limitações metodológicas condicionou a potencialidade de apresentar valores 
preditivos razoáveis em alguns estudos, além disso, noutros estudos os valores de 
sensibilidade e especificidade apresentados para as provas neuropsicológicas enquanto 
preditoras de futura progressão para demência eram consideravelmente díspares. No entanto 
será importante salientar que também foi possível identificar em parte dos estudos descritos a 
presença de valores muito positivos e de razões equilibradas entre sensibilidade e 
especificidade (≥80%), principalmente para provas de avaliação da memória verbal episódica, 
contudo os tempos de seguimento eram na sua maioria curtos (aproximadamente 2 anos). 
Com certeza que seria relevante encontrar um consenso que pudesse futuramente guiar uma 
escolha viável e precisa das provas neuropsicológicas a aplicar para melhor predizer uma 
futura progressão para demência. Por outro lado, a existência de estudos de coorte 
longitudinais com períodos de seguimento mais alargados seria essencial para melhorar a 
precisão dos valores preditivos da avaliação neuropsicológica, tornando-se estes clinicamente 
mais relevantes no que respeita a uma futura progressão para demência. 
 
2.º Os novos métodos de classificação estatística associados a técnicas de Prospecção de 
dados (em inglês data mining) e Sistemas de Aprendizagem (em inglês machine learning) 
foram aplicados com o intuito de melhorar a precisão, sensibilidade e especificidade dos 
preditores obtidos pela avaliação neuropsicológica. Para a comparação dos métodos 
classificatórios recorreu-se à base de dados CCC (CCC – Cognitive Complaints Cohort) que 
era constituída na altura por 775 casos de pacientes idosos não-dementes com queixas de 
alterações cognitivas e que foram referenciados para realizarem uma avaliação 
neuropsicológica. A comparação dos métodos estatísticos realizou-se entre 7 classificadores 
não-paramétricos provenientes de métodos de Prospecção de dados (Redes Neuronais com 
Perceptrões Multicamada; Redes Neuronais com Funções de Base Radial; Máquinas de 
Vectores de Suporte; CART; CHAID; Árvores de Classificação QUEST e Árvores de 
Classificação Aleatória) que foram comparados com três classificadores tradicionais (Análise 
Discriminante Linear; Análise Discriminante Quadrática, e Regressão Logística) em termos 
de precisão classificatória, especificidade, sensibilidade, área abaixo da curva ROC e Press’Q. 
O modelo para a predição consistia em 10 testes neuropsicológicos utilizados recorrentemente 
para o diagnóstico de demência. A comparação de classificadores identificou três métodos 
como os mais adequados para testar o valor preditivo dos testes neuropsicológicos em estudos 
longitudinais de coortes clínicas. As Máquinas de Vectores de Suporte demonstraram valores 
mais elevados de precisão classificatória (Mediana (Me)= 0,76) e de área abaixo da curva 
ROC (Me= 0,90). De salientar que, no que respeita à especificidade, este método revelou um 
valor elevado (Me= 1,0), contudo o valor de sensibilidade era consideravelmente baixo (Me= 
0,30). As Florestas Aleatórias foram o segundo método com melhores resultados em termos 
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de precisão (Me= 0,73), área abaixo da curva ROC (Me= 0,73), especificidade (Me= 0,73) e 
sensibilidade (Me= 0,64). A Análise Discriminante Linear demonstrou igualmente valores 
razoáveis de precisão (Me= 0,66), área abaixo da curva ROC (Me= 0,72), especificidade 
(Me= 0,66) e sensibilidade (Me= 0,64). Os resultados apresentados indicam que os melhores 
métodos classificatórios para analisar os preditores neuropsicológicos de futura progressão 
para demência correspondem às Florestas Aleatórias no âmbito dos mais inovadores métodos 
de Prospecção de dados e à Análise Discriminante Linear, enquanto método de eleição de 
entre os mais tradicionais para classificação de dados. 
 
3.º A memória verbal é considerada uma das primeiras áreas cognitivas a manifestar declínio 
nos casos de Doença de Alzheimer. Por conseguinte, o valor preditivo de progressão para 
demência (Doença de Alzheimer) associado ao Defeito Cognitivo Ligeiro (DCL) foi analisado 
contemplando para o diagnóstico de DCL quatro testes diferentes de avaliação da memória 
verbal (Memória Lógica (LM); Teste de Aprendizagem Verbal de Califórnia (CVLT); 
Aprendizagem Verbal Associativa com Pares de Palavras (VPAL); e, Memória de Dígitos 
(DS)). Para o estudo foi seleccionada uma amostra consecutiva de pacientes com queixas de 
alterações cognitivas que em consequência das mesmas foram referenciados para realizar uma 
avaliação neuropsicológica pormenorizada numa clínica de memória, mas que não 
preenchiam ainda os critérios para o diagnóstico de demência. Uma amostra inicial de 272 
pacientes com queixas cognitivas e não-dementes foram seleccionados da coorte CCC para o 
presente estudo. No decurso do período de seguimento (3,0±1,9 anos) ocorreu a conversão 
para demência em 58 pacientes, enquanto 214 permaneceram cognitivamente estáveis. Nas 
provas de LM, VPAL e CVLT verificaram-se diferenças estatisticamente significativas entre 
o grupo que converteu e o que não converteu. Através de uma análise de Regressão 
Multivariada de COX com um modelo constituído pelas quatro provas de memória verbal 
demonstrou-se que apenas a prova CVLT mantém a significância enquanto preditor de futura 
conversão para demência. Assim sendo, pacientes que não se encontram dementes mas que 
manifestam queixas de alterações cognitivas, com o diagnóstico de DCL recorrendo à 
pontuação na prova CVLT, se apresentarem defeito nesta prova (< 1,5 desvios-padrão abaixo 
da média de referência) têm um risco acrescido de evoluir para demência dentro do período de 
seguimento. Consequentemente, uma avaliação neuropsicológica incluindo a prova CVLT 
deve ser contemplada para os critérios de diagnóstico de DCL de modo a predizer com maior 
precisão uma futura conversão para demência. 
 
4.º Uma coorte constituída por 250 indivíduos (seleccionados da base de dados CCC) com 
queixas cognitivas mas sem critérios de demência e com seguimento clínico superior a 5 anos 
(com excepção para os casos que evoluíram para demência antes dos 5 anos) foi analisada 
com vista à determinação do valor preditivo dos testes neuropsicológicos a longo prazo. 
Durante o período de seguimento (2,6±1,8 anos para os indivíduos que evoluíram para 
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demência e 6,1±2,1 anos para os que permaneceram estáveis a nível cognitivo) 162 indivíduos 
(64,8%) apresentaram os critérios para o diagnóstico de demência (principalmente para 
Doença de Alzheimer), enquanto que 88 (35,2%) permaneceram estáveis. Foi possível 
discriminar entre os indivíduos que progrediram para demência e os que permaneceram 
estáveis através de um modelo de Análise Discriminante Linear (ADL) com os resultados 
iniciais da avaliação nas provas: Memória de Dígitos inversa, Fluência Semântica, Memória 
Lógica (evocação imediata), e o Índice de Esquecimento da Memória Lógica (λ Wilks= 0,64; 
χ2 (4)= 81,95; p< 0,001; RCanonical= 0,60). O preditor neuropsicológico mais robusto, com 
coeficiente estandardizado da função discriminante (canónica) de 0,70, foi a prova de 
Memória Lógica (evocação imediata). O modelo classificatório da ADL demonstrou valores 
muito positivos para a sensibilidade, especificidade e precisão classificatória (78,8%, 79,9% e 
78,6%, respectivamente), dos testes neuropsicológicos para predizer uma futura progressão 
para demência a longo prazo. Os resultados apresentados evidenciam a possibilidade de 
predizer, com base numa avaliação inicial, clínica e neuropsicológica, com uma bateria de 
provas cognitivas aplicada na rotina clínica, se o indivíduo que apresenta queixas cognitivas 
irá evoluir para demência ou permanecer estável nos próximos anos. Será de salientar que o 
valor preditivo foi obtido com uma precisão bastante aceitável (≈ 80%), na ordem dos valores 
obtidos para os biomarcadores mais recentes, e no âmbito de um período de seguimento 
consideravelmente longo e portanto clinicamente relevante (5 anos). 
 
Conclusão: 
O declínio cognitivo constitui um sintoma inicial e crucial para o diagnóstico de Doença de 
Alzheimer, e por conseguinte, a avaliação neuropsicológica poderá permitir a identificação de 
alterações cognitivas associadas a uma futura progressão para demência a um custo 
relativamente acessível e sem sujeição do indivíduo a métodos de diagnóstico mais invasivos. 
A presente tese de doutoramento demonstra que a avaliação neuropsicológica poderá oferecer 
valores preditivos significativos no que respeita a uma futura conversão para demência num 
grupo de indivíduos com queixas cognitivas. Nos nossos dias, os profissionais que trabalham 
na área da geriatria, principalmente os neurologistas e psiquiatras, têm de dar assistência e 
tomar decisões a respeito de um número considerável de indivíduos que surgem diariamente 
com queixas cognitivas. Isto ocorre numa altura em que se começam a integrar meios 
complementares de diagnóstico mais inovadores e dispendiosos, assim como ensaios clínicos 
com potenciais tratamentos dirigidos às causas da demência, mas num contexto socio-
económico onde as restrições financeiras se encontram bem patentes. Assim sendo, urge 
avaliar no momento presente o risco de progressão para demência o mais precocemente 
possível, de modo a identificar se existe uma probabilidade baixa de futura conversão para 
demência, caso em que um acompanhamento regular e manutenção das medidas de prevenção 
serão os procedimentos mais adequados, ou se pelo contrário existe um risco elevado, caso 
em que será mais adequando propor a realização dos meios complementares de diagnóstico 
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Illustration dating from the 1500s and published at the Guild Book of the 
Barber-Surgeons of York portraying the four temperaments, top-down 
left-right, melancholic, sanguine, choleric, and phlegmatic, respectively. 
The phlegmatic humour denoting apathy or sluggishness was back then 
associated with old age. Printed by permission of The British Library 
(R97/1263). Source: Berchtold and Cotman, 1998.  
mais inovadores e dispendiosos, assim como referenciar o indivíduo para iniciar os 
tratamentos dirigidos aos mecanismos causadores, assim que os mesmos estiverem 
clinicamente bem estabelecidos. 
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PART I – INTRODUCTION 
1.1 Dementia before Alzheimer’s Disease 
 
The word dementia comes from the Latin dēmēns based on the words de (“down from, 
concerning”) and mēns (“mind”) and had the meaning: out of one’s mind. The medical 
connotation associated to the word was only established by the early eighteenth century, 
however the concern given to age-related cognitive decline dates back to the antiquity. 
Earliest references to age-related mental deficiency in the 7th century BC were attributed to 
the Greek physician Pythagoras. Back then, not only Pythagoras but also Hippocrates, Plato, 
Aristotle and Galen seemed to believe that the aging process was a life phase of expected 
degeneration and inevitable age-related cognitive decline. Some have attributed the semantic 
mutation of the word “senile” to the concept of aging, since the term “senile” was no longer 
perceived as only meaning “advance age” but have become to denote a “demented phase” in 
life. However, the Roman philosopher Cicero was perspicacious enough to observe that the 
aging process with cognitive and/or behaviour deterioration occurred only in some elderly 
people, the ones that Cicero called “weak in will” (Berchtold and Cotman, 1998). Around the 
end of second century AD another insightful differentiation on dementia conditions was 
suggested by Aretheus of Cappadocia who described acute disorders as reversible and chronic 
disorders (for instance dementia) as an irreversible affectation of higher cognitive functions 
(Boller and Forbes, 1998). Clearly, ancient thinkers, like the Latin elegiac poet Maximianus, 
were sharp enough to observe and describe the key cognitive deficits and typical behavioural 
manifestations in old demented subjects. Notwithstanding these poignant perspectives, the 
classification of dementing disorders (see Table 1.1) remained confusing until the late 
nineteenth and twenty centuries. From the ancient Greek and Roman periods to the 19th 
century no major evolution occurred in the conceptualization of the aging process. The next 
important step was taken with the meticulous work of Pinel and Esquirol in the 19th century. 
By presenting a systematic description of mental disorders, it was possible to identify subtle 
differences that set apart senile dementia from other mental diseases, and that way the concept 
became more concrete (Román, 1999). Pinel distinguished four broad groups of mental 
disorders: melancholy, mania, dementia, and mental retardation. Esquirol (one of the most 
outstanding students of Pinel) gave continuity to Pinel’s work through the identification of 
subtypes and categories of mental disorders that became the pillars of modern classification of 
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mental diseases (Cipriani et al., 2011). Until the proposal of the anatomo-clinical model by 
the nineteenth century alienists, dementia was considered no more than an inevitable 
consequence of normal aging process. 
 
Table 1.1 – Different designations for dementia since antiquity and attributed causes.  
Nosologic entities corresponding to “dementia”* Causes of dementia according to Esquirol* 
Alienation Menstrual disorders 
Amentia Sequelae of delivery 
Anoea (extinction of the imagination and judgment) Head injuries 
Dotage or ‘second childhood’ Progression of age 
Fatuitas (silliness) Ataxic fever 
Foolishness Hemorrhoids surgery 
Idiocy Mania and monomania 
Imbecility Paralysis 
Insanity Apoplexy 
Lethargy Syphilis 
Morosis  Mercury abuse 
Organic brain syndrome  Dietary excesses 
Phrenesis Wine abuse 
Senile dementia Masturbation 
Senile psychosis Unhappy love 
Senility Fears 
Simplicity Unfulfilled ambitions 
Stupidity Poverty 
 Domestic problems 
*See source for further references: Boller and Forbes, 1998 
 
 
1.2 Alzheimer’s Disease 
In the 1890s, Alois Alzheimer and Otto Binswanger described the arteriosclerotic brain 
atrophy frequently accompanied by stroke as a necessary precursory event for the 
development of senile brain atrophy and senile dementia (Forstl and Howard, 1991). Alois 
Alzheimer put together the clinical and pathologic changes associated nowadays with 
Alzheimer’s disease during the lecture in the Meeting of the Psychiatrists of South West 
Germany, in 1906. The worldwide known Auguste D. case described a woman with unusually 
marked dementia symptoms before the 50 years, whose brain in post-mortem examination 
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had marked neurofibrillary tangle pathology, neuronal degeneration and widespread amyloid 
plaques. After retrieving the original clinical files written by Alois Alzheimer, it was possible 
to access the description of Auguste D. behaviour and cognitive capacities documented in his 
daily notes, revealing memory deficits, disorientation and extensive cognitive impairment 
(Maurer, Volk and Gerbaldo, 1997). Notwithstading the clinical symptomatology, 
Alzheimer’s eminent colleague and so called founder of modern scientific psychiatry, Emil 
Kraepelin, was reluctant to consider that dementia at the age of 50 was the same as the oldest 
dementia cases. This neurodegenerative disorder, later on called Alzheimer’s disease (AD), 
was considered by that time as a truly unique disease which main clinical and pathological 
concept essentially remained until nowadays. Currently, it is known that Alzheimer’s disease 
can be of familial/genetic or sporadic type. The familial form is rare and usually early-onset, 
occurring in people with 30 to 60 years old and it is caused by changes in three well-known 
inherited genes, amyloid precursor protein (APP), presenilin 1 and presenilin 2. Most people 
with Alzheimer’s disease have the sporadic form, which usually develops after the age of 60. 
Different genetic and environmental abnormalities can contribute to the brain damage in AD. 
The consensual pathophysiological cascade involves synaptic dysfunction in vulnerable areas, 
mitochondrial damage, local inflammatory reaction, oxidative stress and excitotoxicity, 
leading to the formation of neurofibrillary tangles, amyloid accumulation and ultimately 
neuronal loss (Poirier, Danik and Blass, 2001). Although the definite diagnosis still relies on 
the presence of clinical and neuropathological findings, several criteria for the clinical 
diagnosis of dementia have been used, like those from the Diagnostic and Statistical Manual 
of Mental Disorders, fourth edition (DSM-IV-TR; American Psychiatric Association, 2000; 
see Annex, Table 5.2, page 83), and the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10; World Health Organisation, 1992; see Annex, Table 5.2, 
page 83). Perhaps the most common for over 25 years have been the NINCDS-ADRDA 
criteria (see Annex, Table 5.2, page 83; McKhann et al., 1984; Dubois et al., 2007). As 
mentioned in detail below, the NINCDS-ADRDA criteria, first published in 1984, were 
recently revised to take into account the presence of the most recently recognized biomarkers 
associated to the AD neurodegenerative process. Revision of AD criteria sought to identify 
the earliest detectable phase of neurodegeneration and recently a stage of “preclinical AD” 
has also been identified as a period where biomarkers like brain amyloid deposition and 
cerebrospinal fluid tau and amyloid can be detected in vivo (McKhann et al., 2010). 
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1.3 Alzheimer’s Disease before dementia 
Many histopathological studies in Alzheimer's disease revealed that neuronal damage caused 
by the pathophysiological cascade mentioned above (Poirier, Danik and Blass, 2001) starts at 
particular regions of the brain, namely the hippocampal formation and the enthorinal cortex, 
and spreads through the brain as the disease advances. At first the neurodegenerative process 
entails no discernible symptoms, and is afterwards reflected by progressive clinical 
manifestations. The National Institute on Aging and the Alzheimer’s Association Workgroup 
tried to reflect this concept by proposing to stage AD from the early pre-clinical process. The 
first stage is described as asymptomatic cerebral amyloidosis (altered β-amyloid by positron 
emission tomography (PET) or in the cerebrospinal fluid (CSF)), the second stage is 
characterized as asymptomatic amyloidosis plus markers of neurodegeneration (as revealed 
by magnetic resonance imaging (MRI), 18F-FDG (2-Fluoro-2-deoxy-D-glucose) PET and 
altered tau/phospho-tau ratio in the CSF), and stage 3 combines markers of amyloidosis and 
of neurodegeneration plus subtle cognitive and behavioral decline (Sperling et al., 2011). 
Thus, the term degenerative process within the spectrum of AD nowadays covers different 
early phases of AD-related pathology: histopathological data without clinical and biomarker 
data; altered biomarkers without clinical signs; and the presence of only early or advanced 
stages of mental deterioration and cognitive impairment. The core clinical features for 
diagnosis are based on a careful clinical history and examination, combined with cognitive 
assessment, neuroimaging exams and laboratory tests (Ferrer, 2012). The concept of 
Alzheimer´s disease as a disorder that begins ahead of the first symptoms, and certainly much 
before full-blown dementia, thus relies on the recent development of biomarkers. Biomarkers 
of AD can be signs of molecular or structural pathology or indicators of clinical status. This 
differentiation reflects the upstream (alterations that can occur in a prodromal asymptomatic 
phase) and downstream (symptomatic phase) continuum of the disease process. The 
biomarkers have been extensively studied, namely cerebrospinal fluid biomarkers, Aβ1-42, 
total tau protein and hyperphosphorylated tau protein (Csernansky et al., 2002; Simonsen et 
al., 2007; Mattsson et al., 2009; Snider et al., 2009; Tapiola et al., 2009; Mulder et al., 2010); 
inherited pathogenic mutations (amyloid precursor protein, presenilin 1, and presenilin 2) 
(Growdon, 1999; Finckh et al., 2005; Devi et al., 2000; Poorkaj et al., 2001; Tedde et al., 
2003; Lleó et al., 2004; Kumar-Singh  et al., 2006; Theuns et al., 2006; Ringman et al., 
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2012); the topographic pattern of atrophy measured by neuroimaging techniques (computed 
tomography (CT)/MRI); cerebral metabolism/perfusion studied by functional neuroimaging 
(PET with 18F FDG/ PET with Pittsburgh compound B (PiB)/ functional MRI) (Johnson et al., 
2012b; Whitwell et al., 2012; Klunk, 2011; Herholz et al., 2011; Sabuncu et al., 2011; 
Dickerson, 2010; Pedrosa et al., 2010; Svedberg et al., 2009; Mintun et al., 2006; Neugroschl 
and Davis, 2002); and evidence of cognitive decline (neuropsychological assessment) 
(Wagner et al., 2012; Llano et al., 2011; Razani et al., 2011; Jungwirth et al., 2009; Nordlund 
et al., 2008; Hussain, 2007; Rozzini et al., 2007; Tabert et al., 2006; Lehrner et al., 2005; 
Rapp and Reischies, 2005; Scheurich et al., 2005; Tierney et al., 2005; Perry and Hodges, 
2000; Albert, 1996; Claman and Radebaugh, 1991; Haxby et al., 1990). The upstream and 
downstream markers might represent factors of cause or consequence of the disease process, 
consequently appearing at different stages of neurodegeneration (See Figure 1.1).  
 
 
Figure 1.1 - Hypothetical progression of pathological and clinical events that lead to Alzheimer’s disease. 
ADL=activities of daily living. EMCI=early MCI. FDG-PET=18F-fluorodeoxyglucose PET. LMCI=late MCI. 
Source: Petersen, 2010. 
 
One of the most extensively studied molecular biomarker is amyloid beta-protein (Aβ). Aβ is 
produced mainly in the nerve cells of the brain and secreted about 12 hours later into the 
cerebrospinal fluid (CSF), then excreted through the blood–brain barrier 24 hours later into 
bloodstream (Aβ clearance), and finally degraded in the reticuloendothelial system (Bateman 
et al., 2009). The particular species of Aβ 42 amino acids long (Aβ1-42) is the most 
amyloidogenic form of the peptide and forms insoluble aggregates, which start to deposit and 
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accumulate extracellulary as plaques in the brain. Apparently, Aβ1-42 levels are decreased in 
the CSF of AD patients due to the deterioration of physiologic Aβ clearance into the CSF 
(Kawarabayashi et al., 2001). CSF Aβ1-42 concentrations are decreased by about 50% in 
patients with AD dementia or mild cognitive impairment, compared with age-matched 
controls (Hulstaert et al., 1999). This decrease has been associated with enhanced deposition 
of Aβ1-42 in the brain (Fagan et al., 2007). The main component related to intraneuronal 
changes in AD patients is the microtubule-associated tau protein. This protein is expressed in 
neurons, normally acts to stabilize microtubules in the cell cytoskeleton, and is normally 
regulated by phosphorylation. When hyperphosphorylated tau accumulates as paired helical 
filaments it can aggregate inside the nerve cell bodies into deposits known as neurofibrillary 
tangles (Spillantini et al., 1990). In AD patients, tau protein is present in this 
hyperphosphorylated form. Tau protein was quantified in the CSF under the hypothesis that it 
is released extracellularly as a result of the neurodegenerative process. The methods initially 
analyzed all forms of tau, regardless of their phosphorylation status, but hyperphosphorylated 
tau protein (p-tau) has shown more potential as a biomarker. CSF total tau is increased on 
average by approximately two to three times in AD, whereas some phosphorylated tau species 
can be increased by one or two times when compared to control levels (Blennow et al., 1995, 
2001; Andreasen et al., 2001; Buerger et al., 2002; Buerger et al., 2005; Bouwman et al., 
2009; Lewczuk et al., 2008). Notwithstanding the established potential as biomarker of 
disease, CSF tau levels differentiate more accurately between AD patients and controls for 
ages below 70 years old (Bürger née Buch et al., 1999). In comparison to tau protein and 
other biomarkers, CSF Aβ1-42 concentrations have shown to be the most sensitive and 
informative single AD biomarker both in the Alzheimer’s disease Neuroimaging Initiative 
(ADNI) cohort and the ADNI-independent autopsy confirmed cohort, reaching a sensibility of 
96.4% and a specificity of 76.9% (Shaw et al., 2009). However, the values reported 
correspond to a follow-up of 12 months in patients that where in an advanced phase of the 
disease and not in a prodromal phase of neurodegeneration where the detection should be 
most useful. For the ADNI cohort of mild cognitive impairment patients that converted to 
AD, an incidence of AD-like CSF profile was observed in only 86.5% of patients (Shaw et 
al., 2009). To predict accurately the future conversion to dementia, biomarkers assessment 
should be made in cohort studies with longer follow-up periods, because otherwise the risk of 
false negatives is considerable. An example is the ADNI cohort study on the use of 
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neuropsychological, brain imaging, and CSF neurochemical biomarkers for conversion to 
dementia during a follow-up of approximately 2 years that reported a predictive accuracy for 
conversion to dementia of only 64% (Ewers et al., 2012). Longer follow-up periods would not 
only elucidate the specificity of biomarkers but also increase the understanding of biomarkers 
contribution along the disease process. The “biomarker cascade model” (Jack et al., 2010a; 
see Figure 1.1) proposed that specific Aβ biomarkers foretold the development of dementia 
due to Alzheimer’s disease, whereas time-to-dementia would be predicted by measures of 
neurodegeneration severity, such as atrophy in MRI. Abnormal Aβ processing is a central 
feature of Alzheimer’s pathology and a core biomarker for neurodegeneration associated with 
brain injury, atrophy and subsequent cognitive decline (van Rossum et al., 2012). However, 
CSF level of Aβ1-42 does not predict time-to-dementia because there appears to be a plateau 
early in the course of the disease that remains stable afterwards (Ingelsson et al., 2004; Jack et 
al., 2010a,b; van Rossum et al., 2012).  
Historically, neuroimaging techniques have been used to exclude potentially surgically 
treatable causes of cognitive decline, however nowadays these techniques provide priceless 
information about Alzheimer's disease preclinical phase revealing characteristic patterns 
(signatures) of structural and functional cerebral alterations. 
Magnetic resonance (MR) imaging with high spatial resolution allows visualization of subtle 
anatomic changes and thus can help to detect brain atrophy (with T1-weighted volumetric 
sequences) at the initial stages of the disease. The medial temporal lobe, specially the 
hippocampus, is known to be affected at the earliest stages of AD (Braak and Braak, 1995) 
and assessment of atrophy has revealed an accurate predictive value for AD. Visual 
assessment differentiates mild AD from normal aging with sensitivity and specificity of about 
85% (Scheltens et al., 1992; Duara et al., 2008; Burton et al., 2009). Identifying individuals 
with mild cognitive complaints who will progress to AD in the near future from those who 
will not is more difficult, and medial temporal atrophy on MRI only predicts progression with 
sensitivity of approximately 50%-70% and specificity around 70% during a follow-up time of 
3 years (Korf et al., 2004; DeCarli et al., 2007). 
Longitudinal MRI studies of individuals who were initially asymptomatic but who have 
subsequently developed AD revealed that rates of hippocampal atrophy increase gradually 5 
years before diagnosis, and hippocampal volumes were already reduced by about 10% 3 years 
before receiving a diagnosis of dementia due to AD (Johnson et al., 2012). Although 
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volumetric measurements of the volumes of the temporal lobe and hippocampal formation 
have demonstrated that both volumes decreased with age for AD patients and elderly controls, 
the hippocampal formation volume accurately differentiates AD patients from cognitively 
normal elderly individuals, thus being considered a biomarker with relevant potential (Jack et 
al., 1992). In addition to the hippocampal volumetry, the volumetric measurement of the 
entorhinal cortex is valuable in distinguishing patients with AD from elderly controls. In the 
discriminant function analysis, volumetry of the entorhinal cortex yielded a specificity of 94% 
with a sensitivity of 90%. No essential difference was found in the discriminative power of 
entorhinal and hippocampal volumetry (Juottonen et al., 1999). Notwithstanding the 
remarkable value of hippocampal volumetry to differentiate AD patients and elderly controls, 
the accuracy obtained for patients in the prodromal phases of AD is usually much lower, 
ranging from 60% to 74% (Convit et al., 1997; de Santi et al., 2001; Du et al., 2001; 
Pennanen et al., 2004). Moreover, most volumetric studies previously relied on manual 
segmentation, which is time-consuming and requires specific training and is thus not suitable 
to clinical practice. Gerardin and colleagues (2009) presented a study using multidimensional 
classification of hippocampal shape features done automatically to overcome that difficulty 
however, predictive results clearly require confirmation in longitudinal studies with larger 
samples of individuals. 
Several PET tracers are available to assess molecular aspects of Alzheimer’s 
pathophysiological process in vivo. 18F-FDG is a glucose analogue and, as such, its uptake is 
strongly associated with neuronal function. Pittsburgh compound B (11C-PiB) is used in PET 
scans to image beta-amyloid plaques in neuronal tissue, and it is well known that AD patients 
show significantly higher retention of this compound in brain cortical areas (Klunk et al., 
2004; Buckner et al., 2005; Rowe et al., 2007). Although the hippocampus is a structure of 
acknowledged importance to assess the prodromal phase of AD, the early amyloid burden 
apears to spare or is difficult to detect in the hippocampus; therefore 11C-PiB is unlikely to 
replace the need for other imaging techniques on hippocampal formation structures (Schuff 
and Zhu, 2007). 
More recent studies, addressing the question whether these amyloid traces in vivo changed 
longitudinally in patients with AD, revealed that increased cortical 11C-PiB binding was seen 
earlier in mild cognitive impairment patients and decreased 18F-FDG uptake only occurred in 
AD patients (Ossenkoppele et al., 2012). At early stages of the disease, accumulation of Aβ is 
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an ongoing event while no or only minor metabolic changes occur. As the clinical course of 
AD progresses, the amyloid curve flattens and evident generalized glucose hypometabolism 
arises (Jack et al., 2010a). Therefore, an earlier detection of neurodegenerative process would 
be preferable using 11C-PiB scan. According to twin studies, Alzheimer-like β-amyloid plaque 
pathology is influenced by genetic but also environmental/acquired factors that modulate the 
relationship between brain amyloidosis and neurodegeneration and its clinical expression as 
cognitive impairment (Scheinin et al., 2011). Notwithstanding, PiB is an 11C labelled 
compound with a short half-life that can only be used at academic medical centers equipped 
with with a cyclotron, which hampers the widespread use for diagnostic purposes. Besides, 
the extent to which amyloid retention changes over time is not clearly established (Sojkova et 
al., 2011). Moreover, cognitively normal elderly individuals can also present beta-amyloid 
(Aβ) deposition and although a slight 11C-PiB elevation might have a biological relevance 
(Mormino et al., 2009, 2012), endeavors are needed to determine whether ambiguously 
elevated 11C-PiB values represent a biologically meaningful signal. A recent review raised the 
question whether Aβ would be cause or consequence of Alzheimer’s disease symptoms 
because a decreased brain synaptic/metabolic activity, independent of etiology, could lead to 
cognitive decline and indirectly to Aβ deposition (Struble et al., 2010).  
  
1.4 Cognitive markers of Alzheimer’s disease 
Cognitive symptoms have been crucial not only to the diagnosis of Alzheimer’s disease but 
also to staging the neurodegenerative progression (Flicker et al. 1984; Vitaliano et al., 1984; 
Cummings and Benson, 1986; Storandt and Hill, 1989; Storandt, 1991). Moreover, cognitive 
markers were for long proposed to detected future converters to dementia, and may constitute 
a particularly feasible and accessible way to reveal the subjects at risk (Small et al., 1997; 
Stern et al., 1994). 
A lot of recent knowledge about the initial cognitive decline in patients with AD actually 
came from many studies performed in patients with Mild Cognitive impairment (MCI), 
developed as a clinical entity linking healthy aging and dementia. The diagnosis of MCI 
actually relies on the finding of specific alterations in cognitive tests. Petersen and colleagues 
(1999) defined MCI as a condition characterized by subjective cognitive complaints, objective 
memory deficit, normal general cognitive performance and maintained activities of daily 
living (see Annex, Table 5.1, page 82). Thereafter, criteria were revised by Portet and 
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colleagues (2006) and slight changes were introduced to improve the identification of patients 
at high risk of progression to dementia and establish the prognosis more accurately. 
According to this revision, the diagnosis should rely on clinical impression and not on 
memory performance solely, the cognitive complaints gained an important prognostic role, 
some repercussions on complex day-to-day activities might occur due to cognitive 
impairment and, finally, a decline in cognitive function should be detected. The syndrome 
subtype may be recognised as early as the initial evaluation and would correspond to amnestic 
MCI, involving predominant impairment of the memory domain; non-amnestic MCI, 
characterised by slight impairment of multiple cognitive domains (multiple-domain MCI); or 
impairment of a cognitive domain other than of memory (single-domain MCI) (Petersen, 
1998; Portet et al., 2006). 
Later on, the MCI criteria were revised for research purposes and newly biomarkers were 
incorporated to assiste the estimation of the likelihood of conversion to dementia. Albert and 
colleagues (2011; see Annex, Table 5.1, page 82) revised criteria proposed that high 
likelihood was present if a positive Aβ biomarker and a positive biomarker of neuronal injury 
were detected; intermediate likelihood if a positive Aβ biomarker was present whenever 
neuronal injury biomarkers were not tested, or otherwise, if there is a positive biomarker of 
neuronal injury but Aβ biomarkers were not tested. So, if the subject met the core clinical 
criteria for MCI and in addition had positive biomarkers for both Aβ and neuronal injury, this 
would provides the highest level of certainty that over time the individual will progress to AD 
dementia. 
 
We can certainly acknowledge that MCI represents a relevant clinical concept, and 
longitudinal studies in patients with MCI have shed light on changes associated with the 
development of AD. In large epidemiological studies performed in subjects above 65 years 
old, about 5% have Alzheimer’s disease (Lobo et al., 2000), and as much as 16% suffer from 
MCI (Artero et al., 2006). The term MCI assumes that some type of cognitive continuum 
exists between normality and Alzheimer’s disease, the main cause of dementia (Jelic, 
Kivipelto and Winblad, 2006; Portet et al., 2006), since it corresponds to a condition likely to 
progress to Alzheimer’s disease (AD) at an accelerated rate with well-established reports of 
conversion in a clinical setting of about 80% in 6 years (Petersen et al., 2001b; Portet et al., 
2006). Patients suffering from AD at a prodromal stage have been, mostly, clinically 
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classified as amnestic mild cognitive impairment (MCI) (Petersen et al., 1999; Dubois and 
Albert, 2004), but not all patients with amnestic MCI will develop AD. The consideration of 
different cognitive and functional factors for MCI diagnosis is important to better predict 
future conversion in dementia (Saxton et al., 2009). A decline in episodic memory, confirmed 
by neuropsychological tests, has been the hallmark to identify a prodromal phase of AD and 
establish the diagnosis (Dubois et al., 2007; Albert et al., 2011), however cognitive changes 
may be observed 3 to 4 years before the diagnosis of MCI (Howieson et al., 2008). The MCI 
condition may not have the same evolution for all patients, however amnestic MCI (aMCI) 
with consistent memory loss preferentially progresses to AD (Petersen et al., 2001a). Patients 
categorized as having aMCI have roughly 8.6-fold higher odds of developing AD than 
patients without evident memory impairment on neuropsychological testing. Since MCI is a 
heterogeneous entity and different pathological processes may contribute to the cognitive 
impairment, it is reasonable to expect different trajectories of cognitive decline among people 
with MCI and heterogeneous outcomes (Xie, Mayo and Kosk, 2011). Cognitive domains can 
be affected differently in MCI subtypes and, although episodic memory has been pointed out 
as the core deficit observed early in the course of the disease, multi-domain MCI patients 
convert at a higher rate to dementia (Tabert et al., 2006; Mitchell et al., 2009; Peraita, García-
Herranz and Díaz-Mardomingo, 2011). From what is known from the pathological 
progression of Alzheimer’s disease, we could expect that impairment in several cognitive 
areas might relate to a more advanced neurodegeneration stage.  
On the other hand, the MCI concept has some important limitations. Since it represents a 
phase of cognitive decline between normality and dementia, it is a clinical description of a 
stage rather than a disease itself (Gauthier et al., 2006). Heterogeneity of MCI entity also 
requires more careful consideration, regarding not only the MCI subtype but also the criteria 
by which it is diagnosed, as well as the neuropsychological tests used and the cutoff selected, 
all of which can interfere with the predictive accuracy of MCI (Ritchie and Tuokko, 2010; 
Trittschuh et al., 2011; Silva et al., 2012). Some patients with MCI remain intriguingly stable 
for a very long period of time and it is not certain if they will eventually progress to dementia 
(Petersen et al., 2001a,b). Clearly, the MCI diagnosis is not sufficient or a necessary condition 
for progression to dementia (Nunes et al., 2010). Moreover, 10–20% of persons meeting 
criteria for MCI at a particular time will not progress to dementia (Petersen, 2003), and some 
may even revert to normal levels, at least in community-based studies (Ritchie, 2004). 
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Although the probability of patients without objective memory decline to develop AD is 
small, some patients convert to AD (Lehrner et al., 2005). More longitudinal studies are 
needed to assess the way in which cognitive impairments develop during the MCI phase. 
Recently, need to identify markers of progression, independently of MCI diagnosis, in the 
subjects more prone to progress to AD dementia was emphasised (Tian et al., 2003; Powell et 
al., 2006; Andersson et al., 2008; Craig-Schapiro, Fagan and Holtzman, 2009; Jungwirth et 
al., 2009; Leow et al., 2009; Lekeu et al., 2010). 
Cognitive deficits may appear many years before the clinical diagnosis of AD, almost 7 years 
before it is possible to detect deficits on verbal memory. However, the magnitude of these 
deficits is relatively small, up until the point at which the diagnosis of AD is rendered (Linn et 
al., 1995; Small et al., 2000). In younger samples of cognitively impaired people this stability 
on performance is even more noticeable, with obvious compromise of specificity for 
predictive diagnosis (Anstey et al., 2008). Episodic memory deficit is a constant, precocious, 
and reliable neuropsychological marker of AD in relation to early involvement of medial 
temporal structures, namely hippocampal formation (Deweer et al., 1995). Memory 
impairment, in close association to reduced hippocampal volume, contributes to the decrease 
in temporoparietal metabolism associated with AD (Kuczynski et al., 2008). Other studies 
also mention motor speed as an early predictor of AD, representing a type of age-related 
slowing of functions that associated with deficits in episodic memory could indicate a 
preclinical phase of AD (Jungwirth et al., 2009). Importantly, the inability to recall 
information from a prose passage suggests impaired encoding of the contextual information 
that makes up complex events (Rubin et al., 1998). Since the episodic memory deficit of AD 
patients is due in large part to ineffective consolidation or storage of new information, the 
assessment through tasks of word list learning may also be very useful to identify reduced 
free and cued recall, impaired recognition, and impaired associative learning. Indices of rapid 
forgetting have clinical utility for the early detection of prodromal AD, but decreased use of 
memory aids might also be a relevant marker and was associated with poorer performance on 
verbal memory tests (Archer et al., 2007). Brain areas underlying acquisition and 
consolidation of new information are expected to be impaired at a very early stage of AD 
process. Regarding the brain correlates of consolidation, hippocampal structures are 
responsible for the efficacy of learning and initial storage of new information, whereas 
acquisition is associated with a broader brain network and is severely impaired earlier in AD 
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progression than short or even long-term consolidation, sometimes referred to as retention 
(Genon et al., 2012). The explicit semantic encoding of new information, namely through 
association, is affected in AD patients, reflecting decreased metabolism in the hippocampus, 
which accounts for the described acquisition deficits in these patients (Sperling et al., 2003). 
Besides acquisition, the retrieval component of episodic memory was shown to be altered 
through increased sensitivity to interference associated to decreased inhibitory processes, 
which leads to the production of more intrusion errors in AD patients (Delis et al., 1991). 
Similarly, confabulation in episodic memory has been described in AD patients, particularly 
the "provoked" confabulation present in story recall tasks, while spontaneous confabulation is 
detected in the more advanced stages of disease (Kopelman, 1987). Beyond impairment in 
semantic encoding, AD patients show deficits in semantic memory, probably due to 
progressive loss of semantic knowledge (Mårdh, Nägga and Samuelsson, 2012), even though 
the semantic alteration has been previously proposed to be dependent of inhibitory deficits 
affecting semantic search (Duong et al., 2006). Semantic deficits are revealed in cognitive 
assessment of AD patients by impairment of lexical or perceptual means of semantic access, 
rather than on word and object meaning, more consensually associated with semantic 
dementia (Balthazar et al., 2007; Reilly et al., 2011). AD patients show deficits in semantic 
category fluency more frequently than deficits in letter fluency, which relies on initiative and 
retrieval supported by subcortical frontostriatal circuits (Rosser and Hodges, 1994). Despite 
the presence of executive or frontal components in the initiative nature of fluency tasks, they 
are often defined as language tests (Lezak, Howieson and Loring, 2004). Language 
impairment is not considered a foregoing indicator of prodromal AD, however the tasks that 
imply reaction time, such as category fluency, are sensitive to MCI and predictive of future 
conversion to AD, even if mainly for amnestic MCI patients (Taler and Phillips, 2008). Not 
only semantic fluency, but also complex language abilities have been described to be 
impaired in MCI patients (Ribeiro, de Mendonça and Guerreiro, 2006). Indeed, despite the 
importance given to the memory deficits in prodromal phases of AD, the presence of deficits 
in other cognitive areas has been pointed out consistently in patients at risk of conversion to 
dementia (Lekeu et al., 2010). Beyond the expected deficits in episodic memory, individuals 
at risk of future conversion to dementia might show deficits in executive functioning as well 
(Chen et al., 2000; Reinvang, Grambaite and Espeseth, 2012). Impairment in executive 
functioning might be a potential marker of conversion to AD, particularly of a more rapid 
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progression (Rozzini et al., 2007; Musicco et al., 2010). Deficits in executive functioning 
have been hypothesized to reflect AD pathology, especially neurofibrillary tangle burden in 
prefrontal cortex (Weintraub, Wicklund and Salmon, 2012). The dorsolateral prefrontal cortex 
is required for the efficient working memory performance, although the contribution of all 
working memory components is not expected to be equal, since there is primarily a disruption 
of the central executive control with relative sparing of immediate memory (Baddeley et al. 
1991; Collette et al. 1999). Noteworthy in prediction on cognitive decline are the attentional 
systems, because they represent an important neuropsychological criterion for the diagnosis of 
Alzheimer's disease, may precede other cognitive impairments, and most of all have a 
substantial impact on the patient's capacity to cope independently (Perry and Hodges, 1999). 
The capacity to divide attention with dual-task performance is of interest because it appears to 
be qualitatively different in AD patients as compared to normal ageing (Baddeley et al., 
2001). According to Perry, Watson and Hodges (2000), capacity to resist distraction and 
rapidly switch attention may be the most sensitive aspect of attentional resources that decline 
even earlier than sustained and divided attention. Since cognitive impairment is not restricted 
to verbal memory impairment, and assessment of other cognitive areas may add relevant 
insight concerning the stage of impairment, a comprehensive neuropsychological battery is an 
essential tool to identify subjects at risk of future conversion to dementia. Importantly, so far 
literature has suggested that cognitive markers at baseline could be as robust predictors of 
conversion as other biomarkers, like regional brain volumes, cerebrospinal fluid levels of Aβ1-
42 and total tau (Gomar et al., 2011). 
One common criticism made to studies using biomarkers and/or cognitive measures as 
predictors of future conversion to dementia is the limited follow-up periods (Jack et al., 
2010b; Biagioni and Galvin, 2011; Lo et al., 2011; Tschanz et al., 2011; Mattsson et al., 
2012a,b; Thurfjell et al., 2012; Zabel et al., 2012; Zhang and Shen, 2012). Longitudinal 
studies testing biomarkers predictive value for the conversion of MCI patients to dementia 
have highlighted the fact that, since conversion occurs at a rate of 8–15% a year, it is relevant 
to have a long follow-up period (>4 years) (Hansson et al., 2006).  
Extensive work has been done to more reliably identify the earliest phases of Alzheimer’s 
disease, in parallel with scientific research on the discovery of new ways of more effectively 
managing the disease and its symptoms. Importantly, some studies allow patients to undergo 
interventions that might involve manipulation of risk and protection environmental factors. 
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Efforts have been made to offer to the patients the participation in cognitive rehabilitation 
procedures and clinical trials with putative new neuroprotective drugs. Research into disease 
modifying drugs for AD has received much attention on the premise that the earlier these 
drugs can be administered, before accumulation of significant neuronal damage, the higher 
the likelihood of maintaining and improving cognitive function. In this context, sensitive 
cognitive screening tools for earlier phases of neurodegeneration are needed to identify non-
demented patients with cognitive complaints that have a high probability of progression to 
dementia. One possible path to reach this goal is the development of advanced statistical 
classification methods derived from data mining and machine learning methods, like Neural 
Networks, Support Vector Machines and Random Forests, that could be used to improve 
accuracy, sensitivity and specificity of predictions obtained from neuropsychological testing. 
Since verbal memory performance is a core predictor of future conversion in AD, it would be 
relevant to compare prediction accuracies of differente verbal memory tests currently used in 
clinical practice. Perhaps even more important, the predictive accuracy of neuropsychological 
assessment may be critically dependent upon the follow-up time defined to establish 
conversion to dementia. Longer follow-up periods may improve the reported 
sensitivity/specificity rates of cognitive markers and therefore contribute to the earlier 
diagnosis of AD, and also establish a more clinically relevant prognosis. As an ultimate goal, 
it would be needed to find better cognitive markers for the evaluation of non-demented 
patients with cognitive complaints, in order to establish if there is a low probability of 
progression to dementia, in which case a regular follow-up and general preventive measures 
might be indicated, or a high probability of progression to dementia, so that in this case the 
patient could be a possible candidate to undergo complex ancillary examinations and new 
disease-modifying treatments. 
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PART II – STUDY DESIGN 
2.1 Objectives 
 
The main objective is to improve the predictive accuracy provided by neuropsychological 
tests for future conversion to dementia of non-demented patients presenting with cognitive 
complaints. For this purpose, four secondary goals will be addressed. 
 
The first is to review the literature of published longitudinal studies assessing the sensitivity, 
specificity and effect sizes of neuropsychological tests to predict future conversion to 
dementia of patients with Mild Cognitive Impairment (MCI). 
 
The second is to compare the accuracy of statistical traditional classifiers vs. newer data 
mining methods to predict future conversion to dementia of non-demented patients with 
cognitive complains. 
 
The third is to determine the best memory test to include in MCI diagnostic criteria to 
improve the predictive value of MCI regarding conversion to dementia. 
 
And finally, to determine the clinical and neuropsychological factors that predict long-term (5 
years) conversion to dementia. 
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2.2        General methodology 
The Cognitive Complaints Cohort (CCC) is a clinical cohort of non-demented patients with 
cognitive complaints referred for neuropsychological examination during the period 1999-
2007. This cohort was established at the Institute of Molecular Medicine, Lisbon, with the 
collaboration of Centro de Neurociências de Coimbra, and a private memory clinic in Lisbon, 
Memoclínica, and was financed by FCT (grant PIC/IC/82796/2007). The purpose of the CCC 
is to investigate the outcome of subjects with cognitive complaints based on a comprehensive 
neuropsychological evaluation and other biomarkers. The study was approved by the local 
ethics committee. CCC is a large clinical cohort, many subjects have long follow-ups and all 
underwent detailed neuropsychological testing. The CCC comprises 775 subjects. Of these, 
568 (73.3%) were reevaluated, 154 (27.1%) converted to dementia (follow-up 2.5±1.8 years) 
and 414 (72.9%) did not (follow-up 2.8±2.1 years). For the reevaluations of the patients, it 
was possible to take advantage of the fact that most patients have regular clinical 
consultations at the participating institutions to schedule the reassessments. Subjects who did 
not attend clinical consultations were contacted by telephone and invited to come to one of 
the participating institutions to perform the same neuropsychological battery of baseline 
assessment. Whenever it was not be possible to re-assess the patient in person, a preliminary 
evaluation was performed during a telephone call using two validated telephone 
questionnaires to identify mild cognitive impairment or dementia (Van Uffelen et al., 2007; 
Kawas et al., 1994). The selection of patients to enter CCC was established according to the 
following criteria: 
 
Inclusion criteria: 
1) Presence of cognitive complaints; 
2) Referral to neuropsychological examination, during the period 1999-2007, at the 
Laboratory of Language, Faculty of Medicine of Lisbon; Memoclínica, a private memory 
clinic in Lisbon; and the Dementia Clinics, Hospitais da Universidade de Coimbra. 
 
Exclusion criteria: 
1) dementia (according to DSM-IV criteria (APA, 2000)); 
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2) disorders that may cause cognitive impairment, like stroke, tumour, significant head 
trauma, haematoma, epilepsy, psychiatric disorders, uncontrolled medical illness 
(hypertension, metabolic, endocrine, toxic and infectious diseases); 
3) treatments interfering with cognitive function; 
4) alcohol or illicit drug abuse.   
 
Neuropsychological assessment 
The neuropsychological results were standardized according to the age and education norms 
for the Portuguese population (BLAD; Garcia, 1984). Impairment on any test was considered 
if a subject scored more than 1.5 standard deviations below the mean for his age and 
education.  
The detailed neuropsychological assessment was carried out by the same team of trained 
neuropsychologists and comprised:  
Battery of Lisbon for the Assessment of Dementia (BLAD; Garcia, 1984) – the battery 
includes tests for the following cognitive domains: attention (Cancellation Task), Verbal 
Semantic Fluency (food products), Motor and Graphomotor Initiatives, verbal comprehension 
(a modified version of the Token Test), verbal and non-verbal abstraction (Interpretation of 
Proverbs and the Raven Progressive Matrices), visuo-constructional abilities (Cube Copy) and 
executive functions (Clock Draw), calculation (Basic Written Calculation), short-term 
memory and working memory (Digit Span), verbal memory and learning (Logical Memory, 
Verbal Paired-associate Learning and Word Recall). 
Mini-Mental State Examination (MMSE; Folstein, Folstein and McHugh, 1975; Guerreiro, 
1998) – the MMSE is one of the most widely used clinical instruments for a brief evaluation 
of cognitive status in adults.  
Trail Making Test – part A and part B (TMT; Reitan, 1958) – the TMT part A measures 
psychomotor speed and attention, and part B assesses the ability to shift strategy, executive 
functions and visual spatial working memory. 
Toulouse-Piéron Test (TP; Toulouse Y and Piéron H, 1986; Mendelsohn, 2000) – the TP 
assesses two components of focused attention: processing speed (sustained attention) and 
accuracy (selective attention). 
California Verbal Learning Test (CVLT; Delis et al., 1987; Ribeiro, Guerreiro and de 
Mendonça, 2007) – the CVLT measures verbal learning assessing constructs such as 
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repetition learning, serial position effects, semantic organization, intrusion, and proactive 
interference. The word lists (List A and List B) are made up of 16 items from 4 different 
categories of “shopping list” items. The trials of interest for the present study are: A1 (number 
of words from List A correctly recalled on the first trial); A5 (number of words from List A 
correctly recalled on the fifth trial); Atot (the total number of words from List A correctly 
recalled on the five learning trials); B (number of words from List B correctly recalled); 
SDFR/Short-delayed free recall (number of words from List A correctly recalled after 
spontaneous recall of List B); SDCR/Short-delayed cued recall (number of words from List A 
recalled in a semantic cued task after short-delayed free recall); LDFR/Long-delayed free 
recall (number of words from List A correctly recalled after an interference period of 20 
minutes); LDCR/Long-delayed cued recall (number of words from List A correctly recalled in 
a semantic cued task after long-delayed free recall); Rec/Recognition hits (number of words 
from List A correctly recognised on the recognition trial). 
Clinical Dementia Rating scale (CDR; Morris, 1993; Portuguese version in Escalas e Testes 
na Demência. 2nd Ed., 2008) – a structured-interview protocol that assesses a patient's 
cognitive and functional performance in six areas: memory, orientation, judgment and 
problem solving, community affairs, home and hobbies, and personal care, in order to 
quantify the severity of dementia symptoms. 
Blessed Dementia Rating Scale (BDRS; Blessed et al., 1968; Portuguese version in Escalas e 
Testes na Demência. 2nd Ed., 2008) – the BDRS is a brief behavioural scale based on the 
interview of a close informant, it assesses functional capacity for activities of daily living and 
changes in personality. 
Geriatric Depression Scale (GDS; Sheikh JI and Yesavage JA, 1986; Almeida and Almeida, 
1999; Portuguese version in Escalas e Testes na Demência. 2nd Ed., 2008) – the GDS is a 30-
item self-report assessment used specifically to identify depression in the elderly. For this 
study a short-form (15 items) of the self-report instrument was used. 
 
Outcome 
The outcome of subjects in the CCC will be determined in a consensus meeting with the 
neurologist and the neuropsychologist. Participants will be considered demented if they have 
multiple cognitive deficits and decline from a previous level, with clear social and 
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occupational impairment, not explained by a delirium, according to the DSM-IV-TR criteria 
(DSM-IV-TR, APA, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints  
Biomedical Sciences Doctoral Program – Faculty of Medicine – University of Lisbon 
 
Dina Lúcia Gomes da Silva 21 
PART III – RESULTS 
3.1 Neuropsychological assessment and progression to dementia: systematic 
review (manuscript in preparation) 
3.1.1 Rationale  
Neuropsychological assessment has been a crucial diagnostic tool for the characterization of 
cognitive deficits along progressive stages of dementia. Importantly, cognitive decline begins 
several years before clinical diagnosis of dementia and subjects in prodromal phases already 
reveal significantly poorer cognitive performance than normal elderly on several 
neuropsychological tests, as a corollary of the underlying pathologic processes (Wilson et al., 
2011). Presence of impairment in neuropsychological tests was associated to further cognitive 
decline and progression to Alzheimer’s disease (AD). This progression, or in other words, the 
transitional stage between normal aging and AD, is known nowadays as a clinical entity 
named Mild Cognitive Impairment (MCI). Although MCI patients are known to be at higher 
risk for cognitive decline than healthy elderly, there is relevant heterogeneity associated to the 
concept, since MCI patients decline at different rates and some never develop AD. The 
amnestic form of MCI (aMCI; i.e., patients presing with isolated deficit in verbal episodic 
memory assessment) is considered the prodromal phase of AD (Petersen et al., 2001a), 
nevertheless the predictive value of diagnosis is dependent on the type of verbal episodic 
assessment applied, follow-up duration, among other conditions (Visser et al., 2006). For 
several years now, longitudinal studies of clinical cohorts of patients diagnosed as MCI to 
predict future conversion to AD based on neuropsychological tests have been published. The 
purpose of the present review is to collect from original published articles the values of 
sensitivity, specificity and effect sizes for neuropsychological tests to predict conversion to 
dementia in patients at risk of future cognitive decline. 
Procedure 
Search strategy 
Selection of eligible studies was conducted on Pubmed and Web of Science databases, 
searched from inception to May 2012. Search terms delimited first the condition in study or 
outcome (dementia OR AD OR alzheimer OR alzheimer's OR "cognitive decline" OR 
"cognitive deterioration" OR "cognitive impairment"), then the baseline features of interest 
Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints  
Biomedical Sciences Doctoral Program – Faculty of Medicine – University of Lisbon 
 
22 Dina Lúcia Gomes da Silva 
(AND ("mild cognitive impairment" OR MCI OR presymptomatic OR incipient OR "memory 
impairment" OR preclinical OR "memory impaired" OR "questionable dementia")), and 
finally, the independent variable in study ("cognitive test" OR neuropsychol* OR memory OR 
"executive function" OR "executive functions" OR language OR orientation OR visuospatial 
OR attention OR "abstract reasoning" OR initiative). Filters for the type of study and 
statistical analysis of interest were applied ((cohort OR prospective OR longitudinal OR 
follow-up) AND (sensitivity OR specificity OR "odds ratio" OR "hazard ratio" OR "relative 
risk")). Key words were screened as text words in Pubmed to increase sensitivity, however 
that option was not always possible for Web of Science where only titles were screened. 
Other restrictions were the limitation to human research and English language. Studies 
published either as full paper or as abstract were considered, as long as relevant information 
could be extracted. 
Selection criteria 
Studies were selected according to the following criteria: longitudinal cohort studies; baseline 
sample of cognitively impaired non-demented patients; and report of sensitivity, specificity or 
effect sizes of baseline neuropsychological testing to predict conversion to dementia. Some 
studies had a sub-sample of cognitively normal subjects included in the cohort, and as long as 
the cohort was not limited to cognitively normal subjects they were included. Access to full 
content of published paper was compulsory to extract the data. Data presentation in the paper 
should also be clear and straightforward to allow the proper fulfilling of the predefined form.  
Data extraction 
Data from selected studies were inserted in the predefined form filling demographic, 
procedural and neuropsychological information. Predefined form was established in a 
consensus meeting with experts on literature review and meta-analysis. Information extracted 
from each study corresponded to: first author and year of publication; country of origin and 
designation of cohort study; main sample characteristics; follow-up time and outcome; 
cognitive domain and neuropsychological tests; predictive value of neuropsychological tests 
for conversion to dementia reported as sensitivity, specificity and different types of effect 
sizes. Authors were not contacted to provide additional data. More specific information 
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concerning cut-off scores or adjustment for confounders was not included in the present 
predefined form for a better synthesis of information but will be explored in further studies.  
3.1.2 Results 
Five hundred and four studies were retrieved from Pubmed database and 34 from Web of 
knowledge from inception to May 2012. Twenty-four studies were considered eligible 
according to selection criteria already mentioned and the summary of data extracted is shown 
in Table 3.1.1. 
Studies selected for the present review were published in the last 20 years and are 
representative of population from Europe (United Kingdom, France, Austria, Italy, Belgium 
and Ireland), as well as North and South America (USA and Brazil). 
Cohort characteristics differed widely across studies in sample size and criteria for diagnosis 
of cognitive impairment at baseline. Sample sizes ranged from 31 to 320 subjects that were 
considered mildly impaired according to Global Deterioration scale, Clinical Dementia Rating 
scale, “questionable dementia/Alzheimer’s disease” criteria, and Mild Cognitive Impairment 
criteria (see Table 3.1.1).  
Some studies (n=5) presented conversion rates higher than expected from what has been 
usually reported, for instance, conversion rates ranging from 41% to 72% of the sample in a 
follow-up period of approximately 2.5 years. Nevertheless, the majority of the studies showed 
in Table 3.1.1 and analysed for the present review have annually conversion rates not 
overcoming 15%.  
Approximately half of the studies presented a number of females that outnumbered males. 
Mean age reported for the baseline sample was more than 60 years old for the 24 studies. 
Mean years of education ranged from 7.5 to 17 years. Follow-up times reported were of 
around 2/3 years for 80% of the studies. 
Neuropsychological tests administered varied considerably among studies, yet the battery of 
tests applied always assessed verbal memory performance, and many included also cognitive 
areas such as executive functions, attention and language (Flicker, Ferris and Reisberg, 1991; 
Tierney et al., 1996; Devannand et al., 1997; Griffith et al., 2006; Tabert et al., 2006; Blacker 
et al., 2007; Dickerson et al., 2007; Rozzini et al., 2007; Sarazin et al., 2007; Gallagher et al., 
2010; Lekeu et al., 2010; Aretouli et al., 2011). 
Some studies have reported rather disparate global sensitivity and specificity values for the 
neuropsychological tests to predict conversion to dementia (Devannand et al., 1997; Sarazi et 
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al., 2007; Rabin et al., 2009; Gallagher et al., 2010). Conversely, other studies reported high 
and balanced sensitivity/specificity ratios (≥80%) and effect sizes (HR=4.68, RR=12.26,), 
mainly for verbal episodic memory tests, and also for verbal initiative and executive functions 
tests, however the follow-up period of those studies was generally short (≈2 years) (Flicker, 
Ferris and Reisberg, 1991; Lehrner et al., 2005; Sarazin et al., 2007; Landau et al., 2010; 
Aretouli et al., 2011). 
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Table 3.1.1 – Review of literature concerning predictive value of neuropsychological tests for future conversion to dementia  
First author, 
publication 
year  
Country 
(Cohort 
Study) 
Sample characteristics 
[Cohort and follow-up groups; gender %; 
mean age±standard deviation (SD) or 
standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Flicker, 1991 
USA 
32 mildly impaired subjects consecutively 
screened at the Aging and Dementia 
Research Center of NYU Medical Center 
with Global 
Deterioration Scale (GDS) rating of 3; 
Follow-up: 23 decliners and 9 
nondecliners;Gender: NS (not specified); 
Age: 71.3±1.4; 
Education: 13.1±0.6. 
2.11±0.09; significant cognitive 
deterioration 
  
 
Verbal recall  Shopping List 90.0 94.7 Not reported (NR) 
Visuospatial recall Misplaced Objects 70.0 93.3 NR 
Language  
 
 
  
Object Function Recognition 85.7 100.0 NR 
Object Identification 57.1 100.0 NR 
Tierney, 1996 
Canada 
 
123 non-demented patients with memory 
impairment (Global Deterioration Scale of 
2 or 3);  
Follow-up: 29 converted to Probable AD 
and 94 were cognitively impaired; 
Gender: NS; 
Age: 13.48±3.02 Probable AD group; 
71.51±7.83 cognitively impaired group 
(p=0.14); 
Education: 13.48±3.02 Probable AD 
group; 14.13±3.26 cognitively impaired 
group (p=0.35). 
≈ 2 years; Probable AD 
C
om
po
si
te
 m
ea
su
re
 
Verbal episodic 
memory and 
learning 
Rey Auditory Verbal Learning 
Test (RAVLT) 
75.9 93.6 NR 
Wechsler Memory Scale 
(WMS; Paired-Associate 
Learning subtest) 
Wechsler Memory Scale 
(WMS; Logical Memory 
subtest) 
Mental control Wechsler Memory Scale 
(WMS; Mental Control subtest) 
Sustained 
attention 
Trail Making Test A 
Verbal 
Fonologic 
Fluency 
Controlled Oral Word 
Association Test (F,A,S) 
Executive 
functions 
Trail Making Test B 
Devanand, 
1997 
USA 
62 cognitively impaired patients defined as 
“questionable dementia”; 
Follow-up: 26 converted to dementia; 36 
did not converted; 
Gender: 59.1% females; 
Age: 66.2±10.0 (68.6±9.8 dementia group 
at follow-up and 63.0±8.5 stable group, 
p=0.010);  
Education: 14.2±3.1 (no significance 
difference among follow-up groups). 
2.5±1.7; dementia 
 
Verbal memory Mini-Mental State Examination 
(MMSE) three words delayed 
recall task 
66.7 71.0 NR 
Selective Reminding Test 
(long-term retrieval) 
76.0 55.6 NR 
Language and initiative  Category Fluency (naming 
animals) 
59.3 55.6 NR 
Abstract reasoning, visuospatial 
abilities and processing speed  
(WAIS-R) 
Digit subtest 74.1 43.5 NR 
Picture Arrangement subtest 80.0 58.3 NR 
Block Design subtest 78.6 50.0 NR 
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First author, 
publication 
year  
Country 
(Cohort 
Study) 
Sample characteristics 
[Cohort and follow-up groups; gender %; 
mean age±standard deviation (SD) or 
standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Tian, 2003 
UK 
129 “questionable dementia” patients seen 
in a National Health Service hospital 
outpatient clinic 
Follow-up: 37 converted to dementia; 92 
remained stable; 
Gender: 47.3% females; 
Age: 73.2±8.5 dementia group; 68.7±10.2 
stable group (p=0.020); 
Education: 10.8±3.0 dementia group; 
10.9±2.6 stable group (p=0.848). 
2.04±1.64; dementia Episodic memory, initiative and 
executive functions 
Hopkins Verbal Learning Test 
(verbal recognition) and Letter 
Fluency  
64.4 76.7 NR 
Amieva, 2004 
France 
90 elderly volunteers diagnosed as MCI 
Follow-up: 29 converted to dementia and 
61 remained MCI; 
Gender: Converters females 24.1%; non-
converters females 54.1%; 
Age: 73.3±5.8 converters; 
68.7±7.9 non-converters (p=0.0025); 
Education: Primary school diploma 89.7% 
converters; 88.5%  non-converters 
(p=0.99). 
≈ 2 years; dementia Selective attention ability Letter Cancellation Task (LCT) 
– total score 
NR NR OR=0.98* 
LCT-subtest 1 (crossing of a 
target letter randomly 
distributed among distractor 
items) 
NR NR OR=0.96* 
LCT-subtest 2 (crossing of a 
target letter surrounding a 
space) 
NR NR OR=0.94* 
LCT-subtest 3 (task combining 
both LCT1 and LCT 2 
instructions) 
NR NR OR=0.95* 
Lehrner, 
2005 
Austria 
 
107 patients with memory complaints (22 
aMCI; 85 cognitively normal); 
Follow-up: 14 converters; 93 non-
converters; 
Gender: 40.9% females in the aMCI 
group; 60% females in the cognitively 
normal group; 
Age: 71.8±4.6 demented group; 
66.1±8.6 non-demented group 
(p=0.017); 
Education: 10.0±3.7 demented group; 
11.8±3.6 non-demented group (p=0.085). 
1.84±0.68; Convertion of 
patients with memory 
complaints to dementia 
Global cognitive status Mini-mental Status 
Examination 
83 68 NR 
General intelligence Wortschatztest (WST) 
vocabulary test 
64 63 NR 
Verbal short-term memory Digit Span (HAWIE-R) 35 72 NR 
Non-verbal short-term memory Corsi Block Tapping (block 
span)  
72 60 NR 
Concentration capacity Alters-Konzentrations (AKT) 63 67 NR 
Visuospatial abilities and 
processing speed 
Wechsler Adult Intelligence 
Scale (digit-symbol) 
81 76 NR 
Visual associative memory Memory Assessment Clinics 
(MAC) (misplaced objects) 
83 73 NR 
Verbal memory MAC (name-face association) 71 75 NR 
MAC (selective reminding total 
recall) 
79 78 NR 
MAC (selective reminding 
delayed recall) 
87 85 NR 
MAC (first-last names) 66 68 NR 
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First author, 
publication 
year  
Country 
(Cohort 
Study) 
Sample characteristics 
[Cohort and follow-up groups; gender %; 
mean age±standard deviation (SD) or 
standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Facial memory MAC (recognition of faces) 58 65 NR 
Spatial/topographic memory MAC (topographic memory) 63 71 NR 
Griffith, 2006 
USA 
49 Mild Cognitive Impairment patients; 
49 normal control participants 
Age: 68.47±8.65 MCI patients; 
65.92±7.66 controls 
Education: 13.39±2.03 MCI patients; 
13.55±1.40 controls 
≈ 2 years; MCI conversion to 
dementia 
Memory and executive functions Dementia Rating Scale 
(initiation/perseveration item) 
and Visual Reproduction 
Percent Retention 
76.9 88.9 NR 
Tabert, 2006 
USA 
 
148 patients reporting memory problems 
(Mild Cognitive Impairment) (and a sub-
sample of 115 MCI patients with a fixed 
follow-up period of 3 years); combined 
sample of 83 controls recruited by 
advertisement and participation in other 
studies; 
Follow-up (n=148): 39 (26.4%) MCI 
patients converted to AD; 
Gender (n=148): 56.4% females 
converters; 55.0% females non-converters 
(p=0.85);  
Age (n=148): converters 72.6±7.2; non-
converters 65.0±10.0 (p=<0.001);  
Education (n=148): converters 14.1±4.4; 
non-converters 15.4±4.2 (p=0.11).  
3 years; MCI conversion to 
dementia 
Verbal memory, visuospatial 
abilities and processing speed 
Selective Reminding Test 
(SRT; immediate recall) and 
Wechsler Adult Intelligence 
Scale-R (Digit Symbol test) 
76% 90% NR 
3.9 ±2.1; MCI conversion to 
dementia 
Verbal memory  SRT (immediate recall) NR NR OR=1.10* [1.06-
1.14] 
SRT (delayed recall) NR NR OR=1.09* [1.05-
1.12] 
Non-verbal memory Wechsler Memory Scale- 
visual reproduction subtest 
NR NR  OR=1.03* [1.01-
1.06] 
Visuospatial abilities and 
processing speed 
Wechsler Adult Intelligence 
Scale -R Digit Symbol Test 
NR NR OR=1.09* [1.04-
1.14] 
Language Action Naming Test (ANT) NR NR OR=1.04* [1.01-
1.08] 
Boston Naming Test (BNT) NR NR OR=1.01* [1.00-
1.03] 
Blacker, 2007 
USA 
 
235 Mild Cognitive Impairment patients; 
107 cognitively normal subjects 
Follow-up: 69 of MCI converted in AD; 7 
of normal converted in AD 
Gender: 56.6% females in the MCI group; 
59.8% females in the normal group 
(p>0.05); 
Age: 72.90±5.8 MCI; 71.38±4.6 normal 
group (p=0.009); 
Education: 15.41±2.9 MCI; 15.64±2.9 
normal group (p>0.05). 
4.1±3.2; MCI conversion to 
AD 
Episodic memory 
 
California Verbal Learning 
Test (total score from trials 1-
5) 
NR NR HR=0.59* [0.44-
0.78]  
Selective Reminding Test NR NR HR=0.52* [0.40-
0.66]  
Language and executive functions 
 
Trail Making Test B NR NR HR=1.64* [1.28-
2.10]  
Letter Fluency Test (total of  F, 
A, and S)  
NR NR HR=0.64* [0.48-
0.84]  
Self Ordering Test NR NR HR=1.04 [0.98-
1.10]  
Alpha Span Test NR NR HR=0.76 [0.58-
1.00]  
Dickerson, 
2007 
244 community volunteers (167 Mild 
Cognitive Impairment, Clinical Dementia 
Rating (CDR)=0.5; 77 normal, CDR=0) 
≈ 5 years; conversion of 
community volunteers to 
probable AD 
Severity of cognitive impairment 
in daily life 
Clinical Dementia Rating (sum 
of boxes) 
 
NR NR OR=4.8*  [3.0-7.8] 
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First author, 
publication 
year  
Country 
(Cohort 
Study) 
Sample characteristics 
[Cohort and follow-up groups; gender %; 
mean age±standard deviation (SD) or 
standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
USA Follow-up: 107 (44%) subjects evidenced 
clinical decline (increase in CDR-SB_1.0) 
of whom 42 (17% of the sample) were 
diagnosed with probable AD; 137(56.1%) 
remained stable; 
Gender: 92% females in the MCI group; 
47% females in the normal group (p>0.05); 
Age: 72.7±5.8 MCI; 71.6±4.5 normal group 
(p>0.05); 
Education: 15.3±2.9 MCI; 15.4±2.8 
normal group (p>0.05). 
Verbal memory Free and cued Selective 
Reminding Test (free recall 
measure) 
NR NR OR=0.57* [0.42-
0.76] 
California Verbal Learning 
Test (CVLT; total learning 
score) 
NR NR OR= 0.62* [0.45-
0.87] 
CVLT (delayed retention 
score) 
  OR= 0.61* [0.46-
0.81] 
Executive functions Trail Making Test (part B)  NR NR OR= 0.57* [0.42-
0.79] 
Self-Ordering Test NR NR OR= 0.60* [0.43-
0.83] 
Perri, 
2007(a) 
Italy  
(ITINAD) 
 
190 subjects with amnesic Mild Cognitive 
Impairment; 
87 healthy subjects 
Follow-up: 79 aMCI converted to 
dementia; 111 remained aMCI; 
Gender: 44 (55.7%) females converted; 64 
(57.7%) females did not converted; 51 
(58.6%) females in the control group 
(p>0.05); 
Age: 73.2±5.5 in the group that converted; 
67.8±7.5 in the group that remained aMCI; 
68.04±10.86 in the control group 
(p<0.001); 
Education: 7.5±3.2 in the group that 
converted; 7.7±3.6 in the group that 
remained aMCI; 8.13±4.27 in the control 
group (p>0.05). 
≈ 2 years; MCI conversion to 
dementia 
Staging severity of 
dementia 
Clinical Dementia Rating 
(CDR) 
NR NR OR=1.04* [1.01-
1.07] 
Episodic memory Rey’s Figure Form B 
Reproduction (delayed recall) 
35.4 NR OR=0.92* [0.87-
0.97] 
Word-List Recall (semantically 
related; immediate recall) 
50.6 NR NR (no 
significance) 
Word-List Recall (semantically 
related; delayed recall) 
77.2 NR NR (no 
significance) 
Word-List Recall (semantically 
unrelated; immediate recall) 
35.4 NR NR (no 
significance) 
Word-List Recall (semantically 
unrelated; delayed recall) 
63.3 NR OR=0.84* [0.74-
0.97] 
Word-List Recognition (related 
word list) 
54.4 NR NR (no 
significance) 
Word-List Recognition 
(unrelated word list) 
38.0 NR OR=0.66* [0.48-
0.91] 
Prose Recall (immediate) 35.4 NR NR (no 
significance) 
Prose Recall (delayed) 59.5 NR NR (no 
significance) 
Rozzini, 2007 119 subjects with amnesic Mild Cognitive 1.0±0.2; conversion to Executive functions Trail Making Test B NR NR OR=1* [1.0-1.0] 
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publication 
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[Cohort and follow-up groups; gender %; 
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standard error of the mean (SEM); mean 
years of formal education ±standard 
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Follow-up time [mean 
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value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Italy Impairment  
Follow-up: 40 demented; 79 stable; 
Gender: 72.5% female in the demented 
group; 57% female in the stable group 
(p>0.05); 
Age: 73.5±8.5 demented group; 69.2±7.0 
stable group (p=0.006); 
Education: 7.7±3.7 demented group; 
7.9±3.7 stable group (p>0.05). 
dementia Global cognitive function Alzheimer’s Disease 
Assessment Scale-Cognitive 
part (ADAS-Cog) 
NR NR OR=1.4* [1.1-1.8] 
Basic and instrumental daily 
functions 
IADL NR NR OR=35.9* [6.7-
191.5] 
Language and initiative Letter fluency NR NR OR=1.0 (no 
significance) 
Non-verbal abstraction Raven’s coloured matrices NR NR OR=1.1 (NS) 
Sustained attention and motor 
speed  
 Trail Making Test A NR NR OR=1.1 (NS) 
Sarazin, 2007 
France  
(PreAl study) 
217 patients with Mild Cognitive 
Impairment  
Follow-up: 59 converted in Alzheimer 
disease; 158 stable MCI; 
Gender: 54.2% females in the demented 
group; 60.1% females in the stable MCI 
group (p=0.61); 
Age: 74.8±4.1 demented group; 70.9±5.4 
stable MCI group (p<0.0001); 
Education: Bachelor degree 39% 
demented group; 
44.3 % stable MCI group (p=0.39). 
≈ 3 years; conversion to AD Verbal memory Free and Cued Selective 
Reminding Test (FCSRT) (total 
recall) 
79.7 89.9 RR=12.26 * [6.37-
23.60] 
FCSRT (index of cueing) 78.0 84.8 RR=10.26* [5.47-
19.28] 
FCSRT (free recall) 71.2 91.8 RR=8.68* [4.76-
15.82] 
FCSRT (delayed free recall) 76.3 90.5 RR=10.64* [5.66-
20.01] 
FCSRT (delayed total recall) 69.5 88.6 RR=7.22* [4.11-
12.70] 
FCSRT (number of intrusions) 64.4 85.4 RR=0.18* [0.10-
0.34] 
FCSRT (false recognition) 20.3 98.1 RR=0.25* [0.15-
0.43] 
Visual perception and memory Benton Visual Retention Test 42.4 77.2 RR=1.27* [1.12-
1.45] 
Language and Initiative Category Fluency  55.9 82.3 RR=2.84* [1.60-
5.04] 
Letter Fluency (letter S) 57.6 56.3 RR=1.46 [0.86-
2.48] 
DENO 100 55.9 67.7 RR=1.90* [1.12-
3.23] 
Working memory Serial Digit Learning test 57.6 67.7 RR=1.89 [1.12-
3.19] 
Double task of Baddeley 50.8 56.3 NR 
Conceptual elaboration Wechsler Adult Intelligence 
Scale  (WAIS) (similarities) 
49.2 72.2 RR=3.21* [1.82-
5.64) 
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[Cohort and follow-up groups; gender %; 
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[HR/OD/RR/LR; 95%; 
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Executive functions, visuospatial 
abilities, sustained attention and 
motor speed 
WAIS Digit Symbol test 37.3 71.5 RR=1.64 [0.92-
2.92] 
Stroop test (inhibition 
condition) 
52.5 58.2 RR=1.24 [0.72-
2.13] 
Trail Making test A 62.7 58.9 RR=1.58* [0.33-
1.00] 
Trail Making test B 62.7 67.1 RR=0.43* [0.25-
0.75] 
Devanand, 
2008 
USA 
148 MCI patients (73% of patients met 
criteria for amnestic MCI with or without 
other cognitive domain deficits, 13.5% had 
non-amnestic MCI, and 13.5% did not meet 
diagnostic criteria for MCI according to 
authors but had cognitive scores < 1.5 SD 
below norms; 
Follow-up: 39 converted to AD (31 had 
probable AD and 8 had possible AD); 109 
did not progressed to AD;  
Gender: 56.4% females converted to AD; 
55.1% females remained MCI (p=0.971);  
Age: 73.2±7.1 group that progressed to 
AD; 64.9±9.9 group that remained stable 
(MCI) (p<0.0001); 
Education: 14.0± 4.7group that progressed 
to AD; 15.4±4.1 group that remained stable 
(MCI)  (p=0.0014). 
1-9 years of follow-up (mean ≈ 
4 years: 41.5±18.5 for the 
group that progressed to AD; 
57.3±28.3 for the group that 
remained stable in MCI); 
conversion to AD (CDR rating 
was confirmatory (≥ 1, 
indicating dementia)) 
Global cognitive status Mini-Mental State Examination 
(MMSE) 
26.8 90.0 LR+ = 4.5 [1.6- 
12.7]  
LR –  = 0.8* [0.7- 
1.0] 
Verbal memory Selective Reminding Test 
(SRT) immediate recall score 
(SRT Imm Rec) 
50.9 90.0 LR+ = 5.8 [2.6- 
13.1]  
LR – = 0.6* [0.4- 
0.8] 
Dierckx, 
2009 
Belgium 
31 MCI patients; 
Follow-up: 7 (23%) fulfilled criteria for 
probable AD; 21 (68%) MCI- patients 
remained stable; 2 (6%) improved; 1 (3%) 
was diagnosed with progressive nonfluent 
aphasia;  
Gender: 14 (45%) females at follow-up;  
Age: 75.4± 6.2 in the group with follow-up; 
Education: 11.6±3.3 in the group with 
follow-up. 
≈18 months (17±1.98); 
Dementia diagnosed according 
to DSM-IV criteria 
Verbal learning with category 
cues  
MISplus (Dutch version of the 
original 
Memory Impairment Screen 
plus) 
71.5 91.5 OR=0.28* [0.10–
0.79] 
Rabin, 2009 
USA 
32 MCI patients 
Follow-up: 9 (28%) converted to AD;  
Gender: 20 (62.5%)  females in the MCI 
2.97±1.16; probable 
mild AD (defined by the 
NINCDS-ADRDA criteria) 
Verbal episodic memory and 
learning 
Mini-Mental State Examination 
(MMSE; three words delayed 
recall task) 
100  00 OR=1.18 
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baseline group;  
Age: 71.58±6.21 in the MCI baseline 
group;; 
Education: 16.55±3.16 in the MCI baseline 
group. 
California Verbal Learning 
Test (16-item) (5 learning 
trials) 
96  11 OR=0.93 
CVLT (short delay free recall) 91  44 OR=0.59* 
CVLT (long delay free recall) 100  44 OR=0.44* 
Wechsler Memory Scale III - 
Logical Memory (LM; 
immediate recall) 
91  33 OR=0.84* 
LM (Story A delay recall) 87  67 OR=0.65* 
LM (delay recall) 83  56 OR=0.79* 
LM (recognition) 96  63 OR=0.53* 
Remote memory WAIS-III Information subtest 100  0 OR=0.99 
Gallagher, 
2010 
Ireland 
182 consecutive new referred patients to a 
memory clinic with a diagnosis of MCI; 
Follow-up: 75 (41%) converted to AD; 107 
(59%) did not progress to dementia; 
Gender: 53.3% females converted to AD; 
58.9% females remained MCI (p=0.46); 
Age: 73.9±5.9 demented group; 73.8±7.2 
stable MCI group (p=0.88); 
Education: primary level of education 48% 
demented group; 42% stable MCI group 
(p=0.59). 
2.17±1.46; conversion to AD Core cognitive functions required 
for a diagnosis of dementia 
Cambridge cognitive 
examination battery 
(CAMCOG; total)  
80 68 NR 
CAMCOG (orientation) 38 89 NR 
CAMCOG (memory) 78 74 NR 
CAMCOG (language) 78 49 NR 
CAMCOG (attention) 82 41 NR 
CAMCOG (abstraction) 64 64 NR 
CAMCOG (calculation) 42 83 NR 
CAMCOG (praxis) 56 60 NR 
CAMCOG (perception) 37 80 NR 
Verbal initiative Letter fluency 52 65 NR 
Category fluency 94 48 NR 
Language Boston naming test 81 58 NR 
Verbal memory Delayed word recall (DWR) 
test (free recall) 
77 76 NR 
DWR (recognition) 57  85 NR 
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Forlenza, 
2010 
Brazil 
97 amnestic MCI (20 with single-domain 
amnestic MCI and 77 multiple-domain 
amnestic MCI); 
Follow-up: 13 (from 76 that had at least 
one follow-up assessment - 17%) converted 
to AD;  
Gender: 74 (76%)  females in the MCI 
baseline group;  
Age: 70.7±6.5 in the MCI baseline group; 
Education: 9.1±4.9 in the MCI baseline 
group. 
38.8 ± 17.7 months; conversion 
to AD (according 
to the NINCDS-ADRDA 
criteria) 
Episodic memory Rivermead Behavioural 
Memory Test (RBMT) 
NR NR OR= 0.78* 
Grober, 2010 
USA 
194 non-demented participants; 101 (53%) 
patients with normal cognition (CDR 0) and 
91 (47%) patients with questionable 
cognition (CDR 0.5); 
Follow-up: 28 converted to dementia; 166 
remained non-demented; 
Gender: 82% females demented; 84% 
females non-demented (p=0.78); 
Age: 83.25±6.0 demented group; 77.4±6.6 
non-demented group (p=0.0001); 
Education: 12.4±2.9 demented group; 
12.5±3.4 non-demented group (p=0.75). 
2.6 years; conversion to 
dementia (DSM-IV) 
Verbal episodic memory Free and Cued Selective 
Reminding Test (FCSRT) (total 
recall) 
54 90 NR 
FCSRT (free recall) 78 90 NR 
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publication 
year  
Country 
(Cohort 
Study) 
Sample characteristics 
[Cohort and follow-up groups; gender %; 
mean age±standard deviation (SD) or 
standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Landau, 2010 
USA 
(ADNI 
database) 
85 MCI patients; 
Follow-up: 28 converted to AD; 57 
remained MCI; 
Gender: 9 (32%) females in the group that 
converted to AD; 20 (35%) females in the 
group that remained MCI (p>0.05); 
Age: 78.3±7.5 for the group that converted 
to AD; 78.0±7.4 for the group that 
remained MCI (p>0.05); 
Education:16.4±2.6 for the group that 
converted to AD;  16.3±2.8 for the group 
that remained MCI (p>0.05). 
1.9±0.4; conversion to AD 
(according 
to the NINCDS-ADRDA 
criteria) 
Verbal memory and learning Auditory Verbal Learning Test 
(AVLT; 5 immediate recall 
trials) 
93 88 HR=4.68* [1.37–
15.98] 
Lekeu, 2010 
Belgium 
(NEST-DD 
European 
multicentre 
study) 
34 questionable Alzheimer’s disease; 
Follow-up: 17 converted to AD; 17 
remained QAD; 
Gender: 12 (71%) females in the group 
that converted to AD;  6 (35%) females in 
the group that remained QDA (p>0.05); 
Age: 72.0± 5.9 for the group that converted 
to AD; 66.6 ±6.9 for the group that 
remained MCI (p>0.05); 
Education: 10.8±2.5 for the group that 
converted to AD; 12.3 ±5.2 for the group 
that remained MCI (p>0.05). 
36 months; conversion to AD 
(according 
to the NINCDS-ADRDA 
criteria) 
Working memory Digit span NR NR ES=0.021* 
Block Tapping Test NR NR ES=0.131* 
Visual episodic memory  Rey’s figure (delayed recall) 76 76 ES=0.383* 
Verbal memory and learning California Verbal Learning 
Test (CVLT; 5 trials total free 
recall) 
NR NR ES=0.479* 
CVLT (Short-delay free recall) NR NR ES=0.499* 
CVLT (Short-delay cued 
recall) 
NR NR ES=0.477* 
 CVLT (Long-delay free recall) NR NR ES=0.496* 
CVLT ( Long-delay cued 
recall) 
NR NR ES=0.419* 
CVLT (Free recall - list B) NR NR ES=0.337* 
CVLT (Total intrusion errors) NR NR ES=0.091 
CVLT (Total false 
recognitions) 
NR NR ES=0.283* 
CVLT (False recognitions - list 
B) 
NR NR ES=0.351* 
CVLT (Discrimination index) NR NR ES=0.329* 
CVLT (Response bias) NR NR ES=0.007 
CVLT (Primacy index) NR NR ES=0.018 
CVLT (Recency index) 73 72 ES=0.407* 
CVLT (Constancy learning) NR NR ES=0.164 
CVLT (Semantic clustering) NR NR ES=0.198 
CVLT (Serial order clustering) NR NR ES=0.054 
Language and initiative Category fluency NR NR ES=0.29* 
Letter fluency NR NR ES=0.139 
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standard error of the mean (SEM); mean 
years of formal education ±standard 
deviation (SD) or standard error of the 
mean (SEM)] 
Follow-up time [mean 
years±SD or approximated 
value]; Outcome 
Cognitive domain / Neuropsychological Test Sensitivity (%) 
Specificity 
(%) 
Hazard Ratio; Odds 
Ratio; Relative Risk 
and Likelihood ratio 
[HR/OD/RR/LR; 95%; 
CI] 
 
Executive functions Stroop test (interference index) NR NR ES=0.088 
Visuoperceptive 
function  
Rey’s figure (copy) NR NR ES=0.027 
Lonie, 2010 
UK 
44 amnestic MCI; 
Follow-up: 18 (41%) converted to 
dementia; 26 remained aMCI; 
Age: 76.0 ±1.6 for the group that converted 
to dementia; 73.2±5.4 for the group that 
remained aMCI (p>0.05). 
≈ 4.18 years; 
clinical diagnosis of dementia 
(most often 
Alzheimer’s disease) 
Global cognitive status Addenbrooke’s Cognitive 
Examination 
(total)  
65 (LR 
final 
model) 
80 (LR 
final 
model) 
OR=0.86* [0.75-
1.00] 
Verbal memory and learning Hopkins Verbal Learning Test 
– Revised (HVLT–R; 
discrimination index) 
OR=0.73* [0.53-
1.00] 
Semantic memory Graded Naming Test 38 68 NR 
Graded Faces Test 44 68 NR 
Aretouli, 
2011 
USA 
104 MCI patients (68 aMCI and 36 non-
amnestic MCI); 
Follow-up: 19 (18%)  progressed to 
dementia (CDR≥1); 76 (73.1%) remained 
stable; 9 (9%) reverted to CDR=0; 
Gender: 8 (26.7%)  females in the aMCI 
single domain at baseline; 14 (36.8%)  
females in the aMCI multiple domain at 
baseline; 8 (34.8%)  females in the non-
aMCI single domain at baseline; 10 
(76.9%)  females in the non-aMCI multiple 
domain at baseline; 
Age: 74.97±5.82 in the aMCI single 
domain at baseline; 78.32±7.25 in the aMCI 
multiple domain at baseline; 74.04±8.18 in 
the non-aMCI single domain at baseline; 
76.62±7.34 in the non-aMCI multiple 
domain at baseline; 
Education: 16.17±2.17 in the aMCI single 
domain at baseline; 16.53±2.42 in the aMCI 
multiple domain at baseline; 15.22±2.91 in 
the non-aMCI single domain at baseline; 
15.08±2.25 in the non-aMCI multiple 
domain at baseline. 
≈ 2 years; progression to 
dementia (CDR≥1) 
Verbal episodic memory, 
visuospatial/praxis abilities, 
language and initiative (cognitive 
screening battery for this study) 
Wechsler Memory Scale-R 
Logical Memory (delayed 
recall) 
 94 (LR 
final 
model) 
71 (LR 
final 
model) 
OR=0.820* [0.702-
0.957] 
Clock Drawing Test  OR=0.665* [0.471-
0.939] 
Category Fluency OR=0.914* [0.842-
0.991] 
Executive functions (flexibility, 
inhibition and initiative) and 
semantic memory 
Alternate Uses Test NR NR OR=0.894* [0.808-
0.989] 
Hayling Test NR NR OR=0.637* [0.457-
0.890] 
Verbal Concept Attainment 
Test 
NR NR OR=0.872 [0.761-
0.999] 
Gomar, 2011 
USA 
(ADNI 
 320 MCI patients; 
Follow-up: 116 converted to AD; 204 
remained MCI; 
≈2 years; probable AD 
(according 
to the NINCDS-ADRDA 
Verbal episodic memory and 
learning 
Alzheimer’s Disease 
Assessment Scale-Cognitive 
part (ADAS-Cog;  memory)  
NR NR OR=1.07* [1.01-
1.14] 
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database) Gender:  45 (38.8%) females in the group 
that converted to AD;  72 (35.3%) females 
in the group that remained MCI (p>0.05); 
Age: 74.6±7.2 for the group that converted 
to AD; 75.1±7.4 for the group that 
remained MCI (p>0.05); 
Education: 15.6±2.83 for the group that 
converted to AD;  15.6±3.25 for the group 
that remained MCI (p>0.05). 
criteria)  
 
Wechsler Memory Scale 
(WMS; Logical Memory 
subtest)  
NR NR OR=1.01* [0.96-
1.06] 
Auditory Verbal Learning Test 
(AVLT; delay recall)  
NR NR OR=0.95* [0.85-
1.07] 
Visuospatial/praxis abilities and 
semantic knowledge 
Clock Drawing test NR NR OR=0.80* [0.70-
0.91] 
Speed of processing Trail Making Test A  NR NR OR=0.99* [0.98-
0.99] 
* p-value < 0.05; † p-value not reported.  
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3.1.3 Discussion 
 
The present systematic review of the literature reported the results of twenty-four longitudinal 
studies that evaluated the predictive value of neuropsychological tests for future conversion to 
dementia. The selection of tests to apply varied considerably across studies. A comprehensive 
neuropsychological assessment through a wide battery of cognitive areas tested on different 
levels of difficulty was the most frequent option to discriminate individuals at risk for future 
cognitive decline. However, due to time restrictions, sometimes the cognitive assessment was 
limited to one composite or global measure of cognitive function such as the Mini-Mental 
Status Examination (MMSE; Folstein, Folstein and McHugh, 1975). These global 
assessments are considered screening instruments since they provide a brief overview of 
functioning in terms of basic attention, memory, language, and spatial-constructional skills. 
Certainly, it is difficult to offer screening measures sensitive and specific enough to 
accurately detect those at risk for dementia, essentially because they have a ceiling effect, thus 
lacking sensitivity for patients with very mild impairment (Devannand et al., 1997; 
Devannand et al., 2008; Tierney et al., 2000). Hence, these global measures do not substitute 
for a detailed neuropsychological assessment, but should still be indicative of an index of 
functioning in primary cognitive domains. The MMSE is a widely used screening test but 
there are several more, for instance, the Short Test of Mental Status, that revealed a slightly 
better accuracy for identification of MCI cases in comparison to the MMSE (AUC 0.82 vs. 
0.75, p=0.002, respectively) (Tang-Wai et al., 2003). Another instrument extensively used to 
screen for MCI patients is the Montreal Cognitive Assessment (MoCA), with a very good 
sensitivity and specificity profile (90% and 87%, respectively) (Nasreddine et al., 2005). The 
MoCA has evidenced to be more sensitive than MMSE (0.97 vs 0.65), but less specific (0.60 
vs 0.89), with better diagnostic accuracy (area under Receiver Operating Characteristic curve 
0.91 vs 0.83) (Larner, 2012; Freitas et al., 2011). The MMSE remains the most frequently 
used cognitive screening instrument for dementia, however, the improved sensitivity and 
consideration of other relevant deficits, such as executive functions, in MoCA have 
complemented the standard screening scope. Also to address limitations of MMSE in 
assessment of verbal, frontal-executive and visuospatial functions the Addenbrooke’s 
Cognitive Examination (ACE) (Mathuranath et al., 2000), and subsequently its revised 
version of ACE-R (Mioshi et al., 2006), have been proposed to screen for cognitive decline. 
The ACE-R and MoCA total scores showed to be similar, having high sensitivity but low 
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specificity (Lonie et al., 2010; Ahmed, de Jager and Wilcock, 2011). Another important 
screening tool is the Cambridge Cognitive Examination (CAMCOG), which is part of 
Cambridge Examination for Mental Disorders in the Elderly (Roth et al., 1986). The 
CAMCOG also presented very good accuracy in the discrimination of MCI from AD patients, 
particularly for those with multiple-domain MCI (AUC=0.92±0.02; CI 0.88–0.96; p<0.001) 
(Aprahamian et al., 2011). For the prediction of MCI patients’ future conversion to dementia, 
the CAMCOG presented high sensitivity (> 75%) in the measures of attention, memory, 
language and total score, for a mean follow-up time of approximately 2 years (Gallagher et 
al., 2010). 
Several more comprehensive batteries are used to assess in more detail the cognitive 
performance of elderly and determine the risk of future conversion to dementia. Noteworthy, 
published studies over the last twenty years indicated that verbal memory tasks included in 
neuropsychological batteries of tests are the best measures to predict future conversion to 
dementia.  
The verbal memory assessment is routinely present and the story recall test (SRT) is one of 
the most reliable measurements for distinguishing normal aging from mild cognitive 
impairment (MCI) and AD, but also to assess the degree of progression (Storandt et al., 
1984). The most representative test of the SRT is the logical memory test in Wechsler 
Memory Scale (Wechsler, 1981). It requires attention, learning ability, language 
comprehension, and provides a specific examination of the encoding, storage, and retrieval 
processes of the memory system (Lezak, 1995). Baek and colleagues (2011) have shown that 
immediate recall test (sensitivity, 72%; specificity, 71%) and the 20-minute delayed recall test 
(sensitivity, 74%; specificity, 73%) can discriminate MCI and AD, but the recognition test 
(sensitivity, 83%; specificity, 46%) revealed a ceiling effect that reduced the specificity of this 
measure to AD-typical memory decline (Wolk, Signoff and Dekosky, 2008). Several studies 
have shown very reasonable predictive values for future conversion to dementia by the 
administration of SRT (Tierney et al., 1996; Tabert et al., 2006; Rabin et al., 2009; Aretouli et 
al., 2011; Gomar et al., 2011). Sensitivity to semantic cueing seemed relatively preserved in 
the early stages of AD but decreased with the progression of the disease. Neuropsychological 
characterization of suspected prodromal AD in research settings should therefore include such 
cued recall measures. In clinical settings, cued recall measures (more than recognition 
measures from frequently applied list learning tasks) likely add specificity with regard to the 
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memory deficit indicative of prodromal AD, while free recall measures may be the most 
sensitive screening tools (Tounsi et al., 1999; Wagner et al., 2012). 
List learning tasks have provided remarkable sensitivity and specificity values for decline or 
conversion to AD, ranging from 90% sensitivity / 94.7% specificity (Flicker, Ferris and 
Reisberg, 1991; Shopping List applied to small sample of already mildly impaired 
individuals) and 71.2% sensitivity / 91.8% specificity (Sarazin et al., 2007; Free and Cued 
Selective Reminding Test (FCSRT) free recall applied to MCI patients followed for 
approximately 3 years). Delayed recall tasks presented inferior results for prediction of 
conversion to dementia but even though, the Memory Assessment Clinics selective reminding 
delayed recall evidenced 87% sensitivity and 85% specificity to predict conversion of 
individuals with cognitive complaints followed for approximately 2 years (Lehrner et al., 
2005). Sensitivity and specificity values presented by these studies are very good but seemed 
to correspond to MCI patients at an advanced stage of progression that converted soon after 
cognitive assessment. More studies with longer follow-ups and individuals with no 
established diagnosis of MCI are needed to better ascertain the predictive value of cognitive 
tests to future conversion to dementia. Since the conversion occurs at different times for 
distinct individuals and distribution of time to conversion is rarely normal, survival analysis 
may provide relevant information about the effect of cognitive deficits on time to conversion 
to dementia. Blacker and colleagues (2007) reported that by each standard deviation rise in 
FCSRT, the score risk of conversion to dementia decreased by 48%. Remarkably, Sarazin and 
colleagues (2007) study demonstrated a relative risk of progression from MCI to AD for 
patients with a low baseline FCSRT total recall of about 12 times (95% CI [6.24 to 23.2]; 
p<0.0001).   
Visuospatial abilities, processing speed and executive functions have showed predictive 
values for conversion similar to verbal memory tests mentioned previously (Wechsler Adult 
Intelligence Scale – digit symbol: sensitivity 81% and specificity 76%; Trail Making Test part 
B: HR=1.64, p<0.05) (Lehrner et al., 2005; Blacker et al., 2007). 
Likewise, short batteries of carefully selected tests proved to be a fruitful option reaching 
good predictive values for future conversion to dementia. For instance, Aretouli and 
colleagues (2011) reported for a short battery assessing verbal episodic memory, 
visuospatial/praxis abilities, language and initiative the values of 94% and 71% for sensitivity 
and specificity, respectively. 
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Some studies proposed models combining neuropsychological measures and different 
biomarkers to establish predictive values for future conversion to dementia (Gomar et al., 
2011; Ewers et al., 2012). Including neuropsychological measures in biomarker prediction 
models might help to overcome misleading data, for instance when age-dependent increase of 
AD-type brain pathology is detected in cognitively unaffected elderly. Despite acknowledging 
their different nature, the combination of predictive markers might be interestingly 
complementary, and a significant and specific association between Aβ1-42 or tau and episodic 
memory recall measures has been demonstrated (Wagner et al., 2012). Accordingly, other 
studies found significant correlations between episodic memory performance and Aβ1-42 
burden in the brain measured with PIB-PET (Pike et al., 2007; Forsberg et al., 2008; 
Mormino et al., 2009). Importantly, Schmand, Huizenga and Van Gool (2010) reported 
recently in a meta-analysis study that baseline cognitive markers were better predictors of 
conversion than brain volumetric or CSF biomarkers. Therefore, because cognitive changes 
are a prominent and early feature of AD, focusing on neuropsychological markers would 
seem appropriate, as they can be reliable and non-invasive instruments for the prediction of 
future conversion to dementia. 
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3.2 Data mining methods in the prediction of Dementia (BMC Research 
Notes) 
3.2.1 Rationale and Procedure 
It is estimated that about 25 million people suffer from dementia today and, as a consequence 
of the population aging, the number of people affected is expected to double every 20 years 
(Ferri and Brayne, 2005). The presence of cognitive complaints is very common in aged 
people and may be the first sign of an on-going dementing disorder like Alzheimer’s disease. 
Nowadays, it is possible to identify people with cognitive complaints who are at risk for the 
progression to dementia, that is to say, who have Mild Cognitive Impairment (MCI) (Petersen 
et al., 2001a,b; Portet et al., 2006). Since the establishment of MCI requires the demonstration 
of cognitive decline greater than expected for an individual's age and education level, 
neuropsychological testing is a key element in the diagnostic procedures (de Mendonça et al., 
2004). Recently, it has become possible to identify the traces, or biomarkers, of Alzheimer’s 
disease in patients with MCI, by the use of Magnetic Resonance Imaging (MRI) volumetric 
studies, neurochemical analysis of the cerebrospinal fluid, and Positron Emission 
Tomography (PET) scan (Dubois et al., 2007). These studies, however, are expensive, 
technically challenging, some invasive, and not widely available. Longitudinal studies 
assessing the predictive value of neuropsychological tests in progression of MCI patients to 
dementia have shown an area under the receiver operating characteristic curve of 61-94% 
(being higher for tests assessing verbal episodic memory) but with lower accuracy and 
sensitivity values (Chong and Sahadevan, 2005; Lehrner et al., 2005; Fleisher et al., 2007; 
Perri et al., 2007b; Sarazin et al., 2007). It would be important to improve the value of 
neuropsychological tests to predict the progression of MCI patients to dementia. This can be 
achieved at a clinical level by increasing the number of patients with longer clinical follow-
ups. Predictive power of these tests may be also increased through innovating statistical 
classification and Data Mining techniques. Traditional statistical classification methods (e.g., 
Fisher’s Linear Discriminant Analysis (LDA) and Logistic Regression (LR)) have been 
extensively used in medical classification problems for which the criterion variable is 
dichotomous (Efron, 1975; Goss and Ramchandani, 1995; Fan and Wang, 1999; Lei and 
Koehly, 2003; Pohar, Blas and Turk, 2004; Michael et al., 2006; Peter, 2007). More recently, 
research has been steadily building on the accuracy and efficiency of Data Mining, with 
classifiers like Neural Networks (NN), Support Vector Machines (SVM), Classification Trees 
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(CTrees) and Random Forests (RF) used for medical prediction and classification tasks (Goss 
and Ramchandani, 1995; Pitarque, Roy and Ruiz, 1998; Kestler and Schwenker, 2001; Poon 
et al., 2001; Nabney, 2004; Sommer, Olbrich and Arendasy, 2004; Peter, 2007; Suka et al., 
2007; Sut and Senocak, 2007; Maglogiannis et al., 2008; Zollner, Emblem and Schad, 2010). 
Research on the comparative accuracy of traditional classifiers (LDA and LR) vs. new, 
computer intensive, Data Mining methods have been growing steadily. Several authors defend 
that Data Mining classifiers have higher accuracy and lower error rates than the traditional 
classification methods (Ivanciuc, 2007; Suka et al., 2007; Sut and Senocak, 2007; Kurt, Ture 
and Kurum, 2008). However, this superiority is not apparent with all data sets, especially with 
real data (Gelnarova and Safarik, 2005; Finch and Schneider, 2006; Michael et al., 2006; 
Finch and Schneider, 2007; Peter, 2007). Results regarding the superiority of classification 
accuracy of newer classification methods as compared to traditional, less computer 
demanding methods, as well as the stability of the findings are still controversial (Duin, 1996; 
Meyer, Leischa and Hornik, 2003; Behrman et al., 2007; Finch and Schneider, 2007). Most 
comparisons between methods are based only on total classification accuracy and/or error 
rates; they involve human intervention for training and optimization of the data mining 
classifiers vs. out-of-the-box results for the traditional classifiers. Accordingly to Duin (1996) 
“(…) a straight forward fair comparison demands automatic classifiers with no user 
interaction”. Furthermore, in medical contexts, sensitivity (the ability to predict the condition 
when the condition is present), specificity (the ability to predict the absence of the condition 
when the condition is not present) as well as the classifier discriminant power (as estimated 
from the area under the Receiver Operating Characteristic (ROC)) are key features that need 
to be considered when comparing classifiers and diagnosis methods.  
In this paper we evaluated the sensitivity, specificity, overall classification accuracy, area 
under the ROC and Press’ Q of Data Mining classifiers like Neural Networks (Multilayer 
Perceptrons and Radial Basis Networks), Support Vector Machines, Classification Trees and 
Random Forests as compared to the traditional Linear, Quadratic Discriminant analysis and 
Logistic Regression in the prediction of the evolution into dementia of 400 elderly people 
with Mild Cognitive Impairment.  
 
Classifiers 
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Discriminant Analysis: The oldest classifier still in use was devised almost 100 years ago by 
Sir R. Fisher. Fisher’s Linear Discriminant Analysis (LDA; Fisher, 1936) builds discriminant 
functions that estimate scores for each subjects classified into groups, from linearly 
independent predictor variables. Discriminant analysis predicts membership in two or more 
mutually exclusive groups from a set of predictors, when there is no natural ordering on the 
groups. Linear and quadratic discriminat functions are estimated using within vs. between 
sum of square minimization optimisation and then the subject is classified into the group for 
which its classification function score is higher (McLachlan, 2004). 
Logistic Regression: Binomial Logistic regression (LR) models the probability of occurrence 
of one (success) of the two classes of a dichotomous criterion. A linear combination of 
predictors is used to fit a Logit transformation of the probability of success for each subject. 
Regression coefficients are fitted by maximum likelihood estimation and the probability of 
success for each subject is then estimated. If the estimated probability is greater than 0.5 (or 
other pre-defined threshold value), the subject is classified into the success group; otherwise, 
it is classified into the failure group (Hosmer and Lemeshow, 2000).   
Neural Networks: Neural Networks (NN) methods have been used extensively in 
classification problems and this is one of the most active research and application areas in the 
Neural Networks field (Yang, 2010). Inspired from the biological neuron cells, a NN is a 
multi-stage, multi-unit classifier, with input, hidden or processing, and output layers as 
illustrated by figure 3.2.1.  
 
Input layer Hidden Layer Output layer 
 
Figure 3.2.1 – Pictorial representation of a neural network (multilayer perceptron) with input layer (dendrites), 
hidden layer (nucleus) and output layer (axon) (see text for a description of the neural networks components).  
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Activation functions for the hidden layer and the output layer are one of the general linear, 
logistic, exponential or gaussian function families. Several topologies of Neural Networks 
(NN) can be used in binary classification problems. Two of the most used NN are the 
Multilayer Perceptron (MLP) and the Radial Basis Function (RBF). The main differences 
between these two NN reside in the activation functions of the hidden layer: For the MLP the 
activation function belongs, generally, to a linear or logistic activation function family, for the 
RBF function the activation function belongs to the Gaussian family. A NN is generally 
trained in a set of iterations (epochs) for a subset of the data (train set) and tested for the 
remaining subset (test set). The vector of synaptic weights of the NN is upgraded in each 
iteration in way to maximize the correct classification rate and or minimize a function of the 
classification errors; either a function of the sum of squares of the errors for continuous 
criterion or the Cross-entropy error function for a binary criterion (for a detailed description 
see Bishop, 1995). 
Support Vector Machines: Support Vector Machines (SVM) are machine-learning derived 
classifiers which map a vector of predictors into a higher dimensional linear plane through 
either linear or non-linear kernel functions (Cortes and Vapnik, 1995). In a binary 
classification problem, the two groups, say {-1} and {+1}, are separated in a higher-
dimension hyperplane accordingly to a structural risk minimization principle. The objective is 
to find a linear separating hyperplane constructed from a vector of predictors, a vector of 
weights and a bias offset that classifies all the observation in one of the two groups {-1; +1}. 
The training patterns that respect the above constrains are called support vectors, and carry all 
the relevant information about the classification problem. Since, in a binary classification 
problem, there are infinite separation hyperplanes, the goal is to find the optimum plane, 
which separates best the two groups (for more detailed information see Cortes and Vapnik, 
1995; Bennett and Campbell, 2000; Karatzoglou, Meyer and Hornik, 2006; Ivanciuc, 2007). 
Classification trees: Classification trees (CTrees) are non-parametric classifiers that construct 
hierarchical decision trees by splitting data among classes of the criterion at a given step 
(node) accordingly to an “if-then” criterion applied to a set of predictors, into two child nodes 
repeatedly, from a root node that contains the whole sample. Thus, CTrees can select the 
predictors and its interactions that are most important in determining an outcome for a 
criterion variable. The development of a CTrees is supported on three major elements: (1) 
choosing a sampling-splitting rule that defines the tree branch which connects the 
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classification nodes; (2) the evaluation of classification produced by the splitting rule at each 
node and (3) the criteria used for choosing an optimal or final tree for classification purposes. 
According to the features of these major elements, the most usual CTrees can be classified 
into: Classification and Regression Tree (CART; Breiman et al., 1984), Chi-squared 
Automatic Interaction Detector (CHAID; Kass, 1980) and Quick Unbiased Efficient 
Statistical Tree (QUEST; Loh and Shih, 1997).  
Random forests: Random forests (RF) were proposed by Leo Breiman (2001). This 
“ensemble learning” classification method construct a series of CART using random 
bootstrap samples of the original data sample. Each of these trees is build from further 
random sub-set of the total predictors who maximize the classification criteria at each node. 
An estimate of the classification error-rate can be obtained using each of the CART to predict 
the data not in the bootstrap sample (“out-of-the bag”) used to grow the tree, and then average 
the out-of-the bag predictions for the grown set of trees (forest). These out-of-the bag 
estimates of the error-rate can be quite accurate if enough trees have been grown (Liaw and 
Wiener, 2002).  Object classification is then predicted from the majority of predictions given 
by the trees in the random forest. Although this classification strategy may lack a perceivable 
advantage over single CTrees, accordingly to its creator (Leo Breiman) it has unexcelled 
accuracy among current algorithms, performing very well when compared to many classifiers 
including LDA, NN and SVM (for a detailed description of RF see Breiman, 2001). 
Furthermore, this method is quite user-friendly since it has only two parameters that the user 
needs to define: the number of random trees in the forest; and the number of predictor 
variables in the random subset of tree at each node. These parameters can be easily optimized 
although random forests are not very sensitive to their values (Liaw and Wiener, 2002). 
 
Procedure 
Data mining settings and classifiers evaluation: To prevent overfitting and artificial accuracy 
improvement due to the use of the same data for training and testing of classifiers, a 5-fold 
cross-validation strategy was followed to train and evaluate the classifiers. The total sample 
was divided into 5 proportional sub-samples. In each of the 5 steps, 4/5 of the sample was 
used for training and 1/5 was used for testing. Test results for the 5 runs, gathered from the 5 
test samples, were then aggregated. The comparative performances (total accuracy, 
sensitivity, specificity, AUC and Press’ Q) of the different classifiers where compared with 
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Friedman’s ANOVA on Ranks followed by Dunn’s post-hoc multiple comparisons of mean 
ranks. Statistical significance was assumed for p<0.05. Equal a priori classification 
probabilities were used for Linear Discriminant Analysis, Quadratic Discriminant Analysis 
and Logistic Regression. The Multilayer Perceptron was trained with 11 inputs in the input 
layer, 1 hidden layer with 4-7 neurons and a hyperbolic tangent activation function. The 
activation function for the output layer was the Softmax with a cross-entropy error function. 
Synaptic weights were obtained from an 80%:20% train: test setup. The Radial Basis 
Function Neural Network had 11 inputs, one hidden layer with 2-8 neurons and a Softmax 
activation function. The activation function for the output layer was the identity function with 
a sum of squares error function. The radial Gaussian function was the kernel used in the 
SVM. Cost (c) and γ parameters were optimized by a grid search in the intervals [2-3; 215] for 
c and [2-15; 23] for γ, followed by cross-validation of each of the SVM obtained in the 5 train 
sets. The classification function was the sign of the optimum margin of separation. CHAID, 
CART and QUEST classification trees used α to split and α to merge of 0.05, with 10 
intervals. Tree growth and pruning of CART were set with a minimum parent size of 5 and 
minimum child size of 1. Classification priors for both trees were fixed at 0.5:0.5. Random 
Forests were composed of 500 CART trees with 2-9 predictors per tree cross-validation 
optimization. The Predictive Analytic Software (PASW) Statistics (v. 18, SPSS Inc., Chicago, 
Ill) was used for Discriminant Analysis, Logistic Regression, Neural Networks and 
Classification trees. Support Vector Machines and Random Forests were performed with R (v. 
2.8, CRAN) with the e1071 (Meyer, 2001) and random-Forest (Liaw and Wiener, 2002) 
packages, respectively.  
 
3.2.2       Results 
Sample: Subjects were recruited as part of a cohort study of 775 elderly non-demented 
patients with cognitive complaints referred for neuropsychological evaluation at 3 institutions, 
the Laboratory of Language Studies, Santa Maria Hospital, and a Memory Clinic, both in 
Lisbon, and of the Neurology Department, University Hospital, Coimbra, from 1999 to 2007. 
Inclusion criteria consisted in the diagnosis of Mild Cognitive Impairment (according to the 
criteria of the European Consortium on Alzheimer’s disease, Portet et al., 2006); presence of 
at least one follow-up neuropsychological assessment or clinical re-evaluation. Patients with 
dementia (according to DSM-IV-TR; APA, 2000) or other disorders that may cause cognitive 
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impairment, like stroke, brain tumor, significant head trauma, epilepsy, psychiatric disorders, 
uncontrolled medical illness (hypertension, metabolic, endocrine, toxic and infectious 
diseases); medical treatments interfering with cognitive function; and alcohol or illicit drug 
abuse were excluded from the study sample. At the follow-up, the subjects were classified as 
having: Mild Cognitive Impairment (according to the same criteria); or Dementia (according 
to the DSM-IV-TR (APA, 2000) criteria). The final sample was composed by 400 patients 
(see table 3.2.1 for sample demographics) who gave voluntary consent to participate in this 
study. The local ethics committee approved the study. 
 
Table 3.2.1 Sample demographics: The two groups in the criterion were “MCI” - Mild Cognitive impaired 
patients; and “Dementia” patients. The class to predict was “Dementia”.  P-values for group comparison were 
obtained from Student’s-t test (†) or χ2 test (‡). 
 MCI Dementia p-value 
Group size (%) 275 (69%)  125 (31%)  <0.001‡  
Age (M±SD)  67.8 ± 8.8  71.6 ± 8.4  <0.001†  
Sex (♀/♂)  165/ 110  78 / 47  0.649‡  
Schooling years (M±SD)  8.1 ± 4.7  8.64 ± 4.9  0.469†  
Time between assessments 
(year)(M±SD)  
2.3 ± 1.6  2.2 ± 1.4  0.517†  
 
Criterion and Predictors: The criterion was a dichotomous variable with two groups: MCI and 
Dementia. Neuropsychological predictors were a subset of tests with criterion validity (p<0.1) 
from the Battery of Lisbon for the Assessment of Dementia (BLAD; Garcia, 1984), which 
includes multiple neuropsychological tests representing key cognitive domains and was 
validated for the Portuguese population. The selected 11 neuropsychological tests assessed the 
following cognitive areas: verbal initiative (Verbal Semantic Fluency) (Benton and Hamsher, 
1976); verbal and non-verbal abstraction (Interpretation of Proverbs) (Wechsler, 1981); visuo-
constructional abilities and executive functions (Freedman et al., 1994); immediate memory 
(Wechsler and Stone, 1945); working memory (Digit Span backward) (Wechsler and Stone, 
1945); learning and verbal memory (Word Recall, Verbal Paired-associate Learning and 
Logical Memory) (Wechsler and Stone, 1945) and Orientation (adapted from the Mini-Mental 
State Examination (MMSE) Test (Folstein, Folstein and McHugh, 1975; Guerreiro, 1998)) 
(Garcia, 1984). A Forgetting Index was also studied as a predictor variable. This Index is 
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calculated based on the correct information evoked between the immediate and the delayed 
condition of the Logical Memory Test (Forgetting Index= [(LM delayed recall – LM 
immediate) / LM immediate)] × 100) (Ribeiro, Guerreiro and de Mendonça, 2007). Figure 
3.2.2 gives the scatter biplots for all pairs of predictors and their frequency histograms. None 
of the predictors showed a normal distribution judging from Kolmogorov-Smirnov with 
Lilliefors correction tests (p<0.05), but criterion group variances were homogenous according 
to the Levene’s test (p>0.05). No multicollinearity problems were apparent (Variance 
Inflation Factors<5) but several bivariate outliers were detected.  
 
Figure 3.2.2 – Scatter biplots for MCI () and Dementia () patients in the 11 predictors and its histograms 
(DSf – Digit Span Forward; DSb – Digit Span Backward; SF – Verbal Semantic Fluency; Ori – Orientation; WR 
– Word Recall; VPA – Verbal Paired-associate Learning; LM – Logical Memory; Forg – Forgetting Index; 
Clock- Clock Drawing; MPR – Raven Progressive Matrices; Prov – Interpretation of Proverbs). See text for tests 
descriptions. 
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Classification accuracy, sensitivity, specificity, area under the ROC and Press’ Q statistic 
were evaluated in the 5 test sets resulting from the 5-fold cross validation strategy as 
described before. Data gathered is illustrated in box-plots for the different classifiers.  
  
Total Accuracy 
Figure 3.2.3 shows the box-plots of the total classification accuracy for the 10 classifiers 
studied. Judging from the Friedman test on ranks, there were statistical significant differences 
between distributions of the total accuracy (χ2Fr(9)=22.211; p=0.008). Post-hoc, multiple 
mean rank comparisons revealed the SVM and RF had higher mean ranks than the other 
classifiers who did not differ significantly in mean rank accuracy (p>0.05).  
 
 
Figure 3.2.3 – Box-plot distributions of classification accuracy (number of correct classifications / total sample 
size) for the 5 test samples resulting from the 5-fold cross-validation procedure (see text for abbreviations) 
(χ2Fr(9)=22.211; p=0.008). Different letters correspond to methods with statistically significant differences 
according to Dunn’s mean rank post-hoc comparisons (p<0.05). Circles represent outliers (observations greater 
than the 3rd quartile plus 1.5 times the interquartile range or smaller than the 1st quartile minus 1.5 times the 
interquartile range; stars represent extreme outliers that correspond to observations greater than the 3rd quartile 
plus 3 times the interquartile range or smaller than the 1st quartile minus 3 times the interquartile range. 
 
Specificity 
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The distributions of the specificity (the proportion of subjects that did not convert to dementia 
and were correctly predicted) are shown in figure 3.2.4. The differences in the specificity 
distributions were statistically significant (χ2Fr(9)= 37.292;  p<0.001).  SVM scored the 
highest in specificity followed by a second group composed by MLP, LR and RBF with 
significant differences from a third group composed by LDA, QDA, CTrees and RF. 
 
 
Figure 3.2.4 – Box-plot distributions of specificity (number of MCI predicted / number of MCI observed) for the 
5 test samples resulting from the 5-fold cross-validation procedure (see text for abbreviations) (χ2Fr(9)=37.292; 
p<0.001). Different letters indicate statistically significant differences between classifiers on Dunn’s mean rank 
comparison procedure. Circles and stars represent outliers and extreme outliers respectively. 
 
 
Sensitivity 
Figure 3.2.5 illustrates the distributions of the sensitivity (proportion of subjects that were 
correctly predicted to convert into dementia) values obtained by the 10 classifiers in the 5 test 
samples. There were statistically significant differences in the distribution of the sensitivity 
values of the analyzed classifiers (χ2Fr(9)=29.0; p=0.001). LDA, CART, QUEST and RF had 
the highest sensitivity values, which were significantly different from a second group 
composed by LR, MLP, RBF and CHAID. It is worthwhile to mention that this second group 
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had median sensitivity lower than 0.5, and that SVM was the classifier with significantly 
lowest sensitivity. 
 
 
Figure 3.2.5 – Box-plot distributions of sensitivity (number of Dementia predicted / number of Dementia 
observed) (see text for abbreviations) (χ2Fr(9)= 29.0; p=0.001). Different letters indicate statistically significant 
differences between classifiers on a multiple mean rank comparison procedure. Circles and stars represent 
outliers and extreme outliers respectively. 
 
Area under the ROC 
The distribution of the areas under the ROC (AUC) for the 10 classifiers in the 5 test samples 
is shown in figure 3.2.6. There are statistically significant differences between classifiers 
(χ2Fr(9)= 23.745;  p=0.005). SVM shows the highest AUC, however an extreme low value 
removes the significance of the differences with the AUC distributions from the other 
classifiers. LDA, LR, MLP, RBF and RF are a homogenous group statistically different from 
the group composed by QDA, CHART and QUEST who are plagued by extreme low values. 
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Figure 3.2.6 – Box-plot distributions of area under the Receiver Operating Characteristic curve (AUC) (see text 
for abbreviations) (χ2Fr(9)= 23.745;  p=0.005). Different letters indicate statistically significant differences 
between classifiers on a multiple mean rank comparison procedure. Circles and stars represent outliers and 
extreme outliers respectively. 
 
Classification by chance alone 
Press’ Q evaluates the performance of a classifier as compared to chance alone. Under the 
null hypothesis that the classifier is no better than chance alone, Press’ Q has a chi-square 
distribution with 1 degree of freedom. Thus, classifiers with Q≥3.84 classify significantly 
better than chance alone for 0.05 significance level. The Q distributions in the 5 sample tests 
are given by figure 3.2.7. There were statistically significant differences between the Q 
distributions (χ2Fr(9)=21.582; p=0.01). Dunn’s multiple mean rank comparisons revealed that 
SVM had the highest mean rank followed by RF, MLP, CHAID and LR. The smallest mean 
ranks were observed for LDA, QDA, CART and QUEST. All classifiers, with the exception 
of QUEST, had 1st quartiles higher than 3.84.  
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Figure 3.2.7 – Box-plot distributions of Press’ Q (see text for abbreviations) (χ2Fr(9)=21.582;  p=0.01). Different 
letters indicate statistically significant differences between classifiers on Dunn’s multiple mean rank comparison 
procedure. Classifiers with Q≥3.84 classify significantly better than chance alone for a 0.05 significance level. 
Circles and stars represent outliers and extreme outliers respectively. 
 
3.2.3      Discussion  
All classifiers evaluated showed better median classification than chance alone in the 
prediction of evolution into dementia of elderly people with Mild Cognitive Impairment. 
Median Press’s Q statistic was larger or equal to 5 for all classifiers, although in QUEST the 
1st quartile was below the critical level for this statistics. Discriminant power of the classifiers, 
as judged by the AUC, was appropriate for most classifiers (greater than 0.7) with the 
exception for classification trees (median AUC of 0.6). No statistically differences were found 
in the total accuracy of the 8 of the 10 evaluated classifiers (Medians between 0.63 and 0.73), 
but RF (Me=0.74) and SVM (Me=0.76) obtained statistically significant higher classification 
accuracy values. Median specificity ranged from a minimum of 0.64 (CART and LDA) to a 
maximum of 1 (SVM). With the exception of CART and QUEST, all the other classifiers 
were quite efficient in predicting group membership in the group with larger number of 
elements (the MCI group corresponding to 69% of the sample; median specificity larger than 
0.6). Judging from total accuracy and specificity, SVM and RF rank highest amongst the 
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classifiers tested as has been suggested elsewhere (Burges, 1998; Breinam, 2001; Liaw and 
Wiener, 2002; Lehmann et al., 2007). However, a quite different picture emerges from the 
analysis of the sensitivity of the classifiers. Prediction for the group with lower frequency (the 
Dementia group, 31% of the sample) was quite poor for several of the tested classifiers, 
including the ones with some of the highest specificity values. Minimum median sensitivity 
was 0.30 (SVM) and maximum median sensitivity was 0.66 (QUEST, followed by 0.64 for 
LDA and RF). Only six of the ten classifiers tested showed median sensitivity larger than 0.5 
(and only five had 1st quartile sensitivity larger than 0.5). Considering that conversion into 
dementia is the key prediction in this biomedical application and thus higher sensitivity of 
classifiers is required, classifiers like Logistic Regression, Neural Networks, Support Vector 
Machines and CHAID trees are inappropriate for this type of binary classification task. 
Similar findings were observed in studies comparing different classifiers in other biomedical 
conditions (Meyer, Leischa and Hornik, 2003; Lehmann et al., 2007; Maglogiannis et al., 
2008). Total accuracy of classifiers is misleading since some classifiers are good only at 
predicting the larger group membership (high specificity) but quite insufficient at predicting 
the smaller group membership (low sensitivity).  Some of the classifiers with the highest 
specificity (Neural Networks (MLP and RBF) and SVM) are also the classifiers with the 
lowest sensitivity. Unbalance of classification efficiency for small frequency vs. large 
frequency groups has been found in other real-data studies for Logistic Regression and Neural 
Networks (Orr, 1997; Schwarzer, Vach and Schumacher, 2000; Meyer, Leischa and Hornik, 
2003; Finch and Schneider, 2006). Taking in account total accuracy, specificity and 
sensitivity, the oldest Fisher’s Linear Discriminant Analysis does not rank much lower than 
Multiple Layer Perceptrons or Random Forests, the newest member of the binary 
classification family. Similar observations have been made by other authors when classifiers 
were compared on more than total accuracy or total error rates. For example, Breiman and 
colleagues (1984) stated, “LDA does as well as other classifiers in most applications”. Meyer, 
Leischa and Hornik (2003) point out in their comparison study of data mining classifiers, 
including Neural Networks and SVM, that LDA is a very competitive classifier, producing 
good results “out-of-the-box without the inconvenience of delicate and computationally 
expensive hyperparameter tuning”. In a similar application of Random Forests, SVM, Neural 
Networks and Linear Discriminant Analysis for recognition of Alzheimer's disease based on 
electrical brain activity, Lehmann and colleagues (2007) demonstrated that “even though 
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modern computer-intensive classification algorithms such as RF, SVM and Neural Networks 
show a slight superiority, more classical classification algorithms performed nearly equally 
well”.  
It must be pointed out that the relatively small sample size, although in the range of most 
biomedical experimental studies with dementia and cognitive impairment, may limit the 
performance of some data mining methods assessed in this study. Sample size has been 
known to play an important role in the accuracy of Neural Networks (Fukunaga and Hayes, 
1989; Raudys and Jain, 1991). In our study, the number of cases for the training and testing 
sets are at lower limit for recommended data set dimensions for Neural Networks (several 
hundred) (Fukunaga and Hayes, 1989; Raudys and Jain, 1991; Vach, Roβner nd Schumacher, 
1996). Large data sets requirements are also found in LR, but less in LDA if the model 
assumptions are met. The present sample size was not, apparently, limiting for the 
achievement of an acceptable accuracy, specificity and sensitivity of both Random Forests 
and LDA, as reported elsewhere (Vach, Roβner nd Schumacher, 1996; Pohar, Blas and Turk, 
2004). Furthermore, there are studies with relatively small samples where data mining 
techniques, like SVM and Neural Networks have been used with high accuracy in 
classification problems (Lehmann et al., 2007; Jahandideh, Abdolmaleki and Movahedi, 
2010; Oliveira et al., 2010; Zhu et al., 2010). Equivalent or even superior performances have 
been reported for Linear Discriminant Analysis and Random Forest when compared with 
Neural Networks, Classification trees and Support Vector Machines (Breiman, 2001; Meyer, 
Leischa and Hornik, 2003; Lehmann et al., 2007; Statnikov and Aliferis, 2007; Smith, Sterba-
Boatwright and Mott, 2010). However, controversy still prevails regarding the effects on 
classifiers performance of different combinations of predictors, data assumptions, sample 
sizes and classifiers (Fan and Wang, 1999; Lisboa, 2002; Lei and Koehly, 2003; Lemon et al., 
2003; Finch and Schneider, 2007; Lehmann et al., 2007). 
In conclusion, for binary classification problems, like prediction of dementia, where classes 
can be linearly separated and sample size may compromise training and testing of popular 
data mining and machine learning methods, Random Forests and Linear Discriminant 
Analysis proved to have high accuracy, sensitivity, specificity and discriminant power. On the 
contrary, data mining classifiers like Neural Networks and Classification Trees showed low 
sensitivity, recommending against its use in classification problems where the class of interest 
is less represented. It is noteworthy to mention that Fisher’s Linear Discriminant Analysis, a 
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classifier devised almost a century ago, stands up as a simple, efficient and time-proof 
classifier.
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3.3 Comparison of four verbal memory tests for the Diagnosis and 
predictive value of MCI (Dementia and Geriatric Cognitive Disorders Extra) 
 
3.3.1       Rationale and Procedure 
Many elderly people suffer from memory and other cognitive decline that is not severe 
enough to meet the criteria for dementia. These elderly people may be diagnosed as having 
mild cognitive impairment (MCI), implying a high risk of progression to dementia, usually 
Alzheimer’s disease (AD), in the forthcoming years. In the initial formulation by Petersen and 
colleagues (1999), MCI was based on (1) memory complaint, preferably corroborated by an 
informant; (2) memory impairment documented according to appropriate reference values; (3) 
essentially normal performance in non-memory cognitive domains; (4) generally preserved 
activities of daily living, and (5) absence of dementia. As repeatedly pointed out, several of 
these criteria would need operationalization. In particular, the test used to document the 
memory impairment and the cut-off score should be specified (Petersen, 2004). In spite of 
further refinements in the concept of MCI (Winblad et al., 2004; Portet et al., 2006; Chertkow 
et al., 2007; Matthews et al., 2008; Visser and Verhey, 2008; Jak et al., 2009; Petersen et al., 
2009; Saxton et al., 2009), there is still no consensus about the specific memory test that 
should be used for the diagnosis of MCI or prodromal phase of AD (Dubois and Albert, 2004; 
Albert et al., 2011). Thus, there is the need to compare systematically and prospectively the 
inclusion of different verbal memory tests in the MCI criteria, and to examine how this 
modifies the predictive value of the MCI diagnosis for conversion to dementia. 
Deficits in episodic memory are associated with impaired encoding of the contextual 
information and consolidation of new verbal material (Wang and Zhou, 2002; Moulin et al., 
2004; Belleville et al., 2008), and a lower performance on tests of episodic verbal memory is 
a forerunner of future cognitive decline (Almkvist et al., 1998; Blacker et al., 2007; Guarch et 
al., 2008; Rabin et al., 2009). A deficit in delayed recall assessment of episodic long-term 
memory, as opposed to the short-term or implicit memory assessment would be particularly 
characteristic of initial AD (Perri et al., 2007a), since it reflects involvement of the 
hippocampus and related medial temporal lobe structures. Significant verbal memory 
impairment, confirmed by neuropsychological testing, is considered the hallmark of both 
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amnestic MCI and AD (Portet et al., 2006; Dubois et al., 2007). So far, distinct tests of 
memory and learning have been used to establish the presence of memory impairment in 
order to fulfill the criteria for MCI, namely the Logical Memory (LM) test (Cunje et al., 2007; 
Brooks et al., 2008; Guo et al., 2009; Rabin et al., 2009), the Verbal Paired-Associate 
Learning (VPAL) test (Brooks et al., 2008; Pike et al., 2008), and the California Verbal 
Learning Test (CVLT) (Greenaway et al., 2006; Blacker et al., 2007; Ribeiro, Guerreiro and 
de Mendonça, 2007; Wehling et al., 2007; Bläsi et al., 2009; Rabin et al., 2009; Teng et al., 
2009; Riepe et al., 2010).  
The LM test (Wechsler, 1945) has been used for a long time to discriminate between healthy 
older adults and individuals with very mild dementia (Storandt and Hill, 1989) and is still 
commonly used for the assessment of memory impairment in MCI patients nowadays. Recent 
studies associate the presence of impairment in LM with a higher rate of conversion to AD as 
compared with other episodic memory tests (Guo et al., 2009; Baek et al., 2011). 
Furthermore, the LM test was recently proposed as a screening tool for MCI in the 
Alzheimer’s disease Neuroimaging Initiative (ADNI) study (Aisen et al., 2010). 
Previous studies showed that impairment in list learning tests might as well predict accurately 
the conversion to AD (Blacker et al., 2007; Maruff et al., 2004). Rabin and colleagues (2009) 
showed that the impairment in the total learning score from the CVLT (Delis et al., 1987) had 
superior overall accuracy in distinguishing MCI from normal aging, even though that 
accuracy might be enhanced by the inclusion of the delayed recall condition of the LM test. 
The VPAL test was proposed to reveal the presence of memory deficits in MCI and AD 
patients, although the facilitation of the encoding process through the cued recall format could 
lead to a different memory deficit profile than in patients assessed with the CVLT (Pike et al., 
2008). 
Besides verbal memory impairment, some studies have evidenced that other memory domains 
are also altered in MCI, namely those related to working memory (Belleville et al., 2008). 
The Digit Span (DS) test measures auditory attention, immediate span of learning, and 
working memory. Impairment in the DS test was associated with future cognitive decline 
(Kurt, Yener and Oguz, 2011; Wilson et al., 2011). However, it appears that working memory 
does not decline early in the neurodegenerative process of AD (Wiechmann, Hall and 
O’Bryant, 2011). Therefore, the DS test was used in this study as a negative control to other 
applied tests that represent earlier markers of the neurodegenerative process observed in AD 
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patients (e.g., tests assessing episodic memory and verbal learning). Another type of memory 
that evidenced more resistance to AD progression is semantic memory, since the lexical 
semantic system might be spared until the initial phase of dementia (Balthazar et al., 2007). 
In the present study, non-demented patients with cognitive complaints who had a 
neuropsychological battery assessing different types of memory were followed prospectively. 
The aim was to determine whether the inclusion of four distinct memory tests, i.e., LM test, 
CVLT, VPAL test, and DS test, in the diagnostic criteria could modify the predictive value of 
MCI regarding conversion to dementia. 
 
Procedures 
Research Participants: Participants were selected from the Cognitive Complaints Cohort 
(Maroco et al., 2011), which is a prospective study conducted at the Institute of Molecular 
Medicine, Lisbon, to investigate the cognitive stability or evolution to dementia of subjects 
with cognitive complaints based on a comprehensive neuropsychological evaluation and other 
biomarkers. The study was approved by the local ethics committee. 
 
Inclusion Criteria: The inclusion criteria were: (1) presence of cognitive complaints; (2) 
neuropsychological testing including all four memory tests compared in the present study, and 
(3) follow-up >6 months. 
 
Exclusion Criteria: The exclusion criteria were: (1) presence of neurological or psychiatric 
disorders that may induce cognitive deficits; patients with major depression according to 
DSM-IV-TR (APA, 2000) or serious depressive symptoms (indicated by a score on the 
Geriatric Depression Scale short version (GDS 15) > 10 points) were excluded; (2) systemic 
illness with cerebral impact; (3) history of alcohol abuse or recurrent substance abuse or 
dependence, and (4) presence of dementia according to DSM-IV-TR (APA, 2000), or a Mini-
Mental State Examination (MMSE) score below the cutoff for the Portuguese population, or 
significant impairment on activities of daily life according to the Blessed Dementia Rating 
Scale (BDRS) (Blessed, Tomlinson and Roth, 1968; Garcia, 2008). 
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The baseline comprehensive neuropsychological assessment was carried out by the same team 
of trained neuropsychologists, supervised by M.G., following a standard protocol and 
comprising several tests and scales: 
(1) MMSE (Folstein, Folstein and McHugh, 1975; Guerreiro, 1998): the MMSE is one of the 
most widely used brief instruments for the clinical evaluation of cognitive state in adults; 
(2) Battery of Lisbon for the Assessment of Dementia (BLAD) (Garcia, 1984): the BLAD is a 
comprehensive neuropsychological battery evaluating multiple cognitive domains and 
validated for the Portuguese population. Tests of interest for the present study were: LM 
(immediate and delayed recall; Wechsler Memory Scale, WMS); VPAL (immediate recall; 
WMS), and DS (forward and backward; WMS) (Wechsler, 1945); 
(3) CVLT (Delis et al., 1987; Ribeiro, Guerreiro and de Mendonça, 2007): the CVLT 
measures verbal learning assessing constructs as repetition learning, serial position effects, 
semantic organization, intrusion, and proactive interference. The word lists (list A and list B) 
are made up of 16 items from 4 different categories of ‘shopping list’ items. The trials of 
interest (trials with better discriminating ability for different stages of cognitive decline 
according to previous studies) (Greenaway et al., 2006) considered for the present study were: 
the total number of words from list A correctly recalled on the five learning trials (Atot) and 
long-delayed free recall (LDFR; number of words from list A correctly recalled after an 
interference period of 20 min); 
(4) BDRS (Blessed, Tomlinson and Roth, 1968; Garcia, 2008): the BDRS is a brief 
behavioral scale based on the interview of a close informant, assessing functional capacity for 
activities of daily living and changes in personality; 
(5) Geriatric Depression Scale (GDS) (Yesavage et al., 1983; Sheikh and Yesavage, 1986; 
Barreto et al., 2008): the GDS is a self-report assessment used specifically to identify 
depression in the elderly. For this study, a short-form (15 items) of the self-report instrument 
was used. 
 
Diagnosis of MCI: Diagnosis of MCI was based on criteria given by the MCI Working Group 
of the European Consortium on Alzheimer’s disease (Portet et al., 2006): 
(1) Cognitive complaints coming from the patients or their families; 
(2) The reporting of a decline in cognitive functioning relative to previous abilities during the 
past year by the patient or informant; 
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(3) Presence of cognitive impairment: in this study, four distinct memory tests to fulfill this 
diagnostic criterion were compared: LM, CVLT, VPAL, and DS; 3 cutoffs to define 
impairment were also analyzed (1, 1.5, and 2 SD below the mean); 
(4) Absence of major repercussions on daily life (the patient may report difficulties 
concerning complex day-to-day activities). 
 
Patients were assessed at follow-up for the presence of dementia and diagnosis of AD, 
according to the DSM-IV-TR (APA, 2000) criteria. 
 
Data Analysis: Demographic, clinical, and neuropsychological data were analyzed using the 
Mann-Whitney U test for numerical data and Pearson χ2 test for nominal data. All tests were 
two-tailed and a p value < 0.05 was assumed as statistically significant. 
The neuropsychological assessment was standardized according to the age and education 
norms for the Portuguese population and z scores were calculated. The 1, 1.5, and 2.0 SD 
cutoffs below the mean were compared for establishing impairment on the memory tests. 
Survival methods were chosen for analysis, since MCI conversion to dementia occurred at 
different times and the observations were censored. To explore the effect of impairment in 
different memory tests on the conversion to dementia during follow-up, univariate and 
multivariate Cox proportional hazards regression models were performed. For multivariate 
models, the Enter selection method was used to build the regression models. The memory 
tests were introduced as a binary variable (presence or not of impairment, coded as 0 and 1, 
respectively, and according to the cutoffs established, 1, 1.5, and 2.0 SD). Since converters to 
dementia were older at the baseline than non-converters, the multivariate model was adjusted 
for age.  
Survival time was calculated as the interval from the initial baseline evaluation to the 
diagnosis of dementia. For patients who remained non-demented, survival time was censored 
at the date of the last clinical assessment. A forest plot with the estimated hazard or risk of 
conversion to dementia for the different memory tests and cutoffs was displayed. Statistical 
analyses were performed using IBM SPSS Statistics 19 for Windows (2010 SPSS Inc., an 
IBM Company) and GraphPad Prism 5 for Windows (GraphPad Software, Inc., San Diego, 
Calif., USA) for graphical displays. 
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3.3.2       Results 
At baseline, 272 patients reporting subjective cognitive complaints and not demented were 
included. During the follow-up time (3.0±1.9 years), 58 patients (21%) converted to dementia, 
and 214 (79%) did not. Most cases that progressed to dementia were diagnosed as AD (85%). 
The presence of depressive symptoms and functional capacity did not differ between 
converters and non-converters (table 3.3.1). Likewise, the follow-up time was not 
significantly different between the two groups (table 3.3.1). The converters were older than 
the non-converters at the baseline assessment (table 3.3.1).  
Statistically significant differences between the converters and non-converters were present in 
all measures of verbal memory administrated with the exception of the DS test and a measure 
of forgetting from the CVLT (table 3.3.2).  
 
 
 
 
 
 
 
 
 
 
 
Table 3.3.1 - Baseline demographic and clinic characterization data 
 Converters 
(n=58) 
Non-converters 
(n=214) p-value 
Age, years, mean (SD) 69.9 (8.7) 66.2 (9.3) 0.004#* 
Gender, female/male, n 38/20 122/92 0.293‡ 
Formal education, years, mean (SD) 9.3 (5.1) 10.1 (4.8) 0.221# 
Follow-up time, years, mean (SD) 2.8 (1.7) 3.1 (1.9) 0.427# 
Geriatric Depression Scale, mean (SD) 4.8 (3.7) 4.8 (4.1) 0.831# 
Blessed Dementia Scale, mean (SD) 3.4 (2.5) 2.9 (1.9) 0.450# 
Mini-Mental State Examination, mean (SD) 25.4 (2.5) 28.3 (1.9) 0.001#* 
#, Mann-Whitney test; ‡,  χ2  Pearson Chi-Square test; *, Statistically significant (p< 0.05) 
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Table 3.3.2 – Verbal memory tests at the baseline 
 
Converters 
(n=58) 
Non-converters 
(n=214) p-value
#
 
Logical Memory 
Immediate recall, mean (SD) -1.46 (1.09) -0.89 (1.00) <0.001* 
Delayed recall, mean (SD) -1.61 (1.11) -0.84 (1.08) <0.001* 
Forgetting index, mean (SD) -0.38 (0.47) -0.11 (0.45) 0.001* 
Verbal  
Paired-Associate  
Learning 
mean (SD) 
 -1.48 (1.14) -0.74 (1.15) <0.001* 
California Verbal 
Learning test 
Five learning trials total, mean (SD) -3.22 (1.45) -1.81 (1.44) <0.001* 
Long delayed recall, mean (SD) -3.30 (1.77) -1.64 (1.61) <0.001* 
Forgetting index, mean (SD) -0.11 (0.65) 0.06 (0.44) 0.142 
Digit Span 
Forward, mean (SD) 0.40 (1.63) 0.41 (1.27) 0.837 
Backwards, mean (SD) 0.05 (1.30) 0.30 (1.15) 0.084 
Means of z scores, calculated according to the equation [z= (x-mean)/SD]; # Mann-Whitney test; * Statistically 
significant (p< 0.05). 
 
 
The analysis of other neuropsychological tests from the BLAD also showed significantly 
lower performances in converters as compared to non-converters, namely in measures of 
attention, initiative, and conceptual thinking; however, all scores were within 1 SD of the 
mean, showing that the converters had no major impairments in non-memory cognitive 
domains that would qualify them for a diagnosis of dementia (results not shown). Of the 272 
patients reporting subjective cognitive complaints and not demented, 33 (12%) had no 
alterations at the baseline in the memory tests selected for the present study (considering the 
cutoff < 1.5 SD), 72 (26%) had deficits at only 1 of the memory tests, 167 (62%) showed 
deficits in ≥ 2 memory tests (from those, 4 (2%) had deficits in at least 1 measure of all 
memory tests). The number of patients diagnosed as having MCI based on each specific 
memory test and 3 different cutoff values is shown in table 3.3.3. The CVLT test was the 
verbal memory test that categorized more subjects as MCI across the 3 cutoffs (table 3.3.3). 
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Since the conversion to dementia occurred during the follow-up time at different moments, a 
survival analysis was performed. The diagnosis of MCI on the basis of an abnormal value for 
each of the memory tests, LM, CVLT, and VPAL, according to the cutoffs determined for 
impairment, carried a significant risk of conversion to dementia during the follow-up 
(univariate Cox regression model fitted to the results of each memory test; figure 3.3.1). The 
diagnosis of MCI on the basis of an abnormal value for the DS backward condition (all 
cutoffs) and forward condition (1 and 2 SD cutoffs) was not significantly associated with the 
risk of conversion to dementia during the follow-up (figure 3.3.1). The three significant 
memory tests showed overlapping hazard risks for conversion to dementia (figure 3.3.1).  
To test whether the verbal memory tests used in the diagnostic criteria of MCI (LM, CVLT, 
and VPAL) that individually had shown to accurately predict future conversion to dementia, 
could be combined to improve their predictive value, a multivariate Cox regression analysis 
was performed. In an attempt to increase the power of multivariate analysis, we reduced the 
number of measures in the study and selected two at maximum for each memory test. The 
measures not selected for the present study also showed overlapping hazard risks and did not 
add any further accuracy for predicting future conversion to dementia. In the multivariate Cox 
regression analysis only the CVLT (learning measure for the cutoff < 1.5 SD and long 
delayed recall for the other cutoffs) remained significant as a predictor of conversion to 
dementia (table 3.3.4). Non-demented patients with cognitive complaints diagnosed with MCI 
according to abnormal (cutoff commonly used of < 1.5 SD) learning in the CVLT had a 3.61 
Table 3.3.3 – Number of subjects diagnosed as MCI according to distinct measures and cut-offs of memory 
tests 
 1 SD 1.5 SD 2 SD 
Logical Memory 
Immediate recall, n (%) 
152 (55.9) 106 (39) 47(17.3) 
Delayed recall, n (%)   
137 (50.4) 98 (36) 55 (20.2) 
California Verbal 
Learning test 
Five learning trials total, n (%) 
195 (71.7) 166 (61) 123 (45.2) 
Long delayed recall, n (%)   
147 (54) 117 (43) 91 (33.5) 
Verbal Paired-Associate 
Learning  
N (%)    
132 (48.5) 86 (31.6) 47 (17.3) 
Digit Span  
Forward, n (%)    
31 (11.4) 24 (8.8) 3 (1.1) 
Backward, n (%)    
36 (13.2) 14 (5.1) 9 (3.3) 
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higher risk of becoming demented in the follow-up as compared to those who had normal 
learning in the CVLT (table 3.3.4). 
 
 
 
 
Figure 3.3.1 - Verbal memory tests and risk of progression to dementia (hazard ratios and confidence intervals 
from univariate Cox regression analysis). 
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Table 3.3.4 – Verbal memory tests and risk of progression to dementia (Multivariate Cox Regression Analysis) 
 
 B SE Exp (B) 
95% CI for 
Exp (B) Wald statistic p 
-1
 S
D
 
Logical Memory test 
Immediate 
recall  0.03 0.54 1.04 [0.36-2.97] 0.004 0.95 
Delayed recall 0.71 0.50 2.04 [0.77-5.44] 2.04 0.15 
California Verbal 
Learning test 
Five learning 
trials 1.24 0.78 3.45 [0.75-15.91] 2.52 0.11 
Long delayed 
recall 1.30 0.57 3.65 [1.20-11.09] 5.22 0.02* 
Verbal Paired-
Associate Learning 
test 
 0.25 0.35 1.29 [0.65-2.55] 0.53 0.47 
Digit Span test 
Forward 0.29 0.53 1.34 [0.47-3.78] 0.30 0.58 
Backwards 0.31 0.47 1.37 [0.55-3.43] 0.45 0.50 
-1
.5
 S
D
 
Logical Memory test 
Immediate 
recall  0.03 0.43 1.03 [0.44-2.41] 0.004 0.95 
Delayed recall 0.52 0.45 1.68 [0.69-4.06] 1.31 0.25 
California Verbal 
Learning test 
Five learning 
trials 1.28 0.57 3.61 [1.19-10.99] 5.12 0.02* 
Long delayed 
recall 0.76 0.49 2.13 [0.81-5.60] 2.37 0.12 
Verbal Paired-
Associate Learning 
test 
 0.55 0.38 1.73 [0.83-3.61] 2.12 0.15 
Digit Span test 
Forward 0.92 0.53 2.51 [0.89-7.06] 3.04 0.08 
Backwards 0.60 0.75 1.82 [0.42-7.97] 0.64 0.43 
-2
 S
D
 
Logical Memory test 
Immediate 
recall  0.64 0.43 1.89 [0.82-4.37] 2.21 0.14 
Delayed recall 0.43 0.43 1.53 [0.66-3.58] 0.96 0.33 
California Verbal 
Learning test 
Five learning 
trials 0.79 0.55 2.21 [0.75-6.54] 2.07 0.15 
Long delayed 
recall 1.45 0.59 4.26 [1.35-13.43] 6.11 0.01* 
Verbal Paired-
Associate Learning 
test 
 0.28 0.43 1.32 [0.57-3.05] 0.41 0.52 
Digit Span test 
Forward -8.63 408.64 <0.001 [0.00-nd] <0.001 0.98 
Backwards -0.07 1.03 0.94 [0.12-7.11] 0.004 0.95 
* Statistically significant (p < 0.05). 
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3.3.3       Discussion 
The present study shows that different verbal memory tests, LM, CVLT, and VPAL, when 
used in non-demented patients with cognitive complaints to establish memory impairment in 
the diagnosis of MCI, are not significantly different to predict the progression to dementia. 
However, the MCI criteria using the CVLT had the highest predictive value, which was not 
improved by adding other memory tests.  
Although it has been argued that the use of a memory test battery offers a better sensitivity to 
the earlier diagnosis of MCI (de Jager and Budge, 2005), we showed that only the CVLT 
remains significant on the multivariate Cox regression model as a predictor of progression to 
dementia, and other memory tests did not significantly add to the predictive value. The 
assessment of verbal memory based on list learning was found to be predictive of future 
conversion to dementia in earlier phases, possibly due to the reduced use of learning strategies 
(Schrijnemaekers et al., 2006). Previous studies have also suggested that list learning 
represents a more demanding encoding test than story recall, is more sensitive to executive 
dysfunction, and offers a better prediction of conversion to dementia (Rabin et al., 2009; 
Tremont et al., 2000, 2010). The higher frequency of impaired performance for CVLT at 
baseline highlights the demanding character of the task, indicating that it might be an early 
marker for cognitive decline (Blacker et al., 2007).  
Different measures of verbal memory tests used for the diagnosis of MCI may assess different 
stages of the neurodegenerative process by relying on distinct cognitive resources, so the 
contribution to diagnostic accuracy and predictive value is unique (Moulin et al., 2004). Both 
measures of immediate and delayed free recall were analyzed, because there is some evidence 
that long-term memory is more extensively impaired in MCI patients than short-term memory 
and, more importantly, it has evidenced a greater sensitivity for the identification of amnestic 
MCI which will progress to dementia (Perri et al., 2007a). Verbal memory impairment can 
possibly correspond to either a defective consolidation of information relying on an alteration 
of mesiotemporal areas, or to a difficulty in elaborative encoding and afterwards correct 
retrieval of information, which in this case is associated with an alteration of frontal areas. 
MCI patients at risk of conversion to AD are expected to present deficits in learning 
(encoding and storage) rather than in the retrieval process (Traykov et al., 2007; Carlesimo, 
Perri and Caltagirone, 2011). Some verbal memory tests assess primarily the capacity of 
storage, and for that aim semantic cues are systematically provided during the encoding phase 
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in order to facilitate the retrieval process. For instance, the Free and Cued Selective 
Reminding Test (Buschke, 1984) assesses specifically the storage capacity of MCI patients 
with focus on the amnestic syndrome of the medial temporal type associated with a future 
progression to dementia (de Jager and Budge, 2005; Schrijnemaekers et al., 2006). According 
to a recent review, the studies that determined the predictive value of this test for future 
conversion to dementia also evidenced that delayed recall measures were less sensitive and 
specific than immediate recall measures, supporting the hypothesis of a failure at the initial 
learning process (although providing semantic cues), instead of forgetting due to inadequate 
storage of the information (Carlesimo, Perri and Caltagirone, 2011). Other studies have 
shown that MCI patients at risk of conversion to dementia (namely AD) could benefit from 
semantic cues on the encoding phase in a similar way as normal controls, suggesting that the 
deficits in encoding correctly the information during the learning process, and not a difficulty 
in the storage process itself, would lead to retrieval impairment (Buschke, 1984; Perri et al., 
2005; Ribeiro, Guerreiro and de Mendonça, 2007; Sarazin et al., 2007; Auriacombe et al., 
2010; Carlesimo, Perri and Caltagirone, 2011).  
Bearing in mind the above mentioned, we decided to examine the CVLT performance for the 
total learning and delayed recall, which are also the measures associated with a better 
discrimination between normal aging, MCI, and AD (Greenaway et al., 2006). Verbal 
learning tests were analyzed on associative (VPAL) and non-associative (CVLT) conditions 
in order to assess different stages of impairment progression. Deficits in associative learning 
tests are present in a more advanced stage of progression in MCI (Egerházi et al., 2007) and, 
therefore, may not be the best predictors for conversion at earlier phases. Interestingly, the use 
of different cutoffs for CVLT impairment did not considerably modify the risk of progression 
to dementia, although 1.5 standard deviation below mean score for the subjects reference 
group has been considered the most conservative strategy for diagnosing MCI because of the 
greatest stability longitudinally (Petersen et al., 1995; Albert et al., 2001; Arnáiz et al., 2004; 
Lopez et al., 2006; Tabert et al., 2006; Guarch et al., 2008; Jak et al., 2009; Chang et al., 
2010).  
The present results suggest that a measure of working memory, like the DS backward, should 
not be used to qualify for memory impairment in the MCI diagnostic criteria, and the 
prediction of future conversion to dementia would be unreliable. Working memory and 
visuospatial ability have been proposed as functions that decline slowly in MCI patients 
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(Bennett et al., 2002). A recent study showed that subjects presenting subjective cognitive 
complaints and impairment in DS might have a higher risk of future conversion to MCI but 
did not compare the DS predictive value to other memory tests (Kurt, Yener and Oguz, 2011).  
One limitation of the present study is the focus on a restricted number of verbal memory tests 
commonly used in clinical practice to evaluate memory in non-demented patients with 
suspected cognitive decline. Clearly, it would be interesting to evaluate other memory 
modalities, with visual or semantic memory tests. Nevertheless, several studies showed that 
their diagnostic value in the identification of MCI patients at risk of conversion to dementia 
do not clearly overtake that of verbal episodic memory tests (Alescio-Lautier et al., 2007; 
Ahmed et al., 2008; Guarch et al., 2008; Gigi et al., 2010). Another limitation of the present 
study was that it focused on neuropsychological data, and other biomarkers were not 
considered. Recently, many studies have been published combining different biomarkers in 
non-demented subjects with cognitive complaints for predicting future conversion to 
dementia. Consequently, the choice of specific verbal memory tests in the neuropsychological 
assessment, in conjunction with other biomarkers, may be crucial to accurately predict future 
conversion to dementia.  
In conclusion, different memory tests, namely LM, CVLT, and VPAL, can be used to 
establish the diagnosis of MCI and predict the progression to dementia. Considering our 
results, the MCI criteria using the CVLT had the highest predictive value, which was not 
improved by adding other memory tests, and taking into account that there are frequent 
limitations in clinical practice to apply an extensive neuropsychological battery to all 
individuals with suspected cognitive decline (Celsis, 2000), we propose that a list learning 
task could be the preferred test to establish memory impairment in MCI diagnosis. 
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3.4 Prediction of long-term (5 years) conversion to dementia using 
neuropsychological tests (submitted) 
 
 
3.4.1 Rationale and Procedure 
The early diagnosis of Alzheimer’s disease (AD) has become very important. Many people 
now search for medical help when they notice subtle cognitive difficulties. The reliable 
identification of the patients who already have Alzheimer’s disease may open new frontiers in 
the management of the disease, allowing interventions that might involve manipulation of risk 
and protection environmental factors, cognitive rehabilitation procedures, and clinical trials 
with putative neuroprotective drugs.  
The diagnosis of Mild Cognitive Impairment (MCI), initially proposed by Petersen and 
colleagues (1999) as a clinical entity with a high risk of progression to Alzheimer’s disease, 
relied on the presence of cognitive impairment, namely memory deficits. Cognitive deficits 
required to established MCI diagnosis were considered in a more global scope in the revised 
criteria of MCI proposed by Portet and colleagues (2006), however cognitive impairment 
assessed through neuropsychological testing remained an indispensable condition for 
diagnosis. Likewise, the most recent criteria for early diagnosis of Alzheimer’s disease, 
namely prodromal AD (Dubois et al., 2007) and mild cognitive impairment due to 
Alzheimer's disease (Albert et al., 2011) still include the presence of cognitive impairment in 
the core diagnostic criteria. Thus, in spite of the advances in the development of novel 
imaging and biochemical biomarkers, the demonstration of cognitive impairment using 
neuropsychological tests remains a core feature for the early detection of AD. Importantly, 
neuropsychological assessment is more widely available and rather inexpensive in 
comparison to the novel research biomarkers. Moreover, recent studies have shown that 
cognitive markers can provide predictive values for future conversion to dementia as accurate 
as brain volumetric or CSF biomarkers (Schmand, Huizenga and Van Gool, 2010; Palmqvist 
et al., 2012).  
Significant advances have been gathered to determine the first cognitive alterations and 
temporal onset of cognitive decline in the early phases of AD.  Longitudinal studies based on 
large epidemiological cohorts followed-up for decades have evidenced the stability of 
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cognitive performance in the oldest who did not progress to AD, supporting the consideration 
that cognitive decline is not an inevitable consequence of old age, and suggesting a greater 
risk of conversion to AD for those that have experienced gradual cognitive impairment in the 
previous years (Wilson et al., 2011; Amieva et al., 2008; Johnson et al., 2009). Thus, by the 
time clinical criteria for AD diagnosis is met, the person has already experienced many years 
of aggravating cognitive impairment. 
Even so, the use of neuropsychological tests to detect the initial phases of cognitive decline in 
AD still has significant limitations that should be improved. In first place, decline in cognitive 
functions is known to occur earlier in some cognitive domains than in others (Johnson et al., 
2009; Grober et al., 2008), reflecting the evolving neurodegenerative progress, but there is 
still no consensus about which neuropsychological tests should be selected to assess these 
domains, as well as the most appropriate cut-off to use (De Santi et al., 2008; Schink et al., 
2010; Silva et al., 2012) to pinpoint the initial process of decline. 
In second place, most studies published so far were cross-sectional, or longitudinal with 
relatively short follow-up periods (Flicker, Ferris and Reisberg, 1991; Tierney et al., 1996; 
Devanand et al., 1997; Kluger et al., 1999; de Jager, Milwain and Budge, 2002; Tian et al., 
2003; Amieva et al., 2004; Atchison, Bradshaw and Massman, 2004; Lehrner et al., 2005; 
Blacker et al., 2007; Mickes et al., 2007; Carter et al., 2012; Johnson et al., 2012a). The 
importance of conducting longitudinal studies with longer follow-up periods should be 
emphasised. As an example, in the large ADNI cohort, using neuropsychological as well as 
extensive brain imaging and CSF neurochemical biomarkers, a predictive accuracy for MCI 
conversion to dementia of only 64% was obtained (Ewers et al., 2012). This is not surprising, 
since the average follow-up was 2.3 years, and presumably many converters just had not the 
time to progress to dementia. A follow-up period of 2 or 3 years may not be enough and 
longer follow-ups are needed to provide reliable and clinically significant predictive values in 
patients with memory complaints (Stephan et al., 2010; Ewers et al., 2012). 
We believe that, to be clinically meaningful, the clinical and neuropsychological evaluation 
must predict the outcome, in this case dementia, at long term, namely 5 years. Therefore, the 
aim of the present study is to assess the predictive value for future conversion to dementia of 
a comprehensive neuropsychological battery applied to a cohort of non-demented patients 
followed-up for more than 5 years (if patients have not converted to dementia earlier).  
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Research Participants 
Participants were selected from the Cognitive Complaints Cohort (CCC; Maroco et al., 2011; 
Silva et al., 2012), which is a prospective study conducted at the Institute of Molecular 
Medicine, Lisbon, to investigate the cognitive stability or evolution to dementia of subjects 
with cognitive complaints based on a comprehensive neuropsychological evaluation and other 
biomarkers. The study was approved by the local ethics committee. 
 
Inclusion Criteria: 
(1) Subjective complaints of cognitive deficits; 
(2) Cognitive assessment with a comprehensive neuropsychological battery; 
(3) Follow-up ≥ 5 years or conversion to dementia.  
 
Exclusion criteria: 
(1) Presence of neurological or psychiatric disorders that may induce cognitive deficits; 
patients with major depression according to DSM-IV-TR (APA, 2000) or serious depressive 
symptoms (indicated by a score in Geriatric Depression Scale short version (GDS 15; Barreto 
et al., 2008) of more than 10 points) were excluded; 
(2) Systemic illness with cerebral impact;  
(3) History of alcohol abuse or recurrent substance abuse or dependence; 
(4) Presence of dementia according to DSM-IV-TR (APA, 2000) or significant impairment on 
daily life activities detected by the presence of a score ≥ 3 on the first part (items 1-8) of the 
Blessed Dementia Rating Scale (Ribeiro, de Mendonça and Guerreiro, 2006). 
 
Procedures 
The baseline comprehensive neuropsychological assessment was carried out by the same team 
of trained neuropsychologists, supervised by M.G., following a standard protocol and 
comprised several tests and scales:  
(1) Battery of Lisbon for the Assessment of Dementia (BLAD) (Garcia, 1984; Guerreiro, 
1998) – the BLAD is a comprehensive neuropsychological battery evaluating multiple 
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cognitive domains and validated for the Portuguese population. This battery includes tests for 
the following cognitive domains: attention (Cancellation Task); verbal initiative (Semantic 
Fluency), motor and graphomotor initiatives; verbal comprehension (a modified version of the 
Token Test); verbal and non-verbal abstraction (Interpretation of Proverbs and the Raven 
Progressive Matrices – Ab series-B); orientation (personal, spatial and temporal); visuo-
constructional abilities (Cube Copy); planning and visuospatial/praxis abilities(Clock Draw); 
calculation (Basic Written Calculation); immediate memory (Digit Span forward); visual 
memory (Visual Reproduction test); working memory (Digit Span backward); learning and 
verbal memory (Verbal Paired-associate Learning, Logical Memory and Word Recall); 
(2)  Blessed Dementia Rating Scale (BDRS; Blessed, Tomlinson and Roth, 1968; Garcia, 
2008) – the BDRS is a brief behavioural scale based on the interview of a close informant; the 
first part of the scale refers to daily life activities, the second part to habits and the third part 
to changes in personality; 
(3)  Geriatric Depression Scale (GDS; Yesavage et al., 1983; Sheikh and Yesavage, 1986; 
Barreto et al., 2008) – the GDS is a self-report assessment used specifically to identify 
depression in the elderly. For this study a short-form (15 items) of the self-report instrument 
was used. 
 
Outcome 
Patients were assessed at follow-up and the outcome established. The diagnosis of dementia 
and Alzheimer’s disease was established according to the DSM-IV-TR (APA, 2000) criteria, 
in a consensus meeting with the neurologist and the neuropsychologists. 
 
Data analysis 
Demographic, clinical and neuropsychological data were analysed using independent samples 
Student's t test for numerical data and χ2 Pearson Chi-Square test for nominal data. All tests 
were 2-tailed and a probability value of <0.05 was assumed as statistically significant.  
The neuropsychological assessments were standardized according to the age and education 
norms for the Portuguese population, z scores were calculated and the presence of impairment 
on cognitive tests was established for a cut-off 1.5 SD below the mean.  
To determine the value of neuropsychological tests to predict long term (5 years) conversion 
to dementia, a Linear Discriminant Analysis (LDA) classificatory model was used, since this 
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traditional classifier ranked high among several traditional and data mining classifiers for 
prediction of dementia in a previous study (Maroco et al., 2011). A binary classification 
function (converters vs. non-converters) was built from the stepwise LDA to analyse 
sensitivity, specificity, accuracy and area under the ROC curve for prediction of long-term 
conversion to dementia. Equal a priori classification probabilities were used for Linear 
Discriminant Analysis to avoid biases from the data sets. A 5-fold cross-validation strategy 
was followed to assess the model against a set of data that was not used to create the model. 
The total sample was randomly divided into 5 proportional sub-samples. In each of the 5 
steps, 4/5 of the sample was used for training and 1/5 for testing. Mean values of the 5 test 
samples were considered for further comparisons. In all neuropsychological tests the 
proportion of missing data was generally low and tolerable, i.e. < 10%, with the exception for 
Visual Reproduction test (55.6%). LDA was first performed with all neuropsychological tests 
more impaired in converters than in non-converters using a stepwise method to ascertain if the 
presence of Visual Reproduction test would affect significantly the classificatory function 
model, but this test did not impact the final model and because of the elevated rate of missing 
values it was excluded from further analysis. The Logical Memory delayed recall revealed 
considerable collinearity with Logical Memory immediate recall (r=0.676), and for that 
reason the Forgetting Index, a measure that assesses the rate of forgetting between immediate 
and delayed condition, was used instead of Logical Memory delayed recall. Besides, 
Forgetting Index can be preferable since it is a measure of information encoded but not 
retrieved after a long delay period, while Logical Memory delayed recall represents the total 
of information retrieved regardless to whether information was successfully encoded before.  
Statistical analyses were performed using IBM SPSS Statistics 19 for Windows (2010 SPSS 
Inc., an IBM Company) package.  
 
 
3.4.2 Results 
From the CCC cohort of 568 non-demented patients with cognitive complaints referred for 
neuropsychological examination, 250 cases followed for at least 5 years (or until conversion 
to dementia) were selected. During the follow-up period (2.6±1.8 years for converters and 
6.1±2.1 for non converters), 162 patients (64.8%) progressed to dementia, and 88 (35.2%) did 
not. Most cases that progressed to dementia were diagnosed as Alzheimer’s disease (93.2%). 
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Demographic and clinical data are reported in Table 3.4.1. The converters at the baseline 
assessment were older than the non-converters and were more affected functionally (Table 
3.4.1).  
 
Table 3.4.1 – Baseline demographic and clinical characterization data 
 Converters 
(n=162) 
Non-converters 
(n=88) 
p-value 
Age, years, mean (SD) 71.0 (8.4) 65.8 (9.0) <0.001* 
Gender, female/male, n 106/56 57/31 1.000 # 
Formal education, years, mean (SD) 8.5 (4.8) 9.5 (4.6) 0.103 
Follow-up time, years, mean (SD) 2.6 (1.8) 6.1 (2.1) <0.001* 
Geriatric Depression Scale, mean (SD) 5.8 (3.8) 5.6 (4.9) 0.848 
Blessed Dementia Scale, mean (SD) 3.8 (2.1) 2.5 (2.0) 0.002* 
Group comparisons were performed with independent samples t-tests (or χ2  Pearson Chi-Square test when 
appropriate#); *Statistically significant (p< 0.05) 
Table 3.4.2 – Baseline neuropsychological performances of converters and non-converters to dementia. 
Cognitive Domain 
   Neuropsychological Tests 
Converters 
(n=162) 
mean (SD) 
Non-converters 
(n=88) 
mean (SD) 
p – value 
Attention and Executive Functions    
 
 
 
 
 
   Cancellation Task -0.07 (1.24) 0.46 (1.37) 0.003* 
   Digit Span Backward -0.05 (1.03) 0.29 (0.98) 0.013* 
   Clock Draw 0.43 (1.03) 0.69 (0.67) 0.020* 
Initiative    
   Verbal Semantic Fluency -0.89 (1.44) 0.39 (1.53) <0.001* 
   Motor Initiative -0.22 (1.54) -0.19 (1.55) 0.870 
   Graphomotor Initiative -0.18 (0.88) 0.23 (0.61) <0.001* 
Conceptual Thinking    
   Raven Progressive Matrices -0.50 (1.15) 0.32 (0.99) <0.001* 
   Interpretation of Proverbs 0.35 (1.13) 0.84 (1.22) 0.002* 
Orientation    
   Personal, spatial and temporal -2.70 (2.26) -0.58 (1.81) <0.001* 
Means of z scores, calculated according to the equation [z= (x-mean)/SD]; Group comparisons were performed 
with independent samples t-tests; *Statistically significant (p< 0.05) 
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Converters scored at baseline lower than non-converters for all the neuropsychological tests 
administered with the exception of Motor Initiative, Basic Written Calculation, Token test and 
Digit Span forward (Table 3.4.2).  
 
 
To determine the value of neuropsychological tests to predict long term (5 years) conversion 
to dementia Linear Discriminant Analysis (LDA) was performed. The Wilks' λ test indicated 
that the discriminant model constituted by four measures, Digit Span backward, Semantic 
Fluency, Logical Memory (immediate recall) and Forgetting Index, was significant (λ 
Wilks=0.64; χ2(4)=81.95; p<0.001; RCanonical=0.60). Logical Memory (immediate recall) 
was the strongest predictor with a standardized canonical discriminant function coefficient of 
0.70 (Table 3.4.3). The cross-validated classification showed that overall 78.6% were 
correctly classified. The LDA classificatory model showed good sensitivity and specificity 
Table 3.4.2 (cont.) – Baseline neuropsychological performances of converters and non-converters to dementia. 
Cognitive Domain 
   Neuropsychological Tests 
Converters 
(n=162) 
mean (SD) 
Non-converters 
(n=88) 
mean (SD) 
p – value 
Calculation    
   Basic Written Calculation -0.34 (1.31) -0.10 (0.94) 0.116 
Visuo-constructional Abilities    
   Cube Copy -0.05 (1.37) 0.54 (1.11) 0.001* 
Language    
   Token Test -0.47 (1.60) -0.14 (1.42) 0.107 
Memory and Learning    
   Visual Reproduction 0.14 (1.17) 0.88 (1.45) 0.004* 
   Digit Span Forward -0.39 (0.71) -0.27 (0.50) 0.134 
   Word Recall  -1.65 (1.35) -0.82 (1.14) <0.001* 
   Logical Memory (immediate recall) -2.04 (1.09) -0.63 (1.31) <0.001* 
   Logical Memory (delayed recall) -2.71 (1.42) -0.69 (1.53) <0.001* 
(1)Forgetting Index -1.98 (2.50) -0.23 (2.10) <0.001* 
   Verbal Paired-associate Learning -1.73 (1.05) -0.65 (1.10) <0.001* 
Means of z scores, calculated according to the equation [z= (x-mean)/SD]; Group comparisons were performed 
with independent samples t-tests; *Statistically significant (p< 0.05); (1)Forgetting Index = [(LM delayed recall 
– LM immediate) / LM immediate)]*100. 
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(78.8% and 79.9%, respectively) of the neuropsychological tests to predict long-term 
conversion to dementia (Table 3.4.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.3 Discussion 
In the present study, a comprehensive battery of neuropsychological tests was applied to a 
cohort of non-demented patients with cognitive complaints followed for at least 5 years, to 
discriminate the patients converting to dementia from those who remain cognitively stable for 
a long time. The main finding is that neuropsychological tests predict long-term (5 years) 
Table 3.4.3 – Neuropsychological tests contribution to the discrimination of converters and non-
converters to predict long-term (5 years) dementia. 
 β‡ Wilks' λ F† p-value* 
Executive Functions     
       Digit Span Backward 0.36 0.97 6.1 0.027* 
Initiative     
       Semantic Fluency 0.38 0.86 30.0 <0.001* 
Episodic Memory     
       Logical Memory (immediate recall) 0.70 0.76 59.2 <0.001* 
       Forgetting Index 0.39 0.89 23.4 <0.001
* 
‡Standardized canonical discriminant function coefficients; †Wilks' lambda ANOVA (F) test of 
mean differences for independent variables; *Statistically significant (p<0.05). 
Table 3.4.4 – Accuracy, sensitivity, specificity and discriminant power of the neuropsychological 
evaluation to predict long-term (5 years) dementia.  
 Linear Discriminant Function 
 Mean SEM 
Sensitivity (%) 78.8 3.7 
Specificity (%) 79.9 6.6 
Accuracy (%) 78.6 1.5 
Area under the ROC curve (AUC) 0.79 0.02 
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conversion to dementia with high rates of sensitivity, specificity and accuracy (approximately 
80%). 
The classificatory model also identified the neuropsychological tests that were the best 
predictors to discriminate between converters and non-converters. The Logical Memory test 
(immediate recall and rate of forgetting) (Wechsler, 1945/1997) was the most predictive of 
long-term conversion to dementia. Episodic memory, especially the consolidation of memory 
traces, was proposed to decline early in the neurodegenerative process, representing a 
neuropsychological correlate of the neuropathological changes that begin in the temporal 
areas, namely, hippocampal formation and the entorhinal cortex (Reed et al., 2007; Amieva et 
al., 2008; Devanand et al., 2012). Several previous studies have shown that verbal memory 
tasks are among the best measures to predict future conversion to dementia (Flicker, Ferris 
and Reisberg, 1991; Tabert et al., 2006; Sarazin et al., 2007; Grober et al., 2010). 
Accordingly, the Dubois’ work group (Dubois et al. 2007) proposed the use of episodic 
memory impairment as the core of diagnostic criteria for prodromal AD. A previous study 
showed that not only Logical Memory, but also other verbal memory tests, namely Verbal 
Paired-Associate Learning, California Verbal Learning Test (CVLT) and Digit Span, could 
predict the conversion to dementia, and in a multivariate analysis combining the four memory 
tests only the CVLT test remained significant as a predictor of conversion to dementia (Silva 
et al., 2012). It is possible that the use of more extensive or complex assessments of verbal 
memory, like the CVLT (Delis et al., 1987) or the Grober-Buschke paradigm (Grober and 
Buschke, 1987) could improve further the predictive value of the Logical Memory test 
observed in the present study. Nevertheless, it should be noted that the Logical Memory test is 
relatively short to apply, and it allows the assessment of specific memory components 
affected in patients at risk for dementia, namely the forgetting index evaluates the information 
successfully encoded, but lost in delayed recall and not recovered with the cued condition. A 
further remark is that, although the converters showed worse performance than the non-
converters at baseline in almost all neuropsychological tests, as found in previous studies 
(Fabrigoule et al., 1998; Tabert et al., 2006; Sarazin et al., 2007; Jungwirth et al., 2009), 
however the converters performed below the normative values (cut-off <1.5 standard 
deviations) only on the tests of verbal memory as well as orientation, which also relies heavily 
on memory resources. 
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Even though episodic memory has a well-established contribution in the prediction of future 
conversion to dementia, it is still important to assess the cognitive profile through a 
comprehensive neuropsychological battery to have a global understanding of cognitive 
performance and be able to predict more accurately future conversion (Johnson et al., 2009; 
Wilson et al., 2011). Manly and colleagues (2008) found that patients with impairment on at 
least one other non-amnestic domain besides the deficits in verbal memory, were about 4 
times more prone to develop AD. In the present study, verbal initiative and working memory, 
assessed through Semantic Fluency and Digit Span backwards tests, contributed significantly 
to the classificatory model of progression to dementia. Impaired working memory tasks rely 
on executive functions and were found to be predictive of future decline in MCI patients 
(Gagnon and Bellevile, 2011). Neuronal loss is observed in the anterior cingulate in the initial 
phases of AD and may contribute to the executive function deficits (Baddeley et al., 1986; 
Lafleche and Albert, 1995; Traykov et al., 2007; Thillainadesan et al., 2012). Fluency tasks 
were described as involving executive control, however tasks without a switching or shifting 
component, like the present task of Semantic Fluency, are more dependent of semantic 
knowledge, recruit brain regions (e.g., inferior frontal regions) involved in semantic memory 
processing and are known to be impaired in amnestic MCI (Nutter-Upham et al., 2008). This 
semantic impairment evolves and affects more semantic abilities as the disease progresses 
until the dysfunction of temporoparietal-frontal-cingulate network seen in mild AD (Corbett 
et al., 2012). Despite the contribution of executive functions for the classificatory model, with 
the Semantic Fluency and Digit Span backwards, scores of these tests observed at baseline 
were not clearly impaired, even in the converters, considering impairment as 1.5 SD below 
the mean score for the subjects reference group (matching age and formal education). 
Cohort studies of cognitively impaired subjects have reported rather disparate global 
sensitivity and specificity values for the neuropsychological tests to predict conversion to 
dementia (Devanand et al., 1997; Sarazin et al., 2007; Rabin et al., 2009; Gallagher et al., 
2010). Some studies reported high and balanced sensitivity/specificity ratios (≥80%), mainly 
for verbal episodic memory tests, and also for verbal initiative and executive functions tests, 
however the follow-up period of those studies was generally short (≈2 years) (Flicker, Ferris 
and Reisberg, 1991; Lehrner et al., 2005; Landau et al., 2010; Aretouli et al., 2011). The 
present study shows that it is possible to obtain high rates of sensitivity, specificity and 
accuracy (approximately 80%) for the neuropsychological tests for long-term (5 years) 
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conversion to dementia. This value, 80%, has been the recommended cut-off for molecular 
and biochemical markers (The Ronald and Nancy Reagan Research Institute of the 
Alzheimer’s Association and, National Institute on Aging Working Group, 1998).  
One of the strengths of the present study is the length of follow-up, since the patients were 
followed until they were clinically stable for at least 5 years, or converted to dementia. Other 
important point is the large sample size. The methodological option that patients did not 
necessarily meet criteria for MCI at the baseline is also an advantage, since there are 
differences in the available criteria for diagnosis of MCI, and more importantly, elderly 
patients with cognitive complaints may not fulfil the MCI criteria and nevertheless evolve to 
dementia (Nunes et al., 2010). Another positive point is that a rather extensive 
neuropsychological battery was administered, encompassing distinct cognitive domains.  
A couple of limitations also warrant consideration. Converters evidenced more functional 
difficulties than non-converters according to Blessed Rating Scale information at baseline, 
however they were not demented, both from the clinical criteria and the functional evaluation 
point of view. Another limitation is that other biomarkers were not included in the present 
study, which actually focused on the clinical and neuropsychological markers of progression 
to dementia. 
It should be acknowledged that imaging and biochemical research biomarkers represent a 
major advance in the field. However, since they are very expensive and in some cases 
invasive, it is not reasonable that they might be offered to all patients with cognitive 
complaints. On the other hand, it is not expected that new treatments that are presently being 
tested, like those impacting on beta-amyloid, will be as unexpensive and safe as to be used 
broadly in patients with cognitive complaints. From a clinical point of view, it is essential to 
determine, on the basis of an initial clinical and neuropsychological evaluation, whether non-
demented patients with cognitive complaints will probably convert to dementia, or remain 
stable, at a reasonably long and clinically relevant term. The present work shows that 
neuropsychological tests can predict long-term (5 years) conversion to dementia with high 
rates of sensitivity, specificity and accuracy (approximately 80%). It remains to be 
investigated whether the use of advanced classification methods, adding more sophisticated 
tests, or the combination with selective biomarkers, can improve the long-term predictive 
value of the clinical and neuropsychological evaluation in patients with cognitive complaints. 
 
Neuropsychological predictors of the outcome in non-demented subjects with cognitive complaints  
Biomedical Sciences Doctoral Program – Faculty of Medicine – University of Lisbon 
 
80 Dina Lúcia Gomes da Silva 
 
PART IV – DISCUSSION AND FINAL CONCLUSIONS 
Cognitive impairment is present in Alzheimer’s disease (AD) patients several years preceding 
a clinical diagnosis, reflecting the onset and progressive dissemination of the 
pathophysiological process associated to the disease. Neuropsychological assessment should 
offer an important contribution for the early diagnosis of the dementing disorder but also to 
determine a profile that unveils its cause.  
Novel biomarkers emerged in the last decade due to advances in biochemical methods to 
assess the cerebrospinal fluid and sophisticated brain imaging techniques, however cognitive 
measures remain the most accessible, inexpensive and maybe accurately predictive marker of 
progression to dementia. Notwithstanding biomarkers represent a major advance in the field; 
it is not reasonable to believe that they could be offered to all patients with cognitive 
complaints. On the other hand, it is not expected that new treatments that are presently being 
tested, like those impacting on beta-amyloid, will be as inexpensive and safe as to be used 
broadly in patients with cognitive complaints. More studies addressing the improvement of 
predictive accuracy for neuropsychological tests are needed to screen more accurately the 
population with subjective cognitive complaints at risk for future progression to dementia. 
Such a tool would make the use of other biomarkers more efficient since they could be 
focused on those subjects with higher probability of having preclinical AD.  
The aim of the present thesis was to improve the predictive value of neuropsychological 
assessment to foresee future conversion to dementia. For that purpose we defined four tasks.  
The first was a review of literature that could synthesize the longitudinal studies focusing on 
the predictive value of neuropsychological assessment for future conversion to dementia. This 
work allowed us to identify limitations and to propose future work, namely the head-to-head 
comparison of neuropsychological tests, particularly in the core memory domain, 
consideration of different cut-offs, and the importance of looking at longer follow-up periods.  
In the second task, we sought to determine the statistical classificatory method more suitable 
to the characteristics of cohorts recruiting patients with cognitive complaints. We found that 
Random Forests and Linear Discriminant Analysis were the best classifiers, the latter having 
the advantage of simplicity.  
Thirdly, we compared the contribution of four commonly used verbal memory tests in the 
Mild Cognitive Impairment (MCI) diagnostic criteria to predict conversion to dementia. We 
found that these verbal memory tests were valuable to establish the diagnosis of MCI and 
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predict the progression to dementia, however the California Verbal Learning Test had the 
highest predictive value, which was not improved by adding other memory tests. 
Finally, we studied a subset of the CCC cohort followed for at least 5 years, to overcome the 
bias of the converters that are censored prematurely, applying the best statistical classificatory 
method previously obtained. We found that the neuropsychological tests can predict 
conversion to dementia with high rates of sensitivity, specificity and accuracy (approximately 
80%), at a long and clinically relevant term (5 years). 
Nowadays, clinicians have to reconcile assistance to a large number of patients with cognitive 
complaints, novel expensive diagnostic techniques, promising disease-modifying treatments, 
and marked financial constraints. Therefore, it is crucial to assess as early as possible whether 
patients have a low probability of progression to dementia, in which case a regular follow-up 
and general preventive measures might be indicated, or a high probability of progression to 
dementia, so that the patient could undergo complex ancillary examinations and new disease-
modifying treatments. 
We have gone a long way, since the recognition of obvious cognitive decline in ancient times, 
to the description of a particular form of dementia by Alois Alzheimer, and to the present 
revolutionary understanding of the disease. Interestingly, the importance of the cognitive 
symptoms remained, in the sharp observations of Maximianus, in the talented clinical notes of 
Alois Alzheimer, and in the present effort to use better neuropsychological tests. This is 
because the loss of mental abilities is what matters most in the disease, and indeed frightens 
us all. 
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PART V – ANNEX 
 
Table 5.1 Criteria for Mild Cognitive Impairment (MCI) according to Petersen and 
colleagues (1997; 1999) and NIA-AA (2011) 
Petersen et al. (1997; 1999): 
• Memory complaint, preferably corroborated by an informant; 
• Objective memory impairment for age; 
• Normal general cognitive function; 
• Intact activities of daily living; 
• Not demented. 
Diagnosis of mild cognitive impairment due to Alzheimer’s disease (NIA-AA, 2011) - 
Recommendations from the National Institute on Aging-Alzheimer’s Association 
workgroups (Albert et al., 2011)  
• Presence of lower performance in one or more cognitive domains greater than would 
be expected for the patient’s age and educational background (1 to 1.5 standard 
deviations below the mean for their age and education matched peers on culturally 
appropriate normative data); 
• Presence of impairment in episodic memory (i.e., the ability to learn and retain new 
information) as associated to MCI patients who subsequently progress to a diagnosis 
of AD dementia (e.g. assessed by word-list learning tests with multiple trials that 
revealed the rate of learning over time, as well as the maximum amount acquired over 
the course of the learning trials, but also assessed the capacity of paying attention to 
the task on immediate recall, and the relative amount of material retained on delayed 
recall; other possible measure might be episodic memory, and complementary 
assessment domains such as executive functions (e.g., set-shifting, reasoning, 
problem-solving, planning), language (e.g., naming, fluency, expressive speech, and 
comprehension), visuospatial skills, and attentional control (e.g., simple and divided 
attention); 
• If possible, follow-up with neuropsychological re-assessments should be conducted to 
confirm a decline in performance over time; 
• Information concerning independence in daily life activities should revealed the need 
for minimal aids or assistance, however, performance in instrumental activities of 
daily living are expected to take more time and to be executed with more errors than in 
the past; 
And obviously, MCI patient should not be demented. 
To meet the core clinical criteria for MCI it is necessary to rule out other systemic or brain 
diseases that could account for the decline in cognition (e.g., vascular, traumatic, medical). If 
MCI patients presented an autosomal dominant form of AD (i.e., mutation in APP, PSEN1, 
PSEN2) or were APOE ε4 positive clearly would be more prone to progress to AD dementia. 
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Table 5.2 Criteria for diagnosis Alzheimer’s disease according to: NINCDS-ADRDA, 
DSM-IV-TR, ICD-10, and NIA-AA, 2011 
NINCDS-ADRDA Criteria to define Alzheimer’s disease (McKhann et al., 1984) 
Definitive Diagnosis AD 
• Clinical criteria for probable AD; 
• Histopathological evidence from biopsy or autopsy. 
Probable AD: 
• Dementia established by clinical examination, documented by MMSE (Mini-
Mental Status Examination) or equivalent and confirmed by neuropsychological 
tests; 
• Deficits in two or more areas of cognition; 
• Progressive worsening of memory and other cognitive functions; 
• No disturbance of consciousness; 
• Onset between ages 40 and 90, most often > 65; 
• Absence of systemic disorders or other brain diseases that could account for the 
progressive deficits in memory and cognition. 
Possible AD 
• Dementia syndrome without any other neurologic, psychiatric or systemic 
disorders that could cause dementia, in the presence of variations in the onset, 
presentation, and clinical course; 
Dementia syndrome in the presence of a second systemic or brain disorder capable of causing 
dementia but not considered to be responsible for the present symptoms. 
 DSM-IV-TR criteria (APA, 2000) 
A. The development of multiple cognitive deficits manifested by both: 
       1. Memory impairment (impaired ability to learn new information or to recall previously          
learned information). 
       2. One (or more) of the following cognitive disturbances: 
              a. Aphasia (language disturbance).  
              b. Apraxia (impaired ability to carry out motor activities despite intact motor        
function. 
              c. Agnosia (failure to recognize or identify objects despite intact sensory function). 
              d. Disturbance in executive functioning (i.e., planning, organizing, sequencing, 
abstracting). 
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or 
occupational functioning and represent a significant decline from a previous level of 
functioning. 
C. The course is characterized by gradual onset and continuing cognitive decline. 
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following: 
1. Other central nervous systems, conditions that cause progressive deficits in memory and 
cognition (e.g., cerebrovascular disease, Parkinson’s disease, Huntington’s disease, subdural 
hematoma, normal-pressure hydrocephalus, brain tumor). 
2. Systemic conditions that are known to cause dementia (e.g., hypothyroidism, vitamin B12 or 
folic acid deficiency, neurosyphilis, HIV infection). 
3. Substance-induced conditions.  
E. The deficits do not occur exclusively during the course of a delirium.  
F. The disturbance is not better accounted for by another disorder (e.g., major depressive 
disorder, schizophrenia). 
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ICD-10 criteria (WHO, 1992) 
F00 - F09 Dementia – Evidence of each of the following: 
• A decline in memory, which is most evident in the learning of new information, 
although in more severe cases, the recall of previously learned information may be 
also affected. The impairment applies to both verbal and non-verbal material and 
should have been present for at least six months for a confident clinical diagnosis. The 
decline should be objectively verified by obtaining a reliable history from an 
informant, supplemented, if possible, by neuropsychological tests or quantified 
cognitive assessments; 
• A decline in other cognitive abilities characterized by deterioration in judgement and 
thinking, such as planning and organizing, and in the general processing of 
information. Evidence for this should be obtained when possible from interviewing an 
informant, supplemented, if possible, by neuropsychological tests or quantified 
objective assessments. Deterioration from a previously higher level of performance 
should be established; 
• Preserved awarenenss of the environment (i.e. absence of clouding of consciousness 
during a period of time long enough to enable the unequivocal demonstration of 
memory decline. When there are superimposed episodes of delirium the diagnosis of 
dementia should be deferred; 
• A decline in emotional control or motivation, or a change in social behaviour, 
manifest as at least one of the following: emotional lability, irritability, apathy, and 
coarsening of social behaviour. 
F00 – Dementia in Alzheimer's disease: 
• The general criteria for dementia (see row above) must be met; 
• There is no evidence from the history, physical examination or special investigations 
for any other possible cause of dementia (e.g. cerebrovascular disease, Parkinson's 
disease, Huntington's disease, normal pressure hydrocephalus), a sysytemic disorder 
(e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol- or 
drug-abuse. 
 
 
The diagnosis is confirmed by post mortem evidence of neurofibrillary tangles and neuritic 
plaques in excess of those found in normal ageing of the brain.  
 
The following features support the diagnosis, but are not necessary elements: Involvement of 
cortical functions as evidenced by aphasia, agnosia or apraxia; decrease of motivation and 
drive, leading to apathy and lack of spontaneity; irritability and disinhibition of social 
behaviour; evidence from special investigations that there is cerebral atrophy, particularly if 
this can be shown to be increasing over time. In severe cases there may be Parkinson-like 
extrapyramidal changes, logoclonia, and epileptic fits. 
Diagnosis of dementia due to Alzheimer’s disease (NIA-AA, 2011) - Recommendations 
from the National Institute on Aging-Alzheimer’s Association workgroups (McKhann et 
al., 2011) 
Probable AD dementia1 with increased level of certainty: 
• Probable AD dementia with documented decline; 
• Probable AD dementia in a carrier of a causative AD genetic mutation (causative 
genetic mutation in APP, PSEN1, or PSEN2). 
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Probable AD dementia1:  
• Meets the criteria for all-cause dementia*; 
• Insidious onset. Symptoms have a gradual onset over months to years, not sudden over 
hours or days; 
• Clear-cut history of worsening of cognition by report or observation; 
Initial and most prominent cognitive deficits can be amnestic or nonamnestic. 
 
Possible AD dementia: 
Atypical course - Evidence of the core clinical criteria in terms of the nature of the cognitive 
deficits for AD dementia, but either with a sudden onset of cognitive impairment or with 
insufficient historical detail or objective cognitive documentation of progressive decline; 
Aetiologically mixed presentation - all core clinical criteria for AD dementia but has evidence 
of at least one of the following conditions: 
• Concomitant cerebrovascular disease, defined by a history of stroke temporally related 
to the onset or worsening of cognitive impairment;  
• The presence of multiple or extensive infarcts or severe white matter hyperintensity 
burden;   
• Features of Dementia with Lewy bodies other than the dementia itself;   
• Evidence for another neurological disease or a non-neurological medical comorbidity 
or medication use that could have a substantial effect on cognition. 
1The diagnosis of probable AD dementia should not be applied when there is evidence of one 
of the following conditions: 
- substantial concomitant cerebrovascular disease, defined 
- by a history of a stroke temporally related to the onset or worsening of 
- cognitive impairment; or the presence of multiple or extensive infarcts or severe white 
matter hyperintensity burden;  
- core features of Dementia with Lewy bodies other than dementia itself;  
- prominent features of behavioral variant frontotemporal dementia;  
- prominent features of semantic variant primary progressive aphasia or nonfluent/agrammatic 
variant primary progressive aphasia;  
- evidence for another concurrent, active neurological disease, or a non-neurological medical 
comorbidity or use of medication that could have a substantial effect on cognition. 
*All-cause dementia is diagnosed when there are cognitive or behavioral (neuropsychiatric) symptoms that: interfere with the ability to 
function at work or at usual activities; and represent a decline from previous levels of functioning and performing; and are not explained by 
delirium or major psychiatric disorder; cognitive impairment is detected and diagnosed through a combination of (1) history-taking from the 
patient and a knowledgeable informant and (2) an objective cognitive assessment, either a “bedside” mental status examination or 
neuropsychological testing. Neuropsychological testing should be performed when the routine history and bedside mental status examination 
cannot provide a confident diagnosis. The cognitive or behavioral impairment involves a minimum of two of the following domains: 
impaired ability to acquire and remember new information; impaired reasoning and handling of complex tasks, poor judgment; impaired 
visuospatial abilities; impaired language functions; changes in personality, behavior, or comportment. 
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NEUROPSYCHOLOGICAL TESTS (REFERENCES) 
 
Battery of Lisbon for the Assessment of Dementia (BLAD) 
• Garcia C. Doença de Alzheimer, problemas do diagnóstico clínico. Tese de 
Doutoramento. Faculdade de Medicina de Lisboa, 1984. 
 
Mini-Mental State Examination (MMSE) 
• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-
198.  
• Guerreiro M. Contributo da Neuropsicologia para o Estudo das Demências. 
Dissertação de Doutoramento. Faculdade de Medicina de Lisboa,  Ciências 
Biomédicas, 1998. 
 
Trail Making Test part A and part B (TMT)  
• Reitan RM. Validity of the Trail Making Test as an indicator of organic brain 
damage. Percept Mot Skills 1958; 8: 271-286. 
 
Toulouse-Piéron Test (TP)  
• Toulouse Y and Piéron H. Prueba perceptiva y de atención.  Tea Ediciones – Madrid, 
1986; 
• Mendelsohn D (2000). Test de Toulouse-Pieron aplicado a jugadores de fútbol 
profesional Club El Porvenir, años 1996/98. EF y Deportes, 18. Recuperado em 
jun.2004, http://www.efdeportes.com/efd18a/toulouse.htm). 
 
California Verbal Learning Test (CVLT)  
• Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test: 
Research Edition Adult Version. San Antonio; The Psychological Corporation, 1987; 
• Ribeiro F, Guerreiro M, de Mendonça A. Verbal learning and memory deficits in 
Mild Cognitive Impairment. J Clin Exp Neuropsychology 2007; 29: 187-197. 
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Clinical Dementia Rating scale (CDR)  
• Morris JC.The Clinical Dementia Rating (CDR): current version and scoring rules. 
Neurology 1993; 43: 2412-2414. 
• Garrett C, Santos F, Tracana I, Barreto J, Sobral M, Fonseca R. Avaliação Clínica da 
Demência (Clinical Dementia Rating). In: De Mendonça A and Guerreiro M. Escalas 
e Testes na Demência. 2nd Ed., Grupo de Estudos de Envelhecimento Cerebral e 
Demência, 2008. 
 
Blessed Dementia Rating Scale (BDRS)  
• Blessed G, Tomlinson, B, Roth M. Association between quantitative measures of 
dementing and senile change in cerebral grey matter of elderly subjects. Br J 
Psychiatry 1968; 114: 797-811.  
• Garcia C. Escala de Demência de Blessed (Blessed Dementia Rating Scale). In: De 
Mendonça A and Guerreiro M. Escalas e Testes na Demência. 2nd Ed., Grupo de 
Estudos de Envelhecimento Cerebral e Demência, 2008. 
 
Geriatric Depression Scale (GDS)  
• Sheikh JI and Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and 
development of a shorter version. In TL Brink (Ed.), Clinical Gerontology: A Guide 
to Assessment and Intervention, 1986 (pp. 165-173). NY: The Haworth Press, Inc; 
•  Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of 
their validity for the diagnosis of a major depressive episode according to ICD-10 and 
DSM-IV. Int J Geriatr Psychiatry 1999; 14: 858-865).  
• Barreto J, Leuschner A, Santos F, Sobral M. Escala de Depressão Geriátrica 
(Geriatric Depression Scale). In: De Mendonça A and Guerreiro M. Escalas e Testes 
na Demência. 2nd Ed., Grupo de Estudos de Envelhecimento Cerebral e Demência, 
2008. 
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